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Abstract 
It has been known since the 1960’s that mitochondria have a huge capacity to take up and 
accumulate calcium from the cytosol, regulating energy production, autophagy, and 
mitochondrial morphology. Dysfunctional mitochondrial calcium homeostasis is also 
involved in the pathology of many disease states.  Therefore, mitochondrial calcium 
handling represents an interesting therapeutic target. In this thesis I aimed to investigate 
related therapeutic avenues and further understand the role of mitochondrial calcium 
handling machinery.    
When mitochondrial calcium uptake exceeds the calcium buffering capacity of the 
mitochondrial matrix, the mitochondrial permeability transition pore (mPTP) opens in the 
inner mitochondrial membrane.  Pore opening causes mitochondrial depolarisation, 
energetic collapse, swelling, rupture, and cell death. Using isolated mitochondria, I screened 
a range of novel mitochondrial targeted derivatives of the canonical mPTP inhibitor, 
cyclosporin A (CsA), to assess their efficacy as mPTP inhibitors, and as potential therapeutics 
for neurological disease. Two compounds were found to be more effective than CsA at low 
concentrations, and one was selected for further study.  The compound’s target was 
investigated and found to be Cyclophilin D, and it’s effect on various mitochondrial 
parameters was assessed, and it was found to be non-toxic ex vivo and in vitro.   
The molecular identity of the mitochondrial calcium uniporter (MCU) was only recently 
discovered, followed by discovery of several associated proteins – MCUb, MICU1, MICU2, 
MICU3, EMRE, and MCUR1.  I developed a screen using the bioluminescent protein aequorin 
to identify mitochondrial specific inhibitors of the MCU, and I developed a stable cell line in 
which the MCU protein was knocked down, in order to further examine the role of MCU and 
investigate the effect of reduced mitochondrial calcium uptake on mitochondrial and 
cellular properties.  While mitochondrial calcium uptake was significantly reduced upon 
stimulation in these cells, cytosolic calcium, oxygen consumption, cell growth and 
mitochondrial morphology were not affected.  I also investigated the protein expression 
level of the components of the MCU complex in the rat brain throughout development.    
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Chapter 1: Introduction 
 
Mitochondria 
 
Mitochondria are cellular organelles responsible for the generation adenosine triphosphate 
(ATP), which is used as an energy source in the cell, through the process of oxidative 
phosphorylation.  It is thought that mitochondria were originally independent organisms: a 
type of -proteobacteria whose closest living relatives are the typhus bacterium Rickettsia 
prowazekii (Yang et al., 1985; Andersson et al., 1998).  These organisms formed an 
endosymbiotic relationship with early cells around 2 billion years ago in response to 
increasing oxygen concentration in the earth’s atmosphere (Andersson and Kurland, 1998).  
This relationship conferred on the cells the ability to use oxygen to produce energy, and 
provided protection and substrates for the Rickettsia.  Over time, the Rickettsia evolved into 
modern mitochondria, becoming more reliant on the host cell as genetic information was 
donated to the cell nucleus and the mitochondrial genome shrunk.  Mitochondria still 
contain their own DNA (mtDNA), although it consists of only 16600 base pairs, in 
comparison to the nuclear genomes of ~3 billion base pairs, and is circular rather than 
chromosomal.  Human mtDNA encodes 37 genes, 22 encode transfer RNAs (tRNA), 13 
encode polypeptides, and 2 encode ribosomal RNA (rRNA).  The polypeptides encoded in 
the mtDNA are all subunits of the complexes of the electron transport chain, which 
produces ATP for the cell through oxidative phosphorylation (Anderson et al., 1981; 
Macreadie et al., 1983; Chomyn et al., 1985; Chomyn et al., 1986).  The small number of 
polypeptide encoding genes in the mtDNA mean that mitochondria are now heavily reliant 
on genes encoded in the nuclear DNA. There are many copies of mtDNA within each 
mitochondrion, bound within complexes called nucleoids, of around 100nm length.  
Nucleoids also contain the mitochondrial transcription factor A (TFAM), which constitute the 
main protein content of the nucleoid: often a nucleoid contains only one copy of mtDNA 
(Kukat et al., 2011).   
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MtDNA is contained in the mitochondrial matrix, the space in the centre of the 
mitochondria surrounded by the inner mitochondrial membrane.  Mitochondria have two 
membranes, the inner and outer mitochondrial membranes, separated by the 
intermembrane space.  
 
Figure 1.1: Basic mitochondrial 
structure.  Left: the matrix is 
surrounded by the inner 
mitochondrial membrane, which 
forms multiple infoldings called 
cristae.  The inner membrane is 
surrounded by the outer membrane. 
Between the two membranes is a 
distinct compartment, the 
intermembrane space.  
 
 
The two membranes are distinct in their composition; the outer mitochondrial membrane 
(OMM) is a relatively simple phospholipid bilayer, whereas the inner mitochondrial 
membrane (IMM) is more complex.  The IMM consists of a mixture of proteins and 
phospholipids, including phospholipids of all the major classes; it is much more complex 
than the OMM and is permeable only to oxygen, CO2 and H2O (for overview see (Lemasters, 
2007)).  Some of the phospholipids of the IMM - phosphatidylethanolamine (PE), 
phosphatidylcholine (PC) - are common components of cellular membranes, whereas others 
– cardiolipin (CL) – are mitochondria-specific (Zinser et al., 1991).  These phospholipids have 
important roles in mitochondrial structure, the activity of the respiratory protein complexes, 
which require an impermeable membrane to create the proton gradient necessary for 
oxidative phosphorylation, and protein transport into the mitochondria.  The IMM also has 
an unusually high proportion of membrane bound proteins, with a protein:lipid ratio 
potentially as high as 3:1 (Shaikh and Brown, 2013).  The IMM is highly folded, and the 
infoldings of the membrane are called cristae, see Figure 1.1.   These increase the surface 
area of the IMM, increasing the capacity of the mitochondria to produce ATP from the IMM-
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embedded electron transport chain (Mannella, 2006).  Mitochondrial morphology is 
dynamic, and can change between a fragmented or a fused structure in response to cellular 
and environmental stresses.  Mitochondrial dynamics are important to cell health: they have 
roles in embryonic development (Chen et al., 2003), bioenergetics (Chen et al., 2005), cell 
signalling (Li et al., 2004; Verstreken et al., 2005), and are involved in the pathogenesis of 
hereditary optic neuropathies (Rouzier et al., 2012).   
ATP is generated by the electron transport chain, a chain of five complexes in the inner 
mitochondrial membrane (see Figure 1.2).  Complex I receives electrons transferred by 
NADH from the citric acid cycle, which it donates to complex III, moving protons across the 
IMM as it does so; complex II also donates electrons to complex III, via the reduction of FAD 
to FADH2, and the passage of electrons from FADH2 to ubiquinone.  Complex III passes 
electrons onto complex IV, moving more protons across the IMM.  Complex IV combines the 
electrons with oxygen to produce water, and moves more protons across the IMM.  The 
proton gradient across the IMM then drives ATP production by complex V.  Oxidative 
phosphorylation is a more efficient method of producing ATP than glycolysis, the alternative 
method in which ATP is produced during the conversion of glucose to pyruvate in the 
cytosol: it is typically stated that for every molecule of glucose, glycolysis produces 8 
molecules of ATP, whereas oxidative phosphorylation produces 30, although these are 
unlikely to be exact values, due to the energetic cost of substrate transport, and the fact 
that the mitochondria will not always be in optimal condition (Rich, 2003).   
This system, first demonstrated by Peter Mitchell is known as the chemiosmotic mechanism 
of oxidative phosphorylation and can be summarised as: hydrogen ions are pumped across 
the mitochondrial inner membrane from the matrix to the intermembrane space by the 
complexes of the respiratory chain, and thereby generate  an electrochemical concentration 
gradient which is used to drive the production of ATP (Mitchell and Moyle, 1967). This 
electrochemical gradient defines a membrane potential, (ΔΨm) and a pH gradient (ΔpHm) 
across the inner mitochondrial membrane.  The proton driving force is usually around -180-
220mV, of which 150-180mV is contributed by ΔΨm, and 30-60mV by ΔpHm (Perry et al., 
2011).  Therefore ΔΨm is considered an important parameter to indicate cell health or 
injury, as it directly relates to the cell’s capacity for ATP generation, and is essential for 
calcium uptake and protein import (Geissler et al., 2000).   
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Figure 1.2: Oxidative phosphorylation.  The citric acid cycle converts pyruvate (which is imported into the matrix by the 
mitochondrial pyruvate carrier, MPC) to oxaloacetate in a 9 step cycle.  This produces NADH which donates an electron to 
complex I of the electron transport chain in the inner mitochondrial membrane.  Electrons are passed along the electron 
transport chain and generate a proton gradient, which is used to drive the production of ATP by complex V, the ATP 
synthase.  Movement of protons is represented by green arrows, and movement of electrons by purple arrows.   
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Mitochondria and Ca2+ Handling 
 
The intracellular environment is closely monitored and maintained, and mitochondria have 
crucial roles in this; in addition to ATP production they are highly involved in cellular Ca2+ 
homeostasis.  Ca2+ ions were first identified as having control over physiological events in 
1883 (Ringer, 1883), and they are ubiquitous second messenger molecules in eukaryotic 
cells.  Our understanding of their vital role has continued to increase since then, with the 
advent of techniques such as genetically encoded Ca2+ indicators, the bioluminescent 
protein aequorin, and fluorescent Ca2+ indicators.  Ca2+ signals can utilize their localization, 
frequency or magnitude as a means of conveying information, therefore in order for Ca2+ 
ions to perform their many complex and highly specific functions, the existence of Ca2+ 
pumps, channels and buffers is essential.  An excess of free Ca2+ in the cell would be 
damaging to the finely regulated processes which are triggered by specific Ca2+ signals.  
Mitochondria, along with the Golgi apparatus and endoplasmic reticulum (ER), function as 
cellular Ca2+ stores: upon cytosolic Ca2+ increase, Ca2+ is sequestered by Ca2+ binding 
proteins, the ER and mitochondria.  Mitochondria take up Ca2+ from the cytoplasm, buffer it 
in the mitochondrial matrix, and extrude it back into the cytoplasm according to various 
cellular events and signals.  They were the first intracellular organelle to be demonstrated to 
accumulate Ca2+ in 1961 (DELUCA and ENGSTROM, 1961).  Basal mitochondrial and cytosolic 
Ca2+ levels are maintained at ∼100nM, however upon agonist-induced cytosolic 
Ca2+ increase, mitochondria can accumulate up to 100M Ca2+, although this is cell type 
dependent and is more typically in the lower micromolar range  (Rizzuto and Pozzan, 2006).   
Ca2+ has to cross two membranes in order to reach the matrix and have biochemical effects; 
the outer mitochondrial membrane (OMM) is broadly permeable to small solutes and ions 
(<5kDa) due to the non-specific voltage dependent anion channel (VDAC), however the 
inner mitochondrial membrane (IMM) is impermeable – an essential feature of the 
chemiosmotic theory -  and ion specific transporters are required for uptake into the matrix.  
Ca2+ crosses the ion impermeable IMM through the specific mitochondrial calcium uniporter 
(MCU).  Mitochondrial Ca2+ uptake through the MCU depends on the mitochondrial 
membrane potential gradient generated by respiration, and on the electrochemical Ca2+ 
gradient between the mitochondrial matrix and the cytosol.  When oxidative 
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phosphorylation is uncoupled, and membrane potential and therefore the electrical 
gradient dissipated, mitochondrial  Ca2+ uptake ceases (Szabadkai and Duchen, 2008). 
Extrusion of Ca2+ from the mitochondria occurs through the Na+/Ca2+ exchanger (in excitable 
tissue), the H+/ Ca2+ exchanger (in non excitable tissue) (Marchi and Pinton, 2014) – see 
Figure 1.3 -  both of which have a relatively slow kinetic rate. The mitochondrial 
permeability transition pore (mPTP) also releases Ca2+, the release of which is sudden and 
absolute.   
 
Figure 1.3: Components of ion transport through the IMM.  The electron transport chain (complexes I-V) builds up the 
mitochondrial membrane potential (∆Ψ) - the electrical driving force for uptake of Ca
2+ 
through the MCU - through the 
export of H
+
 ions from the matrix.  mPTP, HCX and NCLX extrude Ca
2+ 
from the matrix, and the NHX extrudes Na
+
.  Together 
these consist the essential molecular components of mitochondrial Ca
2+ 
homeostasis.  Adapted from Patron et. al. 2013.   
 
Physiological Roles of Mitochondrial Ca2+ Homeostasis 
Mitochondrial Ca2+ homeostasis is proposed to have a crucial role in regulating energy 
production and cell survival in normal cell physiology, and is frequently disrupted in disease 
states (Szabadkai and Duchen, 2008).   
The first role of mitochondrial Ca2+ homeostasis to be discovered was its role in aerobic 
metabolism: there are three Ca2+ dependent dehydrogenases in the citric acid cycle, which 
consist of a rate limiting step in substrate supply for ATP synthesis (Denton et al., 1972; 
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Denton et al., 1978; Lawlis and Roche, 1980).  Of the three dehydrogenases, pyruvate 
dehydrogenase is activated through a Ca2+ dependent dephosphorylation step, and 
isocitrate dehydrogenase and α-ketoglutarate dehydrogenase are activated through the 
direct allosteric consequence of binding of Ca2+ to the enzyme.  Ca2+ binding increases the 
Vmax of these enzymes, and results in increased reduction of the NADH pool (Duchen, 1992), 
resulting in increased membrane potential, and thus ATP production: ATP demand and ATP 
supply are simply and directly coupled by Ca2+ signalling.  Increased mitochondrial Ca2+ 
uptake also results in increased reduction of the flavoprotein pool (Jouaville et al., 1999; 
Dumollard et al., 2003), and in addition, the Ca2+ regulated aspartate/glutamate carriers 
citrin and aralar – which are involved in transporting NADH into the mitochondria, thereby 
providing reducing power for oxidative phosphorylation - have been shown to increase ATP 
production, providing another avenue for the coupling of Ca2+ regulation and oxidative 
phosphorylation (Lasorsa et al., 2003).  It has also been suggested that mitochondrial Ca2+ 
has a role in regulating the F1F0-ATPase (Balaban, 2009; Cárdenas et al., 2010), and the Ca
2+ 
sensing protein S100A1 has been reported to interact with mitochondrial F1-ATPase and 
result in increased ATP output in cardiomyocytes (Boerries et al., 2007).   
Mitochondrial Ca2+ is also important in the regulation of autophagy, a lysosomal 
degradation pathway which activates in response to metabolic stress, nutrient deprivation 
or growth factor deficiency (Cárdenas and Foskett, 2012).  Autophagy can be suppressed or 
activated through altered mitochondrial ATP production, which indirectly inhibits AMP-
activated protein kinase activity (Cardenas 2010).  Activation of AMP-activated protein 
kinase additionally requires the upstream activation of the calcium/calmodulin kinase kinase 
B (Høyer-Hansen et al., 2007).  
Mitochondrial morphology is also influenced by mitochondrial and cytosolic Ca2+ levels: 
after cytosolic Ca2+ rise, the GTPase dynamin-like protein 1 (Drp1) which drives 
mitochondrial fission relocates to the OMM (Breckenridge et al., 2003), and mitochondrial 
distribution within the cell is governed by the Rho GTPases Miro1 and Miro2 which are Ca2+ 
sensitive (Fransson et al., 2006).  Annexin A6, a Ca2+ binding protein family which modulates 
cellular Ca2+  signals, also plays a role: in cells lacking Annexin A6, mitochondria are 
fragmented, mitochondrial membrane potential reduced, and respiration impaired 
(Chlystun et al., 2013).  Mitophagy, the selective autophagy of mitochondria, is also 
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dependent on mitochondrial morphology, and therefore on Ca2+: it requires the 
fragmentation of the mitochondrial network in order to segment the areas which are to be 
removed (Twig et al., 2008).   
Mitochondria can act as Ca2+ sensors: it has been demonstrated that there are close 
interactions between the mitochondria and the ER, and so the mitochondria are able to 
“sense” microdomains of high Ca2+ released by the ER, by means of the EF hand domains of 
Miro1 and Miro2 (Macaskill et al., 2009), which can then shuttle mitochondria to these 
areas, in order to selectively accumulate Ca2+ in these areas and combat the sigmoidal Ca2+ 
uptake curve (Saotome et al., 2008).  Strategically placed mitochondria can spatially restrict 
Ca2+ waves to a specific area by constructing a barrier of mitochondrial buffers, and can 
control the microenvironment of Ca2+ channels near which they are localized, providing 
positive or negative Ca2+ feedback and thus regulating further transport (Hoth et al., 1997; 
Boitier et al., 1999; Tinel et al., 1999).  
Ca2+ also has pathophysiological roles: Ca2+ ions at critical levels lead to cell injury or death 
by activating various enzymes.  These enzymes include calpains (a 15 member family of Ca2+  
activated cysteine proteases which regulate apoptosis and necrosis), calcineurin (a Ca2+ and 
calmodulin dependent serine/threonine protein phosphatase which induces apoptosis 
through dephosphorylation of BAD, a Bcl-2 family protein), and nitric oxide synthase (NOS, 
responsible for synthesis of nitric oxide, an activator of apoptosis), among others (Pinton et 
al., 2008).  Crucially, mitochondrial Ca2+ homeostasis has a role in the control of cell death 
through both necrosis and apoptosis.   
Mitochondrial Ca2+ in Apoptosis and Necrosis 
It has long been known that cellular Ca2+ overload leads to necrotic cell death, however its 
role in apoptosis was only more recently determined, and the specific role of mitochondrial 
Ca2+ uptake has been hard to establish.  Although the MCU has low Ca2+ affinity, 
mitochondrial Ca2+ overload can occur during cellular stress conditions due to the 
mitochondria’s close proximity to the ER.   
Apoptosis is a highly regulated form of cell death necessary in development and normal 
tissue homeostasis which occurs in a specific sequence of morphological events, whereas 
necrosis is an uncontrolled form of cell death that usually occurs as a stress response and 
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presents as uncontrolled cell swelling due to loss of membrane integrity, until cell death 
occurs (for review, see (Orrenius et al., 2003)).   Whether a cell undergoes apoptosis or 
necrosis also depends on the bioenergetic status of the cell, and the level of mitochondrial 
function (Leist et al., 1997).    Broadly, apoptosis tends to protect from the consequences of 
injury and tends not to be damaging unless activated inadvertently; it is failure of 
appropriate apoptosis that causes damage, whereas necrosis is a response to severe injury 
and inherently damaging.   
In necrosis, excessive mitochondrial Ca2+ uptake leads to matrix Ca2+ overload; this and the 
accumulation of reactive oxygen species (ROS) leads to the sustained irreversible opening of 
the mitochondrial permeability transition pore (mPTP).  This opening causes a bioenergetic 
crisis - in which ∆Ψ collapses, ATP is depleted, and pyridine nucleotides and cytochrome c 
are lost - leading to necrotic cell death (Vandenabeele et al., 2010).  mPTP opening has been 
shown to be an essential component of necrosis  – opening is activated by a high matrix Ca2+ 
concentration, oxidative stress, and low membrane potential, and initial oscillatory opening 
and closing is followed by persistent opening which leads to cell death (Orrenius et al., 
2003).   
In reaction to apoptotic stimuli, the pro-apoptotic members of the bcl-2 oncogene family 
translocate to the mitochondria (where some, such as Bad are indirectly activated by 
Ca2+)(Orrenius et al., 2003).  Ca2+ then regulates a secondary mechanism in which the OMM 
permeabilises, and releases pro-apoptotic mitochondrial proteins (e.g. Diablo, cytochrome 
c), which activate a cascade of caspases, proteloytic enzymes which begin the disintegration 
of the structural components of the cell (Szalai et al., 1999).  Cell death by apoptosis ends in 
the fragmentation of the cell into apoptotic bodies, which are then engulfed by 
macrophages (Kerr et al., 1972).  Necrosis does not share this clean up mechanism and 
results in inflammation in the surrounding tissue - such as in ischaemic reperfusion injury – 
and can therefore be more damaging than apoptosis (Vandenabeele et al., 2010).  
In both modes of cell death, mitochondrial Ca2+ uptake is a key checkpoint of cell death: up 
to the maximum Ca2+ capacity of the matrix, mitochondria will buffer and extrude Ca2+, 
whereas beyond the capacity of the matrix, the mitochondria will become overloaded and 
enter an irreversible cascade toward cell death through necrosis or apoptosis (Figure 1.4).   
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Figure 1.4: Mitochondrial Ca
2+
 in apoptosis and necrosis.  In apoptosis, there is an extrinsic pathway mediated by cell 
death receptors, and an intrinsic pathway mediated by mitochondria.  Cell death receptors activate caspase 8, which 
activates caspase 3, and causes cleavage of Bid.  Mitochondrial ROS production, Ca
2+
 and other stimuli activate Bad, Bax, 
and Bak, which (together with Bid) increase OMM permeability and cause the release of cytochrome c, which causes the 
formation of the apoptosome.  The apoptosome activates caspase 3, beginning the fragmentation of the cell into apoptotic 
bodies.  In necrosis, raised cytosolic [Ca
2+
] (e.g. due to activation of glutamate receptors) leads to raised mitochondrial 
[Ca
2+
].  This causes increased mitochondrial ROS production through stimulation of oxidative phosphorylation, which 
contributes to mPTP opening caused by mitochondrial Ca
2+ 
overload.  mPTP opening results in loss of mitochondrial 
membrane potential and ATP production, and therefore cell death through necrosis. 
 
The mitochondrial Ca2+ uptake complex 
Ca2+ uptake into mitochondria is mediated by the mitochondrial Ca2+ uniporter (MCU).  The 
biochemical properties of the mitochondrial Ca2+ uniporter have previously been extensively 
characterized (for review see (Gunter et al., 2000)), but its molecular identity was only 
recently discovered.  This has sparked a surge of advances in our knowledge of the 
mitochondrial Ca2+ transport system and its components, as described below.  The recent 
discovery of these proteins provides many potential new targets for regulation of 
mitochondrial Ca2+ uptake and its role in bioenergetics, cell survival and cell death.   
MCU 
In 2011, a protein was simultaneously identified by two groups, and named the 
mitochondrial Ca2+ uniporter (MCU) (Baughman et al., 2011; De Stefani et al., 2011).  It was 
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demonstrated to have all of the previously identified characteristics of the MCU, and to be 
essential and sufficient for channel activity.   
The uniporter had been previously described as a rapid electrogenic transporter which takes 
up Ca2+  into the matrix driven by an electrochemical potential gradient for Ca2+, which 
includes the mitochondrial membrane potential (∆Ψ) generated by the respiratory chain 
(Kirichok et al., 2004).  It had been demonstrated that MCU mediated Ca2+ uptake occurs 
almost immediately after  a rise in cytosolic [Ca2+] and that mitochondria could rapidly 
accumulate Ca2+ concentrations of over 100µM (Montero et al., 2000).  The previously 
disputed low affinity of the MCU (KD 20-30µM) had been explained by the discovery that 
mitochondria lie in close proximity to the Ca2+ channels of the endoplasmic reticulum (ER), 
sarcoplasmic reticulum (SR), and plasma membrane, and act by sensing microdomains of 
high Ca2+ (David et al., 1998; Glitsch et al., 2002), thus revealing that mitochondria respond 
to a rapid and transient event.   
The identification of the MCU gene was made possible by the generation of MitoCarta, a 
mitochondrial gene data set detailing gene products with known mitochondrial localization 
(Pagliarini et al., 2008).  Both groups used an in silico search - although with different 
criteria: the Mootha group searched for genes closely related to MICU1, which the same 
group had previously described as essential for mitochondrial Ca2+ uptake (see below), 
whereas the Rizzuto group searched using also using the expected properties of the 
uniporter - to identify the gene ccdc109a.  The gene is located on chromosome 10, and 
produces a 40kDa protein, with a 35kDa mature form after cleavage of its mitochondrial 
targeting sequence, which was found to interact with MICU1 (Baughman et al., 2011).  The 
gene is ubiquitously expressed in mammalian tissues, but absent in S. cerevisiae which are 
known to lack a mitochondrial Ca2+ transporter (De Stefani et al., 2011).  Both groups also 
determined (in HEK293T and HeLa cells) that MCU is essential for mitochondrial Ca2+ uptake: 
MCU silencing almost completely eliminates mitochondrial Ca2+ uptake in intact and 
permeabilised cells, and that MCU overexpression increases uptake (Baughman et al., 2011; 
De Stefani et al., 2011).  The identity of the MCU was further confirmed by measuring the 
electrophysiological properties of the purified protein expressed in a planar lipid bilayer – 
which matched those previously found through patch clamping the IMM in mitoplasts 
(Kirichok et al., 2004) - and the first insight into its structure was determined by the finding 
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that the mutation to glutamine of two negatively charged residues (D260Q, E263Q) could 
abolish MCU activity (De Stefani et al., 2011).   
The initial publications suggested a topology with two transmembrane α-helices with a 
highly conserved DIME motif of acidic residues (EYSWDIMEP) linking the two.  It has since 
been confirmed that both the N and C terminals are in the mitochondrial matrix, and that 
the DIME motif faces the intermembrane space; this has been determined through the 
development of genetically encoded APEX tags for electron microscopy (Martell et al., 
2012).  An in silico model of the quaternary structure of the MCU suggest four identical 
subunits, each containing two helical membrane spanning domains and a short connecting 
water exposed loop containing a DIME motif (Raffaello et al., 2013).  This loop region 
contains critical negatively charged amino acids previously identified as essential to MCU 
function (Baughman et al., 2011; De Stefani et al., 2011).  The structure suggests high 
sensitivity, with a selectivity filter containing highly conserved acidic residues, able to 
identify a single Ca2+ ion above the channel pore.  It is likely that the MCU has a stable 
closed state conformation.  Experimental investigation of this model confirmed that MCU 
monomers interact and form 170kD tetramers; these can be homo- or hetero-oligomers 
(Raffaello et al., 2013), see section on MCUb below.   
A variety of tissue specific work has since been done: the role of the MCU has been 
investigated in β-pancreatic cells (Alam et al., 2012), cardiomyocytes (Drago et al., 2012), 
and neurons (Qiu et al., 2013), among others.  In all of these tissues, MCU has been found to 
be essential for mitochondrial Ca2+ uptake, and to have additional tissue specific roles: in β-
pancreatic cells MCU (and MICU1, see below) was found to have a role in the secretion of 
insulin, in neurons MCU is transcriptionally repressed by synaptic activity resulting in 
protection against excitotoxic cell death, and in cardiomyocytes differing levels of MCU 
regulates cell contraction.  An MCU knockout mouse was created (Herzig et al., 2013; Pan et 
al., 2013), and the mice were found to be fully viable, although slightly smaller than usual, 
and the most apparent phenotypic abnormality was in their performance of high energy 
demand exercise – although basal metabolism was unaltered with a variety of metabolic 
substrates, there were some differences in the phosphorylation and activity of pyruvate 
dehydrogenase in MCU(-/-) mice skeletal muscle.  This was surprising as Ca2+ plays an 
important role in regulating metabolism, and in a follow up paper the authors reported that 
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they were surprised it has been possible to breed the mice at all – due to the important role 
of mitochondrial Ca2+ in a variety of processes it had been thought that the MCU (-/-) mouse 
would be embryonic lethal (Murphy et al., 2014), although curiously they reported that in 
C57 mice the knock out had been lethal during embryogenesis, at E11.5-13.5, due to 
unknown causes.  In the CD1 outbred strain of mice used to create the knockout, the 
pattern of inheritance was not Mendelian and only 12-15% of mice born were MCU (-/-), 
rather than the expected 25%.  This may suggest that in some cases it was embryonic lethal.  
It is unclear why the knock out was possible in CD1 mice and not C57, as there appears to be 
no functional compensation in the CD1s (Murphy et al., 2014).  In mitochondria isolated 
from CD1 MCU (-/-) mice, mitochondrial Ca2+ uptake was reduced - they were unable to 
rapidly uptake Ca2+ - but not absent,  and although they appeared to lack mPTP opening, 
this – surprisingly - does not appear to be protective against Ca2+ induced cell death (Pan et 
al., 2013).  This is in contrast to expectations, and the protective role of MCU knockdown 
found against neuronal cell death from excitotoxicity (Qiu et al., 2013).  Overall the findings 
from the MCU (-/-) mouse have confirmed the role of the MCU for rapid mitochondrial Ca2+ 
uptake, and for activation of mPTP, but in other areas were contrary to expectations, and 
have raised interesting questions for further studies.   
A conditional, cardiomyocyte-specific MCU knock out mouse has also been created (Kwong 
et al., 2015; Luongo et al., 2015).  These data agreed with the work by Pan et. al., on the lack 
of an overt phenotype, that MCU knock out prevented mitochondrial Ca2+ uptake (although 
mitochondria would eventually load with Ca2+, supporting the idea of a compensatory 
mechanism), and that mPTP opening was reduced.  However, Kwong et. al., found that 
reduced mPTP opening led to protection from necrotic death in ischaemia reperfusion 
injury, as was generally expected to be the case, whereas Pan had found no protection.  
Additionally, it was found that MCU is necessary to match metabolic output with contractile 
stress, as the mice had impaired ability to perform strenuous exercise (Kwong et al., 2015; 
Luongo et al., 2015).   
Although in the majority of models, the MCU by itself appears to be sufficient for 
mitochondrial Ca2+ uptake (De Stefani et al., 2011), it cannot provide the fine level of control 
over Ca2+ uptake required in the cell, and it has become clear that the MCU is part of a 
larger and more intricate complex.  This fine tuning is accounted for by other components of 
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the channel, MCUb and EMRE, and regulatory proteins MICU1, MICU2, MICU3, MCUR1 and 
SLC25A23, which together make up the MCU complex.   
 
MCUb 
Sequence analysis of CCDC109A (MCU) recently identified a new gene, CCDC109b, located 
on chromosome 4, which shares 50% sequence similarity with MCU, and is predicted to 
form a highly conserved protein  (MCUb) with two transmembrane domains separated by a 
short loop with a slightly different DIME motif to that of MCU (Raffaello et al., 2013).  The 
gene is present in vertebrates only, suggesting a later date of evolution than MCU; the 
MCUb protein is expressed at a lower level than MCU across multiple tissues, and with a 
different expression profile.   
It was found that in vitro expression established complete colocalization of the MCUb 
protein with MCU.  Immunoprecipitation demonstrated that MCU interacts in situ with 
MCUb, and FRET imaging further showed that MCUb forms hetero-oligomers with MCU, and 
homo-oligomers with itself.  MCUb can additionally form heterotetramers with MCU 
although the stoichiometry of these tetramers has not been determined.     
Predicted structural differences in the DIME motif between MCU and MCUb, due to the 
amino acid substitution E256V, appear to confer different functions on the two proteins by 
affecting the kinetics of Ca2+ permeation and reducing the Ca2+ permeability of MCUb, as a 
result of removing one negative charge.  Electrophysiology supported this, demonstrating 
that whilst MCUb forms a functional channel it is not capable of Ca2+ permeation, in contrast 
to MCU, thus suggesting a role for MCUb as a dominant negative isoform of MCU.  This was 
confirmed by coexpression of MCUb with MCU in a 1:1 ratio, which drastically reduced the 
Ca2+ activity of the channel compared to channels containing MCU only – although in 13% of 
experiments, coexpression of MCUb had no effect on Ca2+ conductance.    RNAi was used to 
silence or overexpress MCUb in intact cells; silencing of MCUb resulted in a significant 
increase of histamine induced mitochondrial Ca2+ peaks, whereas MCUb overexpression 
reduced mitochondrial Ca2+ peaks, without affecting levels of MCU protein, membrane 
potential, or cytosolic Ca2+ levels, confirming that MCUb specifically inhibits the function of 
the MCU protein (Raffaello et al., 2013).   
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MCUb thus has been demonstrated to be a dominant negative isoform of MCU, able to 
specifically inhibit pore activity by incorporation into channel forming heterotetramers, and 
thereby regulate mitochondrial Ca2+ uptake.  The varied expression profile of MCUb 
suggests the level of MCUb is carefully modulated depending on the degree of control over 
Ca2+ uptake necessary to the specific tissue function, suggesting an interesting and 
previously unknown plasticity of the MCU complex which invites further investigation.   
 
MICU1 
MICU1 was identified by integrated searching of IMM proteins in the MitoCarta database 
(Perocchi et al., 2010).  MICU1 is a 54kDa protein which has two Ca2+ binding EF hand 
domains contained in a single pass transmembrane domain, located in the intermembrane 
space (Lam et al., 2015).  MICU1 has been demonstrated to share the same evolutionary 
expression as MCU in a variety of mouse tissues (Bick et al., 2012), being found in all major 
categories of eukaryotic life, although with some protozoan and fungal losses; this suggests 
that both MCU and MICU1 may have been an evolutionarily early feature of mitochondria.  
MICU1 was originally found to be a positive regulator of mitochondrial Ca2+ uptake: silencing 
of MICU1 abrogated mitochondrial Ca2+ entry without affecting membrane potential or 
respiration (Perocchi et al., 2010).   
However subsequent papers quickly disagreed with this role: MICU1 silencing was found to 
have no effect on histamine induced Ca2+ uptake, but significantly increased basal Ca2+ levels 
(Mallilankaraman et al., 2012b), and MICU1 silencing did not prevent mitochondrial Ca2+ 
uptake.  This suggested that MICU1 acts as a gatekeeper, by restricting Ca2+ entry during low 
intracellular Ca2+ concentrations; it was proposed that when high matrix Ca2+ concentrations 
were reached, the Ca2+ sensing EF hands of MICU1 would bind Ca2+ and inhibit MCU 
mediated Ca2+ entry, thus requiring the EF hands to lie in the mitochondrial matrix.  This was 
supported by the finding that MICU1 localizes to the matrix side of the IMM and binds to 
MCU independently of the EF hands, in a homo-oligomeric form (Hoffman et al., 2013).  
Hoffman and colleagues determined the mechanism of MICU1 interaction with MCU: the 
association was found to be between the coiled coil domains of MCU and the N terminal 
polybasic region of MICU1, and the homo-oligomerization of MICU1 was shown to be 
independent of this region.   
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Conversely, the matrix-sensitive MICU1 theory was then contested by the publication of 
another examination of the topology of the MCU: it was found that MICU1 faces the 
intermembrane space not the matrix (Csordás et al., 2013), suggesting that it may primarily 
respond to cytosolic Ca2+ concentrations rather than mitochondrial.  The sensitivity of 
MICU1 to specifically cytosolic Ca2+ was further supported by the findings that when MICU1 
was silenced, at cytosolic [Ca2+] of less than 2µM the rate of mitochondrial Ca2+ uptake was 
increased but at high cytosolic [Ca2+] (>4µM) it was decreased (de la Fuente et al., 2014), 
reinforcing the MICU1 as gatekeeper role.  These findings suggested that MICU1 alone is 
responsible for the sigmoidal response of the mitochondria to cytosolic Ca2+: mitochondria 
have a very large Ca2+ loading capacity at high extramitochondrial [Ca2+] in order to ensure 
rapid responses to cell events, but at resting cytosolic [Ca2+], the uptake is very low (see 
Figure 1.5).  Although Csordas et. al., agreed with Mallilankaraman et. al., that MICU1 is 
essential to keep MCU closed (as MICU1 silencing causes mitochondrial Ca2+ uptake at low 
cytosolic [Ca2+], other findings by Csordas supported the original findings (Perocchi et al., 
2010): that MICU1 silencing abolishes mitochondrial Ca2+ uptake, and resting mitochondrial 
Ca2+ concentrations are unchanged.  There is currently still much debate over the exact role 
and mechanism of MICU1, and further study is needed to confirm and refine the existing 
theories.   
The recently derived crystal structure of MICU1 offers further insight into the mechanism by 
which MICU1 operates (Wang et al., 2014).  It was proposed that when in a Ca2+-free state, 
MICU1 forms an inhibitory hexamer that binds to MCU; upon Ca2+ binding the hexamer 
undergoes large conformational change (especially at the EF hands) to form multiple 
oligomers which activate MCU – the EF hands and a C-helix are both necessary for activation 
(Wang et al., 2014), see Figure 1.5.  Modelling suggested an affinity of MICU1 for Ca2+ of 15-
20µM, in contrast to the low affinity of MCU, which was suggested to imply that Ca2+ uptake 
may be mediated by multiple channels governed by proteins with different Ca2+ affinities.  
Whilst this structure furthers our understanding, it also raises further questions as to where 
and how the other components of the MCU complex fit into this structure – something yet 
to be answered.   
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Figure 1.5: MICU1 acts as a gatekeeper, ensuring the sigmoidal response of mitochondria to cytosolic [Ca
2+
] by 
undergoing a conformational change on Ca
2+
 binding. Top: mitochondrial Ca
2+
 uptake is sigmoidal: at low cytosolic 
concentrations, mitochondrial Ca
2+
 uptake is low, after MICU1 activation and conformational change, mitochondrial Ca
2+
 
uptake increases rapidly, and eventually plateaus.   In MICU1 -/- cells, resting mitochondrial [Ca
2+
] and rate of 
mitochondrial Ca
2+
 uptake are higher, although peak mitochondrial [Ca
2+
] is unchanged.  Bottom: Ca
2+
 binding causes a 
large conformational change in the MICU1 protein: in Ca
2+
 free MICU1 (left) forms a hexamer which binds to and inhibits 
MCU, whereas Ca
2+
bound MICU1 (right) forms multiple MCU activating oligomers.  One Ca
2+
 ion binds to the EF hand of the 
N-lobe, and one ion to the EF hand of the C-lobe; the C-helix is essential for the formation of the Ca
2+ 
free hexamer.  
Models are based on Logan et al 2014, and Wang et al 2014.   
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A recent paper provided an interesting insight into the role of MICU1 in disease: fibroblasts 
from patients with MICU1 loss-of-function mutations were studied to examine Ca2+ uptake 
and mitochondrial characteristics (Logan et al., 2014).  The MICU1 deficient patients 
presented symptoms in childhood, beginning with proximal muscle weakness, elevated 
serum creatine kinase levels and learning difficulties.  10 of 15 subjects developed variable 
motor disorders with involuntary movements, and patients presented various other 
features indicative of mitochondrial disorders (e.g., ataxia, optic atrophy, microcephaly), 
although none suffered from diabetes mellitus, deafness or cardiomyopathy, which are 
symptoms of other mitochondrial diseases (Logan et al., 2014).  Muscle biopsies showed 
core myopathies (areas lacking mitochondria) and other myopathic features.  Upon imaging 
the mitochondria of the patient fibroblasts, it was found that MICU1 deficiency resulted in 
severe mitochondrial fragmentation without affecting ΔΨm, and that the rate of agonist 
stimulated Ca2+ uptake was increased despite the peak mitochondrial Ca2+ being unchanged, 
suggesting an increased mitochondrial [Ca2+] at lower cytosolic [Ca2+] (see Figure 1.5).  It was 
confirmed that the mitochondrial [Ca2+] was higher in MICU1 deficient cells at rest, and that 
the absence of MICU1 caused the loss of the typical sigmoidal curve of mitochondrial Ca2+ 
uptake.  Overall oxygen consumption was not affected in the MICU1 deficient cells, although 
NADPH levels were higher.  This complex mitochondrial phenotype suggests MICU1 has an 
essential role in the MCU complex, which begs further enquiry.   
 
MICU2 and MICU3 
Genome sequence analysis revealed two homologues to MICU1: EFHA1 (MICU2) and EFHA2 
(MICU3), two genes which each share 25% sequence identity with MICU1, and are 
conserved in vertebrates (Plovanich et al., 2013).  Multiple sequence alignment suggests 
that MICU2 and MICU3 evolved from MICU1 prior to vertebrate evolution.  MICU2 and 
MICU3 both localize to mitochondria, in the intermembrane space (Lam et al., 2015), but 
have significantly different expression patterns; MICU1 is more broadly expressed than 
either of its paralogues, MICU2 is expressed most strongly in visceral organs and MICU3 
predominantly in the central nervous system and skeletal muscle, and is not exclusively 
mitochondrial.  Nothing further is yet known about MICU3.   
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MICU1 was suggested to stabilise MICU2: when MICU1 is knocked down, the protein level of 
the MICU2 is also reduced, although MICU2 mRNA levels are not affected, suggesting a post 
translational modification of MICU2 by MICU1; this effect appears to vary between cell 
types.  MICU2 was demonstrated to associate with the MCU/MICU1 complex, and MICU2 
silencing did not affect membrane potential or mitochondrial respiration (Plovanich et al., 
2013).  Mitochondria isolated from mouse liver in which MICU2 or MICU1 had been silenced 
demonstrated impaired Ca2+ handling; when both MICU1 and MICU2 were silenced this 
effect was increased, suggesting that MICU1 and MICU2 have independent, but possibly 
overlapping roles.  This is somewhat supported by the findings of another group, which 
demonstrate that loss of MICU1 or MICU2 leads to a significant reduction in Ca2+ uptake and 
an altered Ca2+ threshold, but that the presence of MICU1 is a requirement for the activity 
of MICU2, and its association with MCU (Kamer and Mootha, 2014).  This suggests that both 
MICU1 and MICU2 act as negative regulators of Ca2+ transport through the pore.  MICU2 
was reported to have conserved EF hands similar to those of MICU1; it was found that 
mutation of these hands in either MICU1 or MICU2  abolishes mitochondrial Ca2+ uptake, 
suggesting they have a crucial functional role (Kamer and Mootha, 2014).   
However, the function of MICU2 as suggested by Plovanich and Kamer was contested by the 
publication of data suggesting that MICU2 controls MCU in the opposite manner to MICU1 
(Patron et al., 2014); whilst this agrees with the previous papers in that MICU1 and MICU2 
play non-redundant roles, the suggested role of MICU2 is entirely different.  It was here 
demonstrated that MICU1 increases the probability of MCU opening in lipid bilayers, 
whereas MICU2 levels appears to inversely control MCU mediated uptake, and thus 
proposed that whilst MICU2 inhibits MCU activity at low [Ca2+], MICU1 stimulates MCU 
activity at high [Ca2+].  It was also shown that MICU1 and MICU2 form a 95kDa dimer which 
interacts with MCU in the DIME motif – a contrast to the 408kDa complex in which MCU, 
MICU1 and MICU2 were found to associate by Plovanich et. al.   
The possibility of contrasting roles, and an interdependence of MICU1 and MICU2 protein 
levels could explain some of the previous conflicting data over the role of MICU1 - it is 
generally agreed that MICU1 silencing does not affect levels of MCU protein 
(Mallilankaraman et al., 2012b; Csordás et al., 2013), although a study in mouse liver 
demonstrated altered protein (but not mRNA) MCU levels when MICU1 was silenced 
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(Plovanich et al., 2013) - perhaps MICU1 silencing also affects MICU2 levels in a tissue 
specific manner, giving rise to varied results.  A recent paper gave more insight on the link 
between MICU1 and MICU2: it was found that the oxidoreductase Mia40 mediates the 
formation of disulphide bonds between the two proteins to form a heterodimer (Petrungaro 
et al., 2015).  It suggested that rather than one MICU protein having an activating role and 
one having an inhibitory, that it is their interaction which confers the action on MCU.  The 
absence of this bond results in increased mitochondrial Ca2+ uptake, the presence of the 
bond, and thus the inhibitory dimer, is Ca2+ dependent: at low [Ca2+], the dimer associates 
with MCU, and at high [Ca2+] concentrations it dissociates. Once more, further work is 
needed to clarify the role of MICU1 and MICU2, and their relative functions to each other.   
 
EMRE 
Essential MCU regulator (EMRE) was identified by quantitative mass spectrometry of 
purified uniporter complex (Sancak et al., 2013).  It is a 10kD protein, predicted to have a 
mitochondrial targeting sequence, a transmembrane domain and an aspartate rich 
conserved C terminus.  It appears to be expressed in all mammalian tissues.  Interestingly, 
EMRE is metazoan specific, not being found in plants, fungi, or protozoa, whereas MCU and 
MICU1 are found in all eukaryotic lineages, suggesting EMRE evolved at a later point in time 
than MCU and MICU1.   
EMRE silencing resulted in loss of mitochondrial Ca2+ uptake similar to that induced by 
silencing of MCU; mitochondrial membrane potential and the abundance of other uniplex 
proteins were not affected.  Uptake was not recoverable by overexpression of MCU, 
suggesting MCU alone is not sufficient for in vivo uniporter current and that EMRE is 
necessary.  This was confirmed by voltage clamping EMRE-deficient mitoplasts and 
measuring mitochondrial Ca2+ current, which was severely reduced in mitoplasts lacking 
EMRE.  EMRE has an additional integral role in mediating the association between MCU and 
MICU1/MICU2; it is proposed that EMRE forms a link between the Ca2+ sensing activity of 
MICU1 and MICU2 in the intermembrane space, and the channel activity of MCU in the 
inner membrane.  
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In the absence of MCU, EMRE stability was found to be compromised, and in the absence of 
EMRE, the MCU complex was found to be smaller, suggesting that EMRE could be an 
essential assembly protein for the MCU complex.  Supporting this idea, in a paper 
reconstituting the MCU complex in yeast, EMRE was a necessary component for the 
function of a mammalian channel, but not a fungal channel (Kovács-Bogdán et al., 2014).  
Currently, EMRE has only been investigated in HEK293T and HeLa cells (Sancak et al., 2013), 
and briefly in yeast (Kovács-Bogdán et al., 2014), and awaits investigation in further cell lines 
and types.   
 
MCUR1 
Mitochondrial Ca2+ uniporter regulator complex 1 (MCUR1) was identified by RNAi screening 
of mitochondrial membrane proteins proposed to have roles in mitochondrial Ca2+ handling; 
RNAi against the gene CCDC90A was found to inhibit mitochondrial Ca2+ uptake 
(Mallilankaraman et al., 2012a).  CCDC90A was found to code for a 40kD protein (now 
designated MCUR1) that localizes to the inner mitochondrial membrane; it is predicted to 
contain two transmembrane helices, with the N and C termini both facing the cytosol.  Using 
immunoprecipitation, MCUR1 was found to bind to MCU but not to MICU1 – although 
MICU1 was also found to bind to MCU when MCUR1 was not bound - or other endogenous 
inner membrane proteins.   
The role of MCUR1 was investigated through the generation and testing of stable MCUR1-
knockdown cell lines, which demonstrated significant inhibition of the mitochondrial Ca2+ 
rise after stimulation in intact and permeabilised cells; this inhibition was reversed by 
MCUR1-rescue shRNA, and MCUR1 overexpressing cells showed an increased (Na+/Ca2+ 
exchanger independent) mitochondrial Ca2+ uptake ability.  The inhibition of mitochondrial 
Ca2+ uptake was proportional to the level of MCUR1 knockdown: in clones in which MCUR1 
knockdown was high (>80%), Ca2+ uptake was almost entirely abrogated, whereas clones 
with only a partial knockdown of MCUR1 demonstrated an intermediate inhibition of Ca2+ 
uptake.  MCUR1 mediated Ca2+ uptake was demonstrated to be dependent on MCU: cells 
overexpressing MCUR1 showed increased mitochondrial Ca2+ uptake, however MCU 
knockdown significantly reduced this uptake.  MCU overexpression was not able to rescue 
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the reduced mitochondrial Ca2+ uptake seen in MCUR1 knockdown cells, showing both 
proteins are required for uptake.   
MCUR1 was suggested to have a regulatory role in MCU mediated mitochondrial Ca2+ 
uptake: knockdown had no effect on ΔΨm, mitochondrial DNA copy number or MCU 
localization, however in MCUR1 deficient cells MCU mRNA and protein levels were 
increased.  MCUR1 was also found to have a role in oxidative phosphorylation, as MCUR1 
knockdown cells demonstrated reduced basal oxygen consumption, constitutively activated 
AMPK, enhanced AMP/ATP ratio (by two fold), and induced pro-survival macroautophagy, 
suggesting MCUR1 is essential for the preservation of typical cellular bioenergetics.   
Overall, MCUR1 was identified as an essential, inner mitochondrial membrane localized 
protein necessary for mitochondrial Ca2+ uptake.  Loss of MCUR1 protein reduced 
mitochondrial Ca2+ uptake in a proportional manner, and interfered with basal metabolism.  
MCUR1 and MCU appeared to act in a dependent manner, and were shown to bind each 
other in the absence of MICU1; knockdown of MCUR1 did not affect MCU localization or 
abundance, suggesting it has a regulatory role, and leading to the designation of the protein 
as the mitochondrial Ca2+ uniporter regulator 1 (Mallilankaraman et al., 2012a).   
However, in 2015, a new study was published identifying MCUR1 as a cytochrome c oxidase 
assembly factor, and not a direct regulator of the MCU complex (Paupe et al., 2015).  It was 
found that knocking down CCDC90A produces a specific defect in cytochrome c oxidase 
(COX) assembly, which resulted in decreased membrane potential and consequently 
decreased mitochondrial Ca2+ uptake.  COX consists of 14 subunits, of which COXI-III are 
encoded by the mitochondrial genome, and form the catalytic core of the enzyme.  The 
molecular process involved in the assembly of the COX complex is not fully understood.  In 
this study, a MCUR1 knockdown cell line was created and the levels of the COX subunits 
assessed: it was found that levels of COXI and COXII were reduced, but levels of the other 
components of the ETC were unaffected (Paupe et al., 2015).  The article compared the 
MCUR1 knockdown cell line to patient fibroblasts from patients with a COX assembly defect, 
to establish that the reduced ΔΨm and impaired mitochondrial Ca2+ uptake observed in the 
MCUR1 knockdowns could be caused by a COX assembly defect.  It was argued that a 
homolog of CCDC90A, fmp32 in yeast, produces a COXIV defect, and that the reduction in 
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mitochondrial Ca2+ uptake used as evidence by Mallilankaraman of MCUR1’s role as a MCU 
regulator is merely a consequence of the impaired ΔΨm, itself a consequence of the 
impaired oxygen consumption resulting from defective COXIV.   
The paper demonstrated that whilst COX assembly rates were not affected in MCUR1 
knockdown cells, COXII had a much higher turnover rate in knockdowns than in controls, 
and suggested an alternative function for MCUR1 as a chaperone for COXII, in order to 
stabilize it until the formation of the COX complex (Paupe et al., 2015).  However, the exact 
role of MCUR1 is still not clear, and requires further investigation.   
 
Solute Carrier 25A23 
The mitochondrial carrier superfamily are a family of transport proteins found mostly in the 
IMM, responsible for the transport of inorganic ions, amino acids, nucleotides, cofactors, 
and metabolites across the membrane.  There are two major groups of Ca2+ sensitive 
mitochondrial solute carriers, the aspartate/glutamate carriers (Lasorsa et al., 2003) and the 
ATP-magnesium carriers (Fiermonte et al., 2004).  Solute carrier SLC25A23, an Mg-ATP/Pi 
carrier, and it’s paralogues SLC25A24 and SLC25A25 contain functional, Ca2+ sensing, EF 
hands (Bassi et al., 2005) and the deletion of SLC25A23 reduces oxidative phosphorylation 
(Amigo et al., 2013).  Due to these properties, and predictions that they would form 
multiprotein complexes located on the IMM, the SLC25 family were previously identified as 
being of interest during the search for the molecular identity of the MCU (Mallilankaraman 
et al., 2012a).  Similarly to the MCU, solute carriers are extensively found in eukaryotes, and 
SLC25A23 is highly expressed in brain, heart, skeletal muscle, liver, and small intestine (Bassi 
et al., 2005).  In 2014, the solute carriers were examined in further detail, and it was 
reported that knockdown of SLC25A23 reduces mitochondrial Ca2+ uptake while interacting 
with MCU and MICU1, and that the EF-hand domains of SLC25A23 are necessary for its 
function (Hoffman et al., 2014).   
Knockdown HeLa cell lines were created using shRNA targeting either SLC25A23, SLC25A24, 
or SLC25A25, and it was found by confocal microscopy that cells in which SLC25A23 were 
knocked down demonstrated reduced mitochondrial calcium uptake, and decelerated 
cytosolic Ca2+ clearance (Hoffman et al., 2014).  Cells in which either SLC25A24 or SLC25A25 
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were knocked down were not affected, and none of the knock downs altered total 
mitochondrial Ca2+ or mitochondrial Ca2+ efflux.  Using overexpression constructs of a 
mutant version of SLC25A23’s EF hands, it was demonstrated that the EF hands are 
necessary for Ca2+ sensing and uptake, and it was found by co-immunoprecipitation that 
SLC25A23 interacts with both MCU and MICU1 (Hoffman et al., 2014).  This is in contrast to 
the SILAC study which identified EMRE (Sancak et al., 2013), which did not identify 
SLC25A23 as a part of the MCU complex.   
SLC25A23 knock down did not alter mitochondrial morphology or membrane potential, 
demonstrating that the reduction in mitochondrial Ca2+ uptake was not a side effect of 
altered ΔΨm.  It was also found that whilst SLC25A23 had no effect on basal mitochondrial 
bioenergetics or mitochondrial DNA copy number, ROS levels were decreased in knockdown 
cells, and levels of the antioxidant glutathione were increased (Hoffman et al., 2014).  
Interestingly, SLC25A23 knockdown was also protective against t-butyl hydroperoxide stress 
in a cell death assay, suggesting SLC25A23 has a role linking mitochondrial Ca2+ uptake, 
oxidative stress, and cell death.  Several other members of the SLC25 family are also known 
to have involvement in Ca2+ sensing and metabolism: SLC25A24 is involved in the regulation 
of the ADP/ATP ratio in the mitochondrial matrix (Traba et al., 2012), and aralar (SLC25A12), 
which is located on the IMM, increases NAD(P)H levels in response to Ca2+sensing 
(Satrústegui et al., 2007).  These observations have led to the suggestion of a mitochondrial 
Ca2+ transportome, in which the components of the MCU complex are functionally 
integrated with the mitochondrial solute carriers, which form a microenvironment around 
the uniporter (Hoffman et al., 2014).   
 
Involvement of other proteins in mitochondrial calcium uptake 
 
Due to the surprising results from the MCU knock out mouse (Pan et al., 2013), it has been 
suggested that there may be some functional compensation: that in the absence of MCU, 
mitochondria are able to utilise other pathways for Ca2+ uptake (Murphy et al., 2014).  
These could include the proteins mentioned below, the reversal of the H+/Ca2+ and Na+/Ca2+ 
exchangers, or proteins as yet undiscovered; for review, see (Pendin et al., 2014).  Beyond 
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the MCU complex, there exist other proteins involved in mitochondrial Ca2+ uptake – 
possible candidates for involvement in any parallel system - of undefined roles, such as 
Letm1 and UCP2 and UCP3.     
Leucine zipper EF hand-containing transmembrane protein 1 (Letm1) was identified in 1999 
as a Ca2+ binding protein (Endele et al., 1999), and later as an IMM Ca2+/H+ antiporter which 
undergoes extremely sensitive Ca2+ loading with slow kinetics  (Jiang et al., 2009).  The 
functional role of Letm1 is unresolved, although recently a publication demonstrated that it 
has a role in the control of cellular bioenergetics and proliferation (Doonan et al., 2014).  
Uncoupling proteins 2 and 3 (UCP2/3) are IMM ion transporters, which unlike uncoupling 
protein 1 (UCP1), UCP2/3 are not thought to have a role in heat production (Krauss et al., 
2005).  In 2007 they were identified as being essential for mitochondrial Ca2+ uptake, when 
knockdown of either protein was found to reduce, or in some cases abolish mitochondrial 
Ca2+ uptake in response to agonist stimulation, without affecting cytosolic Ca2+ levels 
(Trenker et al., 2007).  However, another paper found shortly afterward that neither UCP2 
or UCP3 knock out mice showed any differences in Ca2+ uptake in isolated mitochondria, 
and argued that the Trenker work used inappropriate controls and tissue samples (Brookes 
et al., 2008).   
A further study in 2011 aimed to clarify the respective role of these proteins.  It was 
demonstrated that UCP2/3 and Letm1 mediated Ca2+ signals are from different Ca2+ sources: 
UCP2/3 were demonstrated to account for Ca2+ uptake from ER-derived intracellular Ca2+ 
release, and Letm1 for store-operated Ca2+ entry (SOCE) (Waldeck-Weiermair et al., 2011).  
These paths were found to be independent of each other, as knockdown of both UCP2/3 
and Letm1 had an additive effect, and knockdown of Letm1 during overexpression of UCP3 
did not reduce the increased Ca2+ uptake caused by UCP3 overexpression.  As this study was 
carried out prior to the identification of the MCU, the link between these pathways and the 
MCU was not explored, however the pathways were found to be independent of MICU1, 
which was then known (Waldeck-Weiermair et al., 2011). Defining the exact role of these 
pathways, and their relation to each other and MCU, is still an outstanding question.   
 
 48 
The mitochondrial permeability transition pore 
 
The mitochondrial permeability transition pore (mPTP) is a non-specific pore which opens in 
the inner mitochondrial membrane, allowing the passage into the mitochondria of 
molecules <1.5kDa, an event called the mitochondrial permeability transition.  The pore was 
first identified as such by Haworth and Hunter (Haworth and Hunter, 1979; Hunter and 
Haworth, 1979a, b), although it had previously been observed that exposure to high Ca2+ 
concentrations resulted in mitochondrial swelling which was partially reversible by calcium 
chelation (CHAPPELL and CROFTS, 1965; CROFTS and CHAPPELL, 1965).  Patch clamp studies 
on mammalian mitoplasts followed, which revealed the presence of a high conductance 
channel, called the mitochondrial mega channel (MMC), which possessed all the features of 
the mPTP (Kinnally et al., 1989) (Petronilli et al., 1989).  The role of mPTP in healthy cells is 
not yet clear.  One proposal is that ageing mitochondria which are becoming more 
vulnerable to mPTP opening, may have transient openings of mPTP which mark them for 
recognition by autophagic vacuoles, thus keeping the cell’s mitochondrial population 
healthy (Rodriguez-Enriquez et al., 2004).  Short term openings of the mPTP may have a 
physiological role in Ca2+ regulation (by providing a quick release mechanism), and ROS 
homeostasis (Petronilli et al., 2001; Zorov et al., 2014).  In disease states in which previously 
healthy cells experience conditions that lead to the mitochondrial permeability transition, 
the opening of the mPTP is a mitochondrial catastrophe which, unless reversed, results in 
cell death (see Figure 1.6).   
 
Mechanism of mPTP opening  
The primary stimulus for the opening of the mPTP is matrix Ca2+ concentration.  Although 
the specificity for Ca2+ appears to be absolute, the concentration is not – the concentration 
of calcium required for the opening of mPTP is highly dependent on the conditions within 
the cell.  Factors such as oxidative stress, increased phosphate concentrations or decreased 
adenine nucleotide concentrations contribute to mPTP opening (Halestrap et al., 2004), 
whereas factors such as the presence of other divalent cations (Sr2+, Mn2+, Ba2+ and Mg2+), 
and low pH act as inhibitors (Halestrap, 1991; Bernardi et al., 1992).  High [Ca2+] is not 
always an essential requirement: in mitochondria isolated from MCU (-/-) mice, the extent 
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of necrosis after ischaemia-reperfusion injury did not differ from wild-type littermates, 
despite the lack of mitochondrial Ca2+ overload (Pan et al., 2013), although in conditional 
MCU knock out mice there was protection against IR injury (Kwong et al., 2015; Luongo et 
al., 2015).  Therefore, addition of Ca2+ is not always necessary for pore opening, as an agent 
which increases a pore inducing condition such as oxidative stress, can sensitize 
mitochondria to the existing matrix Ca2+, and thus result in pore opening.   
When the mPTP opens, protons are able to freely cross the inner mitochondrial membrane, 
meaning that the proton motive force, and resulting mitochondrial membrane potential are 
lost.  Consequently, oxidative phosphorylation is uncoupled, and the ATP synthase reverses 
its direction of action; this means that the mitochondrion not only stops producing ATP, but 
consumes it.  As ATP is free floating in the cell, mitochondria in which the mPTP has opened 
will consume the ATP produced by other mitochondria and by glycolysis, leading to a 
bioenergetics crisis in the cell (Halestrap et al., 1998).  There is also an abrupt increase in 
permeability: mitochondrial swelling occurs as a result of equilibration of all small molecular 
weight molecules between the mitochondrial matrix and the cytosol, as small molecules 
usually excluded from the mitochondria become able to travel through the mPTP into the 
mitochondrial matrix.   This causes osmotic pressure which results in swelling of the 
mitochondrial matrix; whilst this in itself is not problematic as the cristae unfold, the 
swollen matrix then exerts pressure on the outer mitochondrial membrane, which will 
eventually rupture (Bernardi et al., 2006).  As the mitochondrion ruptures cytochrome c, 
and other pro-apoptotic proteins (such as endonuclease G and AIF) are released which may 
lead to apoptotic cell death (Bernardi et al., 2006), although mPTP opening more commonly 
leads to necrotic cell death due to ATP depletion.   
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Figure 1.6: Irreversible opening of the mPTP leads to cell death.   
 
mPTP and cell fate 
There has long been evidence for transient opening of the pore (Crompton and Costi, 1990; 
Zoratti and Szabó, 1994).  It has been hypothesized that this is a mechanism for fast Ca2+ 
induced Ca2+ release, and plays a role in normal cellular Ca2+ homeostasis (Barsukova et al., 
2011).  Ca2+ uptake through the uniporter can rapidly accumulate Ca2+ into the 
mitochondria, but the efflux mechanisms (the Na+/ Ca2+ exchanger and the H+/ Ca2+ 
exchanger) are slow, meaning a sudden decrease in cytosolic Ca2+ cannot be immediately 
rectified by these pathways: transient opening of mPTP could provide a solution to this 
imbalance (Bernardi and Petronilli, 1996).  Transient opening of the pore can be measured 
by rapid changes between conductance states of the pore, and does not result in cell death 
(see Figure 1.6) (Petronilli et al., 2001; Zoratti et al., 2009); a recent paper demonstrated 
transient (575 seconds) opening in adult cardiac myocytes, which was suppressed by 
suppressing mitochondria Ca2+ uptake, by CsA, and in cyclophilin D knockout mice (Lu et al., 
2016).  This work also demonstrated that the transient pore is smaller in size, with 
permeability of <600Da.   
However, irreversible opening of mPTP marks a point of no return for the mitochondrion, 
and where widespread within the mitochondrial population, for the cell.  Opening of mPTP 
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can lead to cell death through either necrosis or apoptosis, depending on the dynamics of 
opening.  In order to undergo apoptosis, a cell must reach a threshold concentration of pro-
apoptotic factors (released from the intermembrane space by mitochondrial swelling and 
rupture), whilst maintaining sufficient ATP concentrations to carry out pro-apoptotic 
signalling and the assembly of the apoptosome (Rasola and Bernardi, 2011).  Necrotic cell 
death is caused by a deficiency in ATP levels, which through disruption of ionic, metabolic 
and Ca2+ homeostasis activates nucleases, phospholipases and proteases.  Conditions 
favouring apoptotic cell death may be accomplished when mPTP opens in localised sub 
populations of mitochondria, and even if mPTP opening does not happen on a large enough 
scale to deplete ATP levels, apoptosis may occur (Kinnally et al., 2011).  However, if a large 
portion of the mitochondria in a cell undergo mPTP opening simultaneously, this will lead to 
too immediate a loss of ATP to allow apoptosis, and cell death by necrosis will occur as a 
result of the elevated cytosolic [Ca2+] (Kinnally et al., 2011).   
 
Molecular identity of the mPTP 
To date there has been no definitive study which identifies the mPTP, although several 
candidates have been suggested, and structural components of the pore have been 
identified.   
Cyclophilin D  
CypD is a protein encoded by the PPIF gene (in mice) on chromosome 10.  It is synthesized in 
the cytosol and translocates to the mitochondria using a mitochondrial targeting sequence 
(Johnson et al., 1999).  Cyclophilin D was first identified as having a role in mPTP opening 
when it was observed that the potency of various CsA analogues correlated with the extent 
of their inhibition of a matrix peptidyl-prolyl cis-trans isomerase: cyclophilin D (Halestrap 
and Davidson, 1990).  Whilst CypD was not suggested to form the pore itself, its role was 
initially unclear.  This was clarified by the generation of Ppif-/- mice; isolated liver, heart and 
brain mitochondria from the mice do not exhibit CsA sensitive mPTP opening, but do exhibit 
mPTP opening at higher mitochondrial [Ca2+], and primary hepatocytes and fibroblasts are 
protected from Ca2+ overload (Baines et al., 2005; Nakagawa et al., 2005), thus 
demonstrating that cyclophilin D has a role in conferring Ca2+ sensitivity on the pore.  Loss of 
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CypD did not affect the ability of cells to undergo apoptosis, but were resistant to necrotic 
cell death, confirming the role of mPTP in necrosis (Nakagawa et al., 2005).  CypD has had 
an important role in the investigation of the identity of the mPTP, as interactions with it 
have often been used as evidence in favour of various candidates: it is accepted that 
whatever the identity of mPTP, it is an essential requirement that it is regulated by CypD.     
A multiprotein complex: VDAC, ANT, and TSPO 
For a long time, the voltage dependent anion channel (VDAC) and adenine nucleotide 
translocator (ANT) were considered prime candidates for the molecular identity of the 
mPTP.  The theory was founded by the discovery that the peripheral benzodiazepine 
receptor (TSPO) copurified with VDAC and ANT (McEnery et al., 1992).  High affinity ligands 
of TSPO were also identified in the fractions in which these three proteins were co-
expressed; this was of interest as these ligands were known to affect the 
electrophysiological properties of the MMC, thereby suggesting that these proteins could be 
structural components of mPTP (Kinnally et al., 1993).  This idea was further supported by 
the existence of OMM-IMM contact sites, which were proposed to facilitate transport of 
adenine nucleotides to and from the mitochondria; these contact sites included VDAC, ANT, 
hexokinase, and creatine kinase (Kottke et al., 1988).    It was shown that some of these 
fractions formed channels with conductance correlating to that of the mPTP, and conferred 
CsA-sensitive permeability to liposomes (Beutner et al., 1996); these fractions were 
enriched in hexokinases, but not in VDAC or ANT, and also contained Bcl-2 family proteins.  
This lead to the hypothesis that the mPTP was a multiprotein complex containing VDAD, 
ANT, TSPO, cyclophilin D, hexokinase and Bcl-2 family proteins (Zamzami and Kroemer, 
2001).   
Other groups focused on the ANT as the main candidate for the mPTP (Halestrap and 
Brenner, 2003).  This was due to its ability to bind cyclophilin D (Crompton et al., 1998; 
Woodfield et al., 1998), the fact that decreased adenine nucleotides enhance pore opening, 
and that two modulators of mPTP opening, carboxyatractyloside (CAT) and bongkrekic acid 
(BKA) are known to act on ANT (Halestrap and Davidson, 1990).  VDAC was another popular 
candidate: it also found able to bind cyclophilin D (Crompton et al., 1998), and it was 
reported that ubiquinone analogues (which inhibit mPTP) bind to an IMM protein which was 
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identified as VDAC (Cesura et al., 2003), although this was later proved erroneous 
(Krauskopf et al., 2006).     
However, these hypotheses were discredited by a range of knockout mice, in which mPTP 
was still found to occur in the absence of VDAC, ANT, and TSPO (Kokoszka et al., 2004; 
Krauskopf et al., 2006; Šileikytė et al., 2014).  Whilst these proteins may have a role in the 
regulation of mPTP, it is clear they are not essential structural components.   
The mitochondrial phosphate carrier 
Another proposition for the identity of the pore forming component was the mitochondrial 
phosphate carrier, PiC (Leung et al., 2008).  This was suggested due to the ability of the PiC 
to form nonspecific channels in lipid membranes, its direct interactions with CypD in the 
mitochondrial matrix, that mPTP-inhibiting ubiquinone analogues also inhibit PiC, and 
because Pi is a known activator of mPTP (Crompton et al., 1988; Leung et al., 2008).  
However, genetic deletion of the Slc25a3 gene (encoding the PiC) showed that mPTP 
opening could still occur without PiC, but opening was desensitized to Ca2+, confirming that 
the PiC has a regulatory, rather than a structural role (Kwong et al., 2014).   
ATP synthase  
Studies which tracked the interactions of matrix CypD with other mitochondrial proteins 
revealed another potential candidate for the mPTP: the F1F0 ATP synthase itself (Giorgio et 
al., 2009) (Chinopoulos et al., 2011).  There are currently two theories proposing different 
parts of the ATP synthase as candidates.   
The first suggests that the pore is formed from dimers of the ATP synthase (Giorgio et al., 
2013), see Figure 1.7A.  In the study, in phospholipid bilayers containing reconstituted 
dimers of F1F0 ATP synthase, they detected Ca
2+ activated channels with electrophysiological 
properties similar to those of mPTP.  However, channel opening required the presence of 
ATP synthase inhibitor benzodiazepine-423 (Bz-423), and high [Ca2+].  It was found that 
CypD binds to the oligomycin sensitivity conferring protein (OSCP) subunit of the ATP 
synthase, at the same site as the OSCP is bound by Bz-423.  It was further shown that Bz-423 
had a CypD like effect in sensitizing the pore to Ca2+, and that decreasing protein expression 
of OSCP increased the Ca2+ sensitivity of the pore. Channel opening was inhibited by AMP-
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PNP, a known inhibitor of ATP synthase, but the effects of the canonical inhibitor CsA were 
not investigated.  In a recent review, it was also noted that mPTP opening has previously 
been demonstrated in P0 cells lacking mtDNA for some subunits of the ATP synthase 
(Bonora et al., 2015).  An additional contradicting factor is the previous finding the 
dimerization of ATP synthase has previously been shown to be associated with increased 
efficiency of ATP synthesis (Campanella et al., 2008), which is in contrast to mPTP opening, 
which results in cellular ATP depletion.   
The second theory suggests the pore is formed by the c-subunit ring of the membrane 
spanning F0 subunit of the F1F0 ATP synthase.  This theory was first suggested by the finding 
in HeLa cells, that c-subunit siRNA inactivation results in cells with reduced mPTP opening 
(Bonora et al., 2013), and c-subunit overexpression increased mPTP opening, although the 
actual structural role of ATP synthase was not investigated.  In a second study it was 
demonstrated that the c-subunit ring undergoes conformational change on exposure to high 
matrix Ca2+ and becomes detached from the F1 subunit, suggesting a mechanism for PT 
(Alavian et al., 2014), see Figure 1.7B.  The suggested model was that the sites at which 
CypD, CsA and Ca2+ modulate mPTP activity are located on the F1 subunit, which dissociates 
from the c-subunit after Ca2+/CypD binding, enabling the c-subunit ring to expand to form a 
channel, the mPTP.  Reconstituted c-subunits were shown to form a voltage sensitive 
channel in lipid bilayers - sensitive to adenine nucleotides and anti-c-subunit antibodies - 
the opening of which resulted in depolarization of the IMM, although the channels 
conductance range was wide, and not always similar to that of mPTP. However, these 
channels were not sensitive to Ca2+ or CsA; this was further investigated by the 
reconstitution of F1F0 ATP synthase in lipid bilayers which resulted in some channel activity, 
which was increased by the addition of Ca2+ and CypD, and was prevented by CsA (although 
at an unusually high concentration), supporting the notion of a F1 binding site.  Additionally, 
sub-mitochondrial vesicles enriched in F1F0 formed channels sensitive to Ca
2+ and CsA, which 
were not present after the removal of the OSCP and -subunits respectively (located on the 
F1 subunit).  Finally, in HEK293T cells, Ca2+ induced opening and CsA induced closing was 
detected by fluorescent labelling of the c-subunit, and c-subunit depletion in HEK293T cells 
inhibited Ca2+  induced loss of ΔΨm and cell death.   
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Figure 1.7: ATP synthase may form mPTP.  A: A schematic of the Giorgio model.  ATP synthase in its closed state (left) is 
bound by Ca
2+
 and CypD as the OSCP, causing dimerization.  mPTP forms at the interface between two adjacent F0 
subunits.  B:  A schematic of the Alavain model.  ATP synthase in its closed state (left) is bound by Ca
2+
 and CypD at the 
OSCP, causing the c-subunit ring to expand, release the F1, and form the mPTP.  In the closed conformation the pore is 
blocked by the -subunits.   
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Currently, there is not sufficient evidence to conclude which of these theories (if either) is 
correct, but it is possible that both could be partially correct in an as yet unknown 
mechanism, perhaps involving the OSCP, which both theories agree has a role.  The 
interaction of ATP synthase with other regulators of mPTP such as ANT and PiC has not yet 
been investigated, and may shed further light on the mechanism of action, and the relation 
between the protein’s ATP synthesis activity and pore forming activity will also need 
investigation.  Regardless of which is more accurate, it has become apparent that ATP 
synthase may have a role in mPTP, which has interesting implications, especially regarding 
ATP synthesis/hydrolysis during PT.  Since publication of these theories, several responses 
have been published which highlight issues such as inconsistent channel activity, unusually 
high Ca2+ requirements for pore opening, and the protein purity of the sub-mitochondrial 
vesicles used for patch clamping (Halestrap, 2014; Chinopoulos and Szabadkai 2014; 
Chinopoulos and Szabadkai 2013; Szabadkai and Chinopolous 2013).   
Spastic paraplegia 7 
Another gene has recently been identified as being structurally involved in mPTP: spastic 
paraplegia 7 (SPG7) (Shanmughapriya et al., 2015).  Short hairpin RNA (shRNA) was used to 
individually silence mitochondrial proteins in HEK293T and HeLa cells, in order to assess the 
loss of function effect on Ca2+ and ROS induced mPTP opening, by measuring ΔΨm and 
mitochondrial Ca2+ retention.  
It was found that mitochondrial SPG7 was essential for forming the mPTP complex: ROS 
sensitive, Ca2+ induced mPTP opening was delayed in cells in which SPG7 was not present.  
This was also found to be the case for CyPD and VDAC1.  It was demonstrated by 
immunoprecipitation that SPG7 interacts with both CyPD (with it’s matrix portion) and VDAC 
(with it’s intermembrane space portion), and that C-terminal SPG7 is essential for CyPD 
binding, and for mPTP formation.  However, a critique of this study suggested that the 
screening approach is not sufficient to distinguish between core components and regulators 
of mPTP, and that the paper never demonstrated if the proposed VDAC and SPG7 pore 
forming complex was actually capable of forming a channel (Bernardi and Di Lisa, 2015).   
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Mitochondrial Ca2+ as a therapeutic target 
 
Role of mitochondrial Ca2+ overload in neurodegenerative disease 
Excessive mitochondrial Ca2+ uptake is a key step in the pathophysiology of many disease 
states, leading to Ca2+ overload and cell injury or death.   
Mitochondria have an essential role in the central nervous system (CNS), even more so than 
in other systems: Ca2+ dynamics are especially important in the CNS, as signal transduction 
between neurons occurs through the delicate spatiotemporal organisation of local [Ca2+].  
Mitochondria are also essential for maintaining the neuronal energy supply, which comes 
almost entirely from oxidative phosphorylation (rather than glycolysis), although this is to 
some extent dependent on the type of neural activity (Figley and Stroman, 2011; Ivanov et 
al., 2014).  Ca2+ also has a role in neuronal energy supply, as the rate limiting steps of the 
electron transport chain are Ca2+ dependent.  It has also been suggested that the cell-type 
selectivity of neuronal death in different neurodegenerative diseases could be due to 
differences in mitochondrial Ca2+ handling between cell types (Duchen, 2012), as there is a 
huge diversity of Ca2+ channels and receptors within the CNS. Therefore, neurons are 
especially vulnerable to mitochondrial dysfunction and it is a common feature of 
neurodegenerative diseases: mitochondrial defects have been found in Parkinson’s disease, 
Huntingdon’s disease, Alzheimer’s disease and Friedreich’s ataxia, among others (for 
reviews see (Damiano et al., 2010; Swerdlow et al., 2010; Winklhofer and Haass, 2010; 
González-Cabo and Palau, 2013).   
In 1985 it was found that prolonged exposure of neurons to glutamate resulted in Ca2+ 
induced cell death (Choi, 1985).  Glutamate induced excitotoxicity is a process in which 
increased Ca2+ influx in the cell (see Figure 1.8) causes mitochondrial Ca2+ overload resulting 
in increased cell death through necrosis and apoptosis (Stout et al., 1998; Abramov and 
Duchen, 2008).  This leads to the irreversible loss of neurons which characterises 
neurodegenerative disease.  This process occurs through the Ca2+ permeable glutamate 
receptors, the NMDA receptor and the AMPA receptor – while other receptors can also 
allow Ca2+ to enter neurons, it was discovered that there is a ‘source-specificity’ of Ca2+ 
toxicity, and that equal Ca2+ influx through other sources (for example the voltage gated 
Ca2+ channel) do not lead to toxicity and death (Tymianski et al., 1993).  This specificity is 
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due to the colocalization of these receptors with neuronal nitrous oxide synthase (nNOS), 
which produces the toxic nitrous oxide (NO) (Sattler et al., 1999), in addition to dangerously 
high Ca2+ concentrations.   
 
 
Figure 1.8: Ca2+ overload leads to neuronal cell death.  A reduction of ATP due to neuronal insult causes a rundown of ion 
gradients.  This leads to cell depolarization, resulting in loss of Ca
2+
 homeostasis, causing an influx of Ca
2+
 into neurons 
which ends in neuronal injury or death.  NMDA/AMPA receptor activation by glutamate creates a feedback loop by further 
depolarising cells, further increasing [Ca
2+
].   
 
The danger to mitochondria in glutamate toxicity is from the delayed calcium deregulation 
(DCD) which follows up to two hours after the initial glutamate exposure.  The DCD is 
characterised by a secondary, larger Ca2+ rise, simultaneous to a collapse of ΔΨm.  The DCD 
can be prevented using nNOS inhibitors, suggesting a causal link between the glutamate 
induced increase in NO, and the mitochondrial failure that occurs following loss of ΔΨm 
(Keelan et al., 1999; Vergun et al., 1999) – due to neuronal dependence on oxidative 
phosphorylation and their inability to provide sufficient energy through glycolysis, this leads 
to neuronal death.  Whilst this neuronal death is presumed to be mediated by the opening 
of mPTP, it has not yet been definitively proved that this is the case: although infarct size 
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was reduced in the CypD knockout mouse, mitochondria still underwent depolarisation 
after exposure to glutamate (Baines et al., 2005; Abramov and Duchen, 2008).  Whilst the 
mechanism of cell death is not clear, mitochondrial Ca2+ overload is clearly implicated in the 
pathogenesis of many neurodegenerative diseases.    
As mitochondrial Ca2+ overload is a critical checkpoint in cell survival, it has been proposed 
that inhibition of mitochondrial Ca2+ uptake may be protective against cell death.  If 
inhibition of mitochondrial Ca2+ uptake could be targeted to specific cell types or locations 
which were undergoing cell death then this could be a useful therapeutic intervention in 
diseases, such as neurodegenerative disease, which are characterized by excessive cell 
death.  Therefore, the study of the mitochondrial Ca2+ uptake machinery and the expansion 
of our understanding of its molecular function may have great therapeutic potential for the 
treatment of diseases in which Ca2+ induced cell death is a factor.   
 
Role of mPTP in neurodegenerative disease 
Many early researchers of mPTP focused on its role within the heart, as many of the 
activating conditions which stimulate mPTP opening are present during reperfusion 
following cardiac ischaemia (Crompton et al., 1987; Halestrap et al., 1998).  Inhibition of 
mPTP opening has long been the focus of intense research, and is known to be protective 
against cardiac cell death (Nazareth et al., 1991; Griffiths and Halestrap, 1993).  However, 
mPTP also plays an important role in the brain.   
Disruption of Ca2+ homeostasis is a common feature in many disorders of the CNS.  Ca2+ 
enters neurons through many paths: receptors, Na+/Ca2+ exchangers, and acid or voltage 
dependent ion channels (Szydlowska and Tymianski, 2010).  During brain ischaemia and 
neurodegenerative disease, reduced reuptake of neurotransmitters causes overstimulation 
of their receptors, resulting in nerve depolarization and activation of voltage dependent 
Ca2+ channels (for review see (Dong et al., 2009)).  Neuronal excitotoxicity is characterized 
by an excessive influx of Ca2+ into neurons, which results in the activation of hydrolytic 
enzymes, ROS formation, mitochondrial depolarization and eventually neuronal death.  
mPTP opening is believed to be the cause of this neuronal death, as has been demonstrated 
in cultured neurons (Pivovarova et al., 2004) and in mice (Schinzel et al., 2005), and mPTP 
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inhibitor CsA has been found to be protective against hypoglycemic and IR brain injuries 
(Friberg et al., 1998; Khaspekov et al., 1999).  Dysregulation of Ca2+ homeostasis is more 
common as neurons age and Ca2+ gradients in the cell are less tightly maintained, and in 
neurodegenerative disease this progressively worsens.   
Calcium dysregulation has been demonstrated to have a role in many neurodegenerative 
diseases.  For example, in Alzheimer’s disease, aggregates of amyloid beta (a hallmark of the 
disease) can cause the formation of Ca2+ permeable pores in neuronal plasma membranes 
and affect the activity of existing Ca2+ channels (Supnet and Bezprozvanny, 2010).  In 
Parkinson’s disease, characterised by aggregates of α-synuclein and loss of dopaminergic 
neurons in the substantia nigra, α-synuclein causes neuronal Ca2+ accumulation; in the 
autosomal recessive form of Parkinson’s caused by mutations in the PINK1 gene, there is 
dysfunction in the Na+/ Ca2+ exchanger of the IMM, which leads to increased mitochondrial 
calcium both in resting and stress conditions (Gandhi et al., 2009).  In Huntington’s disease, 
caused by mutations in the gene encoding the protein Huntingtin (htt), neurons carrying this 
mutant gene have been found to have dysregulated mitochondrial Ca2+ homeostasis, 
reduced Ca2+ buffering capacity,  and increased sensitivity of mPTP opening (Panov et al., 
2005; Gellerich et al., 2008; Lim et al., 2008).   
Ca2+ dysregulation can lead to mPTP opening through the exceeding of the mitochondrial 
Ca2+ buffering capacity, resulting in excess cell death.  Therefore, inhibitors which reduce 
mPTP opening as a result of Ca2+ dysregulation would be widely applicable to most 
neurodegenerative diseases, and mPTP is a desirable target for the treatment of these 
diseases.   
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Aims 
 
Ca2+ is crucially important to mitochondrial and cellular function.   
Mitochondria are capable of rapidly taking up Ca2+ through the MCU in response to cytosolic 
[Ca2+] increases, which affects mitochondrial energetics, morphology and autophagy, in 
addition to regulating localization, timing and amplitude of cytosolic Ca2+ waves.  The MCU 
was identified in 2011, and a series of associated proteins and regulators have been 
discovered since.  During pathological conditions, excessive mitochondrial Ca2+ uptake leads 
to matrix overload, stimulating the opening of the mPTP and leading to cell death.    
In this thesis, I investigated aspects of the mitochondrial calcium transport system, and how 
it can be targeted for therapeutic use.  My aims were:  
 To investigate the efficacy of a group of novel compounds as inhibitors of the mPTP. 
 To develop a novel screening approach to identify inhibitors of the MCU. 
 To investigate the physiological and pathophysiological role of the MCU and 
associated proteins through genetic manipulation, and to explore the relative 
protein levels of MCU and associated proteins through development. 
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Chapter 2: Targeting the Mitochondrial 
Permeability Transition Pore 
Introduction 
Existing inhibitors of mPTP 
 
As mPTP is a target for neuroprotection (Kristal et al., 2004), it is highly desirable to develop 
pharmacological agents which can target mPTP opening specifically and effectively, without 
unwanted side effects, and which can be protective even against the most potent of mPTP 
inducing stimuli.  Our lack of knowledge of the molecular identity of the mPTP is a 
bottleneck in the development of new therapeutic approaches, as it is difficult to determine 
the mechanism and safety of novel compounds when their target specificity cannot be 
assessed.  However, some compounds are known to inhibit (or desensitize) pore opening.   
Cyclosporin A was the first compound identified as an inhibitor of the mPTP ((Crompton et 
al., 1988; Szabó and Zoratti, 1991; Duchen et al., 1993; Griffiths and Halestrap, 1993).  CsA 
binds to cyclophilins; CsA binds to the cytosolic molecule cyclophilin A, which inhibits the 
protein phosphatase calcineurin, which activates T cell immune response via NFAT, thereby 
giving CsA immunosuppressive properties (see Figure 2.1).  It additionally binds to 
mitochondrial cyclophilin D, and through preventing the peptidyl prolyl isomerase activity of 
cyclophilin D, and preventing the binding of CypD to the adenine nucleotide transporter 
(ANT), thus reduces Ca2+ sensitivity of pore opening (Crompton et al., 1988; Woodfield et al., 
1998).  However, CsA is only effective at a narrow range of concentrations, with optimal 
inhibition at ~200nM (in cells), and no effect at very low or very high concentrations 
(Nazareth et al., 1991): a biphasic response (Griffiths and Halestrap, 1993).  CsA is in clinical 
use, most commonly to prevent organ rejection post transplantation, however it has several 
toxic side effects when used clinically, including nephrotoxicity, renal vascular damage and 
hypertension (Caramelo et al., 2004), and fails to cross the BBB, making alternative 
compounds desirable.   
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Figure 2.1: Cyclosporin A indirectly binds calcineurin and directly binds Cyclophilin D, resulting in its two effects of 
immunosuppression and reduced Ca
2+
 sensitivity of mPTP.  Actions are shown in blue and consequences in green.   
 
To overcome the calcineurin binding issues of CsA, several analogues have been identified 
or synthesized, which do not effect calcineurin, such as Sanglifehrin A, [MeAla6]CsA, 4-
methyl-val-CsA and others (Durette et al., 1988; Aebi et al., 1990; Lee et al., 1990; Clarke et 
al., 2002).  Sanglifehrin A was identified in 2002 as another inhibitor of mPTP opening 
(Clarke et al., 2002).  Like cyclosporin, it also binds cyclophilin A, and is an 
immunosuppressant, but the CypA-SfA complex does not bind calcineurin, and exerts its 
immunosuppressive effects by blocking T cell proliferation directly.  This is an advantage for 
cardiac research, as calcineurin has a role in heartbeat regulation, which CsA can disrupt 
(Halestrap et al., 2004).  Whilst Sanglifehrin is as potent a pore inhibitor as CsA, it has a 
different mechanism, as it does not prevent CypD binding to the ANT; Sanglifehrin is not 
commercially available and therefore has been less widely used and studied.  A problem 
common to both CsA and SfA is that they are not absolute inhibitors of mPTP.  They reduce 
the sensitivity of the pore to Ca2+ but only decrease the probability of opening, they do not 
prevent it indefinitely.  This is a disadvantage, because in conditions in which there is a 
prolonged high [Ca2+] or oxidative stress, these compounds will not prevent pore opening 
once their maximum potency has been exceeded (Clarke et al., 2002) . These conditions can 
be present in disease models in which CsA could be used, such as neurodegenerative 
disease, and ischaemia reperfusion (IR) injury, which could limit the utility of such 
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compounds: in IR injury, it has been demonstrated that the beneficial effect of CsA is due to 
it’s action during reperfusion, and not ischaemia (Halestrap et al., 2004). 
Other approaches to inhibiting mPTP target the stimuli which result in mPTP opening, rather 
than the pore itself: theoretically by modifying the prevailing conditions to an environment 
less favourable to mPTP opening, the likelihood of pore opening can be reduced.  These 
methods include ischaemic pre and post conditioning (Javadov et al., 2003; Gateau-Roesch 
et al., 2006), antioxidants (Kerr et al., 1999; Adlam et al., 2005), and Na+/H+ exchanger 
inhibitors (during ischaemia the Na+/H+ exchanger is activated by a decrease in pH, leading 
to increased [Na+], which causes a reversal of the Na+/Ca2+ exchanger, resulting in Ca2+ 
accrual) (Karmazyn et al., 2001; Javadov et al., 2008).   
A range of new compounds were developed by the Selwood laboratory at UCL, and 
provided to our lab for testing.  These novel compounds were derived from CsA, with 
modifications made with the goal of reducing the immunosuppressive effects of CsA, and 
making the compounds selective for CypD (the mitochondrial cyclophilin) over CypA (the 
cytosolic cyclophilin), with a high potency as inhibitors of mPTP opening.  It was also 
desirable to produce a molecule with a better cytotoxic profile than CsA, and the ability to 
reach significant brain levels, in order to be able to target neurodegeneration and, 
specifically, a mouse model (experimental autoimmune encephalomyelitis, or EAE) which of 
Multiple Sclerosis (MS) collaborators at Queen Mary University possessed.  mPTP has been 
suggested to play a role in MS as it is a disease characterised by chronic inflammation, which 
results in increased levels of ROS and NO, conditions favourable to mPTP opening.  The 
axonal degeneration found in MS has been demonstrated to feature mitochondrial damage 
(Su et al., 2009), and the signal transduction protein p66Shc, which is associated with an 
increase in mPTP opening, has been shown to be protective in EAE (Savino et al., 2013).   
It was desirable to make the compound selective for CypD over CypA: this is difficult as the 
cyclophilins have very similar structures and sequences (Davis et al., 2010).  A potential 
solution to this is to enable cellular localization through structural modification.  Therefore, 
the compound was modified to promote targeting to the mitochondria (as CypD is the 
mitochondrial cyclophilin variant).  Previously, triphenylphosphonium (TPP+), a lipophilic 
cation that is partitioned into the matrix by the mitochondrial membrane potential, has 
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been used for mitochondrial targeting (Ross et al., 2005), as it accumulates in the matrix at 
10-100 fold the accumulation into the cytoplasm (Smith et al., 2003).  However, TPP has a 
high molecular weight and mitochondrial toxicity (Warne et al., 2016), making it non-ideal 
so a different approach was used: the quinolinium cation was chosen due to its small 
molecular weight and chemical simplicity.  Addition of the quinolinium moiety makes the 
compound more lipophilic, and more positively charged, in order to promote its 
concentration into the negatively charged mitochondria (Warne et al., 2016).    
 
Figure 2.2: CsA was modified to produce new compounds.  The chemical structure of CsA (left), of which the new 
compounds are derivatives, and of one of the new compounds, JW47 (right). The quinolinium cation (circled in green) was 
added at the the [Bmt]
1
 side chain (circled in red) by olefin cross-metathesis, due to the prediction that addition at this 
position would have the same effect as addition at the [Sar]
3
 position (circled in pink).  A hydrocarbon chain (circled in 
purple) was used as a chemical linker.  Figure taken from Warne et al., 2016 (with permission), and annotated.   
 
The Selwood lab had previously created a non-immunosuppressive, non-targeted 
compound called SmBzCsA (Malouitre et al., 2010), by adding methylbenzoate to CsA at the 
[Sar]3 position.  The [Sar]3 position has been previously demonstrated to be necessary for 
calcineurin binding (Rasaiyaah 2013), but is predicted to be non-essential for cyclophilin 
binding.  The novel compounds were constructed by modifying CsA by adding the 
quinolinium cation at the [Bmt]1 side chain, which they predicted would have a similar effect 
to addition at the [Sar]3 position (see Figure 2.2).  The immunosuppressive effects of CsA are 
caused by a complex of CsA, CypA and calcineurin which inhibits dephosphorylation of 
nuclear factors of activated T-cells (NFAT), a family of transcription factors important to 
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immune response (Hogan et. al., 2003), so disruption of this binding complex should reduce 
immune suppression.  
In this project, we aimed to screen an array of related novel compounds in order to assess 
the success of the quinolinium ion targeting approach, by investigation of their effect on 
mPTP opening, and by comparison of their potency with CsA; with any successful inhibitors, 
to investigate their molecular target, and mitochondrial toxicity profile.   
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Methods 
 
Mitochondrial isolation 
Subcellular fractionation was performed as previously described (Astin et al. Sci Rep 2013). 
C57BL/6J male mice of 3-6 months were sacrificed by cervical dislocation, and the liver was 
removed and placed immediately into ice-cold isolation buffer (250mM mannitol, 5mM 
HEPES, 0.5mM EGTA, pH 7.4).  In a cold room at 4°C, the liver was rinsed in PBS to remove 
excess blood, and any fat and connective tissue was dissected away.  PBS was then replaced 
with isolation buffer containing 1mM phenylmethanesulfonyl fluoride (PMSF), and the liver 
was chopped into pieces (approximately 2mm cubes).  Tissue was then homogenized in this 
solution until no solid matter remained, and then centrifuged at 800G for 10 minutes at 4°C.  
The nuclear pellet was then discarded, and the post nuclear supernatant retained, and 
centrifuged at 10300G for another 10 minutes at 4°C.  The post-mitochondrial supernatant 
was discarded, and the mitochondrial pellet was resuspended in isolation buffer and 1mM 
PMSF, and kept on ice.  Protein levels were quantified using a ThermoScientific BCA protein 
quantification assay, as per manufacturer’s instructions.   
Calcium retention capacity assay 
Isolated mitochondria were resuspended (500µg protein/ml) in MSK buffer (75mM 
mannitol, 25mM sucrose, 5mM potassium phosphate monobasic, 20mM Tris-HCl, 100mM 
KCl, and 0.1% (w/v) bovine serum albumin, pH 7.4, as previously described by (Rueda et al., 
2015) and others) supplemented with 10mM succinate (a Complex II substrate), 1µM 
rotenone (a Complex I inhibitor) and 1µM Fluo5N (a cell-impermeant calcium indicator). 
200µl mitochondrial suspension per well was used in 96 well microplates. Compounds were 
incubated for ten minutes before the plate was assayed in a Fluostar Optima plate reader, 
using Ex/Em filters at 480/520nM; CaCl2 (10µM) was injected approximately every 6.5 
minutes for 80 minutes (12 total injections, final concentration of 75µM). In order to 
calculate % inhibition of Ca2+ induced pore opening, the method detailed below in Table 2 
was followed.  Significance was assessed by one-way ANOVA, in comparison to a CsA 
control.  When using CypD (-/-) mice, it was found, as would be expected, the pore had 
much lower sensitivity to Ca2+, and therefore to ensure pore opening, the injected CaCl2 was 
increased to 40µM (giving a final concentration of 280µM), and there were 24 total 
 68 
injections rather than 12; to allow room for the additional injection volume, 100µl of 
mitochondria were plated per well (at 1mg/ml, to give the same total protein as in the 
original experiments).    
Where A, B, and C represent the total fluorescence values of no Ca2+ additions (A), no 
mitochondria (total B), and no compound (C): 
Method Example, with sample condition “X” 
1. The total fluorescence value for 
each condition was calculated: 
 
 Sum of timepoints 1-80 (inclusive) 
for condition “X” = X 
2. Background (no Ca2+ additions trace) 
was subtracted from each, for 
background correction: 
 
 X – A = X1 
 
3. The background corrected values 
were then divided by the “no 
mitochondria” control, representing 
the total amount of Ca2+ added 
which remained unbuffered by 
mitochondria: 
 
 X1 / B1 = X2 
4. Percentage inhibition for each 
[compound] was then calculated as 
the % of the corresponding value for 
the untreated condition 
 
 % Inhibition of condition “X” 
= (1 - (X2 / C2))*100 
Table 2: The method used to calculate percentage (%) inhibition for each condition of a calcium retention capacity (CRC) 
assay.   
 
Preparation of rat cortical neurons in culture 
17 days after first showing signs of pregnancy (a vaginal mucus plug), an adult female rat 
(Rattus norvegicus) was sacrificed according to Home Office Regulations, using the Schedule 
1 technique of cervical dislocation, with confirmation of death by decapitation.  The 
embryonic day 17 (E17) embryos were removed from the womb and the amniotic sac, 
decapitated, and their heads stored in 4C phosphate buffered saline (PBS) on ice.  The 
brains were then dissected: scissors were used to cut through the skull from the base of the 
brain stem in a straight line forward to the embryo’s nose.  The skin and skull were then 
peeled back using curved forceps in order to remove the brain, and the cortices were 
dissected from the rest of the brain.  The meninges were then removed, and the cortices 
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gently crushed (in order to increase surface area for enzymatic digestion), and placed in 
fresh PBS on ice.  When sufficient cortices had been dissected (usual yield 15-20million 
cells/embryo), the PBS was then replaced with freshly prepared papain in PBS (0.4mg/ml, 
1ml/pair of cortices), and the cortices were incubated in the papain for 20 minutes at 37C.  
After incubation, the papain was removed and replaced with DNAse (0.4mg/ml, 1ml/pair of 
cortices) in order to prevent viscosity in the subsequent step: using a blunt fill needle (18G x 
1 ½, 1.2mm X 40mm) and a syringe the solution was gently triturated in order to dissociate 
the brain tissue.  When the solution was sufficiently homogenous, it was then centrifuged at 
500g for 5 minutes in order to form a cell pellet.  After centrifugation, the supernatant was 
removed, and the pellet resuspended in neurobasal medium (supplemented with Glutamax 
(1X), B27 (1X), and penicillin/streptomycin (1% v/v)).  The cells were then counted, and 
plated at the required density onto plates which had previously been treated with poly-l-
lysine for at least 30 minutes, and then washed with distilled H2O.  Cells were grown in an 
incubator at 37C with 5% CO2 and 95% humidity.  The medium was changed 48 hours after 
plating, and then half changed every 3-4 days.   
Confocal imaging of fluorescein-tagged compound 
DIV9 rat cortical neurons which had been plated at a density of 1 million cells/well, on glass 
coverslips (22mm) in 6 well plates, were incubated for 30 minutes at 37C with the cell 
permeant cationic dye tetramethylrhodamine methyl ester (TMRM, 25nM), the nuclear 
marker Hoechst (5g/ml), the L-type calcium channel blocker verapamil (40M), and the 
fluorescein-tagged quinolinium compound (1M in DMSO) in recording buffer (NaCl 
(150mM), KCl (4.25mM), NaH2PO4 (1.25mM), NaHCO3 (4mM), CaCl2 (1.2mM), HEPES 
(10mM), glucose (10mM), MgCl2 (1.2mM)).  Cells were imaged on a Zeiss 700 LSM confocal 
microscope, using a 63X oil objective.  Hoechst fluorescence was excited at 405nm, TMRM 
at 555nm and fluorescein at 488nm, and measured using filters at 420-490nm, 488-555nm, 
and a long pass 560nm filter respectively.   
Measurement of mitochondrial membrane potential (in vitro) 
DIV 8-9 rat cortical neurons which had been plated at a density of 50000cells/well in 96 well 
plates, were incubated for 40 minutes at 37°C with TMRM (25nM) in recording buffer, and 
fluorescence was measured using the ImageXpress Micro XL system (Molecular Devices).  
Fluorescence was measured for 7 minutes prior to addition of DMSO, CsA or JW47 (both at 
 70 
40nM and 1µM), and then for a further 50 minutes before the addition of the mitochondrial 
uncoupler carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone (FCCP, 5µM) as a positive 
control.  The MetaXpress analysis software was used to calculate a mean integrated 
fluorescence intensity (using a customised multi-wavelength cell scoring journal).  These 
values were normalized using the baseline reading as 100%, and the FCCP value as 0%, and 
then normalized to DMSO.  Significance was assessed by one-way ANOVA, in comparison to 
DMSO control.   
Measurement of mitochondrial membrane potential (ex vivo) 
Freshly isolated mouse liver mitochondria were suspended in MSK buffer containing 
10ug/ml rhodamine123 (dequench mode), at a concentration of 500µg/ml, and plated in an 
opaque black 96 well plate.  Baseline fluorescence was then measured every 60 seconds for 
5 minutes in a Fluostar Optima (Ex480/Em520) before manual addition of compounds 
(concentrations as specified).  Fluorescence measurements were continued for 45 minutes 
until the addition of 2µM FCCP, followed by a further 10 minutes of fluorescence readings.  
Data were then normalized, using the baseline as 100% and the FCCP value as 0% and 
normalized to DMSO.  Significance was assessed by one-way ANOVA, in comparison to 
DMSO control.   
Respirometry: Oroboros 
Oxygen consumption was measured using Oroboros Oxygraph-2K as previously described 
(Astin et al. Sci Rep 2013).  Prior to the assay, the Oxygraph chambers were calibrated with 
Miro5 buffer (0.5mM EGTA, 3mM MgCl2.6H2O, 60mM K-lactobionate, 20mM taurine, 10mM 
KH2PO4, 20mM HEPES, 110mM sucrose, 1g/l BSA (essentially fatty acid free)).  Isolated 
mitochondria were suspended in Miro5 (at 100-200µg/ml), loaded into the chamber 
together with substrates (L-malate, 2mM; L-glutamate, 10mM), and the O2 flow signal was 
allowed to stabilise to the basal respiration rate (approx. 10 min).  Compounds were added 
to the chambers at the following concentrations and order: DMSO/CsA/JW47 
(concentration as indicated) to produce basal rate after compound (basal AC), ADP (2.5mM) 
to give state 3 respiration, oligomycin (2.5µM) to give leak respiration, FCCP (titrated to 
produce maximal respiratory capacity), and antimycin A (2.5µM) to give non-mitochondrial 
respiration.  Data were analysed by subtracting the antimycin A respiration rate to give 
mitochondrial specific O2 consumption, and were then expressed as a percentage of the 
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basal O2 consumption.  Significance was assessed by one-way ANOVA, in comparison to 
DMSO control.   
Respirometry: Seahorse 
Seahorse assays were carried out using the Seahorse XF FluxPack 24well kit, consisting of a 
cell plate, a probe plate (containing the fluorescent probes which measure cell responses), a 
drug plate, and calibration medium.  Seahorse 24 well cell plates were coated for 30 
minutes with poly-l-lysine, which was then removed, and the plates washed with sterile 
dH2O.  Then freshly prepared embryonic cortical rat neurons were plated at a density of 
125000 cells/well, in all wells except control wells (A1, B4, C3, D6), in 200l neurobasal 
medium (supplemented with Glutamax (1X), B27 (1X), and penicillin/streptomycin (1% v/v)).  
Cells were grown in a 5% CO2, 95% humidity, 37C incubator.  48 hours after plating, the 
medium was replaced, and then half replaced after a further 72 hours.  24 hours prior to 
assay, calibration medium (1ml) was added to each well of the probe plate, and this was 
incubated at 37C.  Immediately prior to calibration, neurobasal medium was gently 
removed from the cell plate, and replaced with 600l seahorse medium (DMEM powder 
(8.3g/L, final composition 0.83% w/v), pyruvate (1mM), glucose (5.5mM), glutamax (1X), 
sodium bicarbonate (44mM), FBS (10% v/v), pH 7.4).  Compounds were then prepared and 
loaded into the drug plate, in order to add (in the following order) either DMSO/JW47/CsA 
(at concentrations specified), oligomycin (5M), FCCP (2.5M), and Antimycin A (5M). The 
drug plate was then fitted on top of the fluorescent probe plate, and these two plates were 
then loaded into the machine, and the calibration protocol run.  Subsequent to calibration, 
the probe plate was removed, and replaced with the cell plate, and the acquisition protocol 
run.  After the acquisition was complete, total protein in each well was quantified using a 
ThermoScientific BCA protein quantification assay, as per manufacturer’s instructions, and 
the oxygen consumption normalized to protein content.   
Measurement of ATP 
Freshly isolated mitochondria were resuspended in MSK buffer (containing 10mM L-
glutamate and 2mM L-malate) at 1mg/ml and plated in opaque white 96 well plates, or for 
neuronal assays, neurons were used 9 days after plating at 15000 cells/well.  Drugs (DMSO, 
CsA, JW47, oligomycin or IAA) were added at the concentrations specified, and for 
mitochondrial assays were incubated for ten minutes before addition of ADP (5mM), 
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followed by another 45 minutes.  For neuronal assays, drugs were added in neurobasal 
medium and incubated for 60 minutes.  Cell Titer Glo reagent was then added, and the plate 
shaken for 2 minutes in the dark to lyse cells/mitochondria and release ATP.  The plates 
were incubated a further ten minutes and then luminescence values read using an Optima 
FluoStar.  Data were normalised to DMSO control, and significance assessed by one-way 
ANOVA.   
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Results 
 
Initial assessment of compounds 
 
Four novel compounds were provided from the laboratory of David Selwood in order to be 
screened to assess their efficacy as inhibitors of mPTP.  In order to do this, the calcium 
retention capacity (CRC) assay was used, a classical assay for measuring Ca2+ mediated pore 
opening in which isolated mouse liver mitochondria are suspended with the membrane 
impermeable low affinity (Kd ~90M) calcium indicator Fluo-5N and subjected to repeated 
boluses of CaCl2.  After each CaCl2 addition, an increase in fluorescence is apparent, 
followed by an immediate decrease as the Ca2+ is taken up by the mitochondria (Figure 
2.3A).  This is repeated until the mitochondria exceed their maximum buffering capacity, 
upon which mPTP opens, which is visible as an uncontrolled rise in fluorescence as Ca2+ is 
released from the mitochondria (marked by red arrows), followed by a lack of buffering of 
subsequent CaCl2 boluses.  Successful inhibition is visible as a delay in pore opening 
compared to untreated controls, as shown by the CsA treated trace in Fig2.3A.   
To assess the efficacy of these novel compounds, they were tested at three concentrations 
using the CRC assay, with CsA as a positive control.  The previously published non-
immunosuppressive, non-targeted SmBzCsA (8MB2) (Malouitre et al., 2010) was used as a 
control in the initial screening, in order to investigate whether the quinolinium targeting 
method was successful.  % inhibition was calculated for each compound and normalised to 
the % inhibition demonstrated by CsA.  It was found that all compounds were as effective as 
CsA at higher concentrations (5µM and 1µM), but that at 200nM – which is the optimal 
concentration for CsA - two compounds, JW47 and JW115 were significantly more potent 
than CsA, whereas the inhibition provided by the other two compounds JW65.2 and 8MB2 
decreased sharply (Figure 2.3B). As compound JW47 was the most effective at 200nM, this 
was selected for further study.   
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Figure 2.3: Novel compound JW47 was an effective inhibitor of mPTP opening.  A: Representative trace of the 
CRC assay.   Red arrows mark mPTP opening, which is delayed by addition of CsA.  B: When assessed by CRC 
assay, all compounds inhibited pore opening to the same extent as CsA at 5µM and 1µM.  At 200nM, 
Compounds JW47 and JW115 were significantly more potent inhibitors of mPTP opening than CsA.  
Significance was assessed by one-way ANOVA, * denotes significance. * = p value <0.05, *** = p value <0.005. 
N of 3, error bars shown are standard error of the mean (SEM).  C: Structure of fluorescein-tagged quinolinium.  
Fluorescein is boxed in green, and quinolinium in purple.  Structure used with permission of David Selwood.   
D: Fluorescein-tagged quinolinium (488 nm) colocalized with mitochondria labelled with TMRM (555nm) in 
DIV10 rat cortical neurons.  
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To demonstrate that the quinolinium modification causes mitochondrial targeting, a 
fluorescein-tagged quinolinium molecule was created by the Selwood laboratory (Figure 
2.3C), and its cellular localization was examined.  It was found that when the fluorescein-
tagged quinolinium entered the cell, it localised to the mitochondria, as shown by the 
colocalization of the fluorescein fluorescence with TMRM (see Figure 2.3D, and for line 
intensity profile plots of the colocalisation, Appendix A1), demonstrating that the 
quinolinium targeting approach was successful.  However, a large proportion of the dye did 
not enter the cells, and formed a clear delineation of the cell membrane, suggesting there 
could be some issues with the permeability of this molecule.   
 
Investigation of JW47 efficacy and target 
 
A dose response was then carried out by CRC assay to compare the inhibition profile of CsA 
with JW47.  Compounds were tested at concentrations from 0.32nM to 1µM; JW47 showed 
half maximal potency at ~10nM compared to ~40nM for CsA (Figure 2.4), showing that 
JW47 is approximately a 4 fold more potent inhibitor than CsA of Ca2+ mediated mPTP 
opening.  Interestingly, there was no apparent difference between JW47 and CsA at 200nM, 
in contrast to the initial dose response at which there was a significant difference.   
 
Figure 2.4: At 40nM JW47 was a 
significantly more potent inhibitor of 
mPTP opening than CsA.  JW47 retained 
inhibitory activity at lower 
concentrations than CsA, with the 
maximal difference at 40nM.  N of 4. 
Significance was assessed by one-way 
ANOVA.  * denotes significance, p value 
<0.05.  Error bars are SEM.   
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In order to confirm that JW47 is selective for CypD and that the mechanism of action is to 
reduce Ca2+ sensitivity by binding CypD, the compound was then tested on mitochondria 
isolated from CypD knockout mice.  The mice were confirmed to be CypD -/- by the absence 
of a band at ~20kDa in a Western blot using anti-CypD antibody (see Figure 2.5B and 2.5C).  
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 Figure 2.5: JW47 inhibits mPTP opening by binding CypD and reducing Ca
2+
 sensitivity of the pore.  A) In 
mitochondria isolated from WT mice, pore opening was inhibited by both CsA and JW47 in a dose dependent 
manner, whereas in mitochondria isolated from CypD KO mice neither drug had any effect.  N of 3.  
Significance was assessed by one-way ANOVA.   * denotes significance, p value <0.05.  Error bars are SEM.  B) 
CypD was not present in a Western blot of mitochondria isolated from CypD -/- mice, in contrast to the WT 
control, in which there was a band of ~20kDa. C) Mitochondrial heatshock protein GRP75 was present in both 
WT and CypD -/- samples, demonstrating there was mitochondrial content in both samples.  D) in wild type 
mitochondria (left), JW47 inhibits mPTP opening by binding CypD and reducing Ca
2+
 sensitivity of the pore.  In 
CypD KO mitochondria (right), JW47 has no effect due to the absence of CypD.   
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It was found that neither CsA nor JW47 had any effect on the CRC assay in mitochondria 
from CypD KO mice, at any concentration (see Figure 2.5A), whereas in the mitochondria 
from WT mice there were significant differences between all concentrations of CsA, and 
between 40nM and 200nM JW47 (there was no difference between 200nM and 1M JW47, 
having attained maximal inhibition by 200nM).  This demonstrated that, as in the absence of 
the CypD protein JW47 and CsA had no effect, the target of these compounds is CypD.  In 
order to induce pore opening in CypD -/- mice, it was necessary to increase the 
concentration and number of CaCl2 injections, reiterating that it is CypD which confers Ca
2+ 
sensitivity on the pore, and that therefore these compounds can be said to work by 
decreasing the Ca2+ sensitivity of the pore via CypD.   
 
Investigation of the effect of JW47 on mitochondrial parameters 
 
Next, essential mitochondrial parameters were measured in order to assess possible 
adverse effects of JW47.  CsA has been shown to induce mitochondrial toxicity (Rodríguez et 
al., 2007), so it is desirable that any derivatives do not possess these toxic properties.  
Parameters were measured both in isolated mitochondria and in primary cortical neurons, 
at concentrations causing maximal (40nM) and supramaximal (200nM, 1M) inhibition of 
mPTP.   
Treatment of isolated liver mitochondria with JW47 had no significant effect at any 
concentration, on mitochondrial membrane potential (Figure 2.6A), ATP production (Figure 
2.6B), or oxygen consumption (Figure 2.6C and 2.6D).   
In rat cortical neurons (at DIV8-9), 40nM and 200nM treatment with JW47 had no effect on 
mitochondrial membrane potential (Figure 2.7A), ATP production (Figure 2.7B), or oxygen 
consumption (Figure 2.7C), however at supramaximal concentration (1M), JW47 
significantly reduced mitochondrial membrane potential.  Whilst JW47 at 1M did not 
produce significant affects in the other measures of mitochondrial function, there was a 
visible, but not significant, reduction in ATP production in both cortical neurons and isolated 
mitochondria, and in state 3 and maximal respiration in isolated mitochondria. Whilst it is 
clear that JW47 does show some adverse affects on mitochondrial function, this 
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demonstrates that these effects take place at least an order of magnitude higher than the 
maximal concentrations for inhibition of mPTP, and there is a wide safety window.   
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Figure 2.6: At low concentrations, JW47 has no effect on mitochondrial membrane potential, oxygen 
consumption or ATP production in isolated mitochondria.  A: Neither CsA or JW47 affected mitochondrial 
membrane potential.  N of 3. B: Neither CsA nor JW47 had a significant effect on ATP production.  N of 4.  C: 
Respiration was not significantly affected by CsA at any concentration, although it visibly reduced maximal 
respiration at 1µM.  N of 3.  D: Respiration was not significantly affected by JW47 at any concentration, 
however at 200nM and 1µM maximal respiration was visibly reduced.  N of 4.  Significance was tested by one-
way ANOVA. * denotes significance, **** = p value <0.001.  All error bars are SEM.   
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Figure 2.7: At low concentrations, JW47 has no effect on mitochondrial membrane potential, oxygen 
consumption or ATP production in rat cortical neurons.  A: CsA did not reduce mitochondrial membrane 
potential at any concentration.  At 40nM and 200nM, JW47 had no effect, however at 1µM JW47 membrane 
potential was significantly reduced.  N of 4.  B: In cortical neurons, neither CsA nor JW47 had a significant 
effect on ATP production.  N of 3.  C: Respiration was not significantly affected by CsA at any concentration, 
although at all concentrations it appeared to cause some reduction in oxygen consumption.  N of 3.  D: 
Respiration was not significantly affected by JW47 at any concentration.  N of 3.  Significance was tested by 
one-way ANOVA. * denotes significance, ** = p value <0.01, **** = p value <0.001.  All error bars are SEM. 
 
Investigation of second generation compounds 
 
Lastly, further compounds were provided for testing from the Selwood laboratory.  These 
compounds were also CsA derivatives, modified according to the success of JW47, and were 
tested on isolated mouse liver mitochondria using the CRC assay.  These were tested only at 
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lower concentrations (40nM and 8nM), as it had been found that differences were more 
detectable at low concentrations.  CsA is only at half maximal inhibition at 40nM, therefore 
JW47 was used as a control in these experiments.  It was found that at 40nM there were 
three compounds (JW28, JW76 and JW83) which were able to inhibit pore opening to the 
same extent as JW47, whilst the other compounds had no effect on pore opening (see Fig 
2.8A).  At 8nM, JW47 no longer effectively inhibited pore opening.  However, at 8nM the 
three new compounds were found to inhibit pore opening to a similar extent as at 40nM 
(Fig 7B), suggesting these compounds are even more efficacious than JW47.   
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Figure 2.8: Three derivatives of JW47 were effective inhibitors of mPTP opening.  A: When assessed by CRC 
assay at 40nM, novel compounds #28, #76 and #83 inhibited mPTP opening to the same extent as JW47, 
although several of the other compounds did not inhibit mPTP opening at all.  N of 3.  B: At 8nM, compounds 
#28, #76, and #83 were significantly more effective inhibitors than JW47.  N of 3.  .  Significance was tested by 
one-way ANOVA. * denotes significance, * = p value <0.05, *** = p value <0.005.  All error bars are SEM. 
 
Summary 
 
Four novel compounds were screened using the CRC assay and two of them were found to 
be more potent inhibitors of mPTP opening than CsA at 200nM.   A fluorescein-tagged 
quinolinium molecule was demonstrated to co-localize with mitochondria in cortical 
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neurons, suggesting that this is a successful mitochondrial targeting approach, and 
explaining the increased potency of the CsA derivatives.  The most potent compound, JW47 
was further investigated and found to act by binding CypD.  JW47 was shown by dose 
response to be approximately a 4X more potent inhibitor than CsA, with a half maximal 
concentration of ~10nM.  In isolated mitochondria, JW47 did not significantly affect 
membrane potential, ATP production, or oxygen consumption at any concentration.  JW47 
was found to inhibit mitochondrial membrane potential in rat cortical neurons at 
supramaximal concentrations but to have no effect at 40nM or 200nM.  A new range of 
compounds which are derivatives of JW47 were found to be more effective than JW47 at 
low concentrations, providing a promising future direction for this investigation.   
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Discussion 
 
The initial compound screen demonstrated that JW47 is an effective inhibitor of mPTP, and 
at low concentration (200nM) is more potent than CsA.  This would suggest that the 
chemical modification of the structure to optimize CypD targeting was successful: the 
modification using the quinolinium ion appears to have successfully localized the compound 
to the mitochondria due to its negative membrane potential, as demonstrated by the much 
higher efficacy of JW47 than CsA and 8MB2 (a compound without mitochondrial targeting).  
This was also confirmed by colocalization of a fluorescein-tagged quinolinium probe with 
TMRM labelled mitochondria; however, not all of the fluorescein compound entered the 
cells, suggesting there may be issues with the membrane permeability of this molecule.  This 
does not necessarily mean that there are issues with the permeability of JW47, as the 
structures differ, (the compound used here was only quinolinium attached to fluorescein, 
without the rest of the JW47 structure), however it would be useful to check this by creating 
a fluorescently tagged JW47.  It would also be useful to verify the effectiveness of 
quinolinium in conferring mitochondrial specificity on a compound: to do this, a fluorescein-
tagged JW47 without the quinolinium ion could be used, to investigate the localization of 
the compound without the mitochondrial targeting.   
 A drawback to this approach is the use of liver mitochondria: as the compounds are of 
interest as potential therapeutics for a neurological condition, it would be more clinically 
relevant to investigate their efficacy using brain mitochondria.  However, liver mitochondria 
are more commonly used, are easy to isolate, and are known to be robust and give high 
yield, and this was our justification for using them.  In future work it would be useful to 
confirm the efficacy of these compounds on mitochondria isolated from the brain, as some 
properties (substrate transport, respiration and ROS production) of mitochondria from the 
brain have been shown to differ to those of mitochondria isolated from the liver (Gusdon et 
al., 2015).   
Mitochondria isolated from CypD knock out mice did not show CsA or JW47 sensitive pore 
opening at any CsA/JW47 concentration, whereas wild type litter mates showed a dose-
dependent inhibition for both drugs.  This confirms that JW47 targets CypD, as is expected 
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as a derivative of CsA, and demonstrates that the chemical modifications to the structure 
did not ablate CypD binding.      It was also shown by other groups that in an X-ray structure 
of JW47, the CypD binding complex is conserved, that JW47 has reduced CypA binding in 
comparison to CsA, and is less immunosuppressive (inhibits T cell proliferation to a lesser 
extent) than CsA (Warne et al., 2016).   
The dose response curve showed that JW47 is approximately 4X more potent than CsA at 
inhibiting mPTP opening, with a half maximal inhibition for JW47 of 10nM, compared to CsA 
at 40nM, supporting the use of the quinolinium ion as a mitochondrial targeting aid.  
However, the dose response raised an interesting point in that no significant difference was 
observed between CsA and JW47 at 200nM, whereas in the initial screen there had been 
one.  This is likely due to instability of JW47 – during experiments it was noted that JW47 
appeared to become less efficient after multiple freeze thaws, whereas CsA was not 
affected.  This could be a potential issue with the therapeutic use of the compound, causing 
issues with mass production and storage, however no effect was noted when tested in vivo: 
JW47 was tested in vivo (see Appendix Figure A2) by the Baker lab at Queen Mary 
University, and was found to be neuroprotective in a mouse model of MS (Warne et al., 
2016).   JW47 treatment did not prevent the onset or severity of MS relapses, but 
significantly improved the clinical score post relapse in comparison to vehicle treated mice.  
JW47 treated mice also performed significantly better in a rotarod test (a measure of motor 
skills) than vehicle treated mice; no side effects were observed in JW47 treated mice.   
It would have been desirable to demonstrate that JW47 prevented pore opening in vitro, in 
rat cortical neurons, however, the mPTP is notoriously difficult to measure reproducibly in 
cells and cell lines.  Different methods were attempted to quantify the effect of JW47 and 
CsA on mPTP in vitro, in cortical rat neurons, however these were without success.   
The first method, the calcein cobalt assay, has previously been described (Petronilli et al., 
1999) as a method with which to measure transitory and permanent pore opening.  The 
assay selectively labels mitochondria using calcein AM, the acetoxymethyl ester of calcein 
dye - a colourless, non-fluorescent substance - and CoCl2, which quenches calcein 
fluorescence.  Calcein AM diffuses throughout the cell and accumulates throughout the 
cytosol and mitochondria; inside the cell esterases cleave the ester group thus preventing 
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further diffusion of the dye, so that the dye which has spread to the mitochondria is then 
trapped.  CoCl2 is then added, which quenches the cytosolic calcein fluorescence, but not 
the mitochondrial, as Co2+ cannot permeate the IMM.  Upon opening of mPTP, Co2+ gains 
access to the mitochondrial-sequestered dye, and quenches mitochondrial calcein 
fluorescence, which can be rescued by CsA (Petronilli et al., 1999).  However, this technique 
was immediately challenged (Lemasters and Nieminen, 1999), in a letter to the editors 
which claimed that calcein loading was not mitochondrial, and that Petronilli had been 
mistaken in identifying mitochondria, which Lemasters said exclude calcein and appear as 
dark voids in the cytosolic fluorescence.  They also noted a strong temperature dependence 
of calcein loading: at 37C cytosolic esterases are so active that the calcein AM is cleaved 
before entry to the mitochondria, although they noted that this may vary between cell 
types.  The mPTP is also sensitive to temperature preconditioning (Khaliulin et al., 2007), 
and temperature sensitivity was also found during our CRC assay optimization.  The calcein 
cobalt assay continues to be used (Quintanilla et al., 2013), however there are many 
difficulties with it: cobalt is a heavy metal ion, known to be toxic to cells (Jones et al., 2002), 
calcein does not universally enter mitochondria (Lemasters et al., 1998), and the technique 
cannot distinguish between calcein release from mitochondria and CoCl2 entry.  In our 
experiments, it was found that cytosolic quenching in rat cortical neurons did not result in 
fluorescent mitochondria: most cells were found to have a combination of non specific 
staining and dark voids, with only some clear mitochondrial staining.   
Modulation of mPTP using photostimulation, has long been described: the pore can be 
inhibited using photostimulation in combination with hematoporphyrin (Salet et al., 1997), 
or can be activated using high levels of radiation, in order to decrease mitochondrial calcium 
retention capacity (Hüser et al., 1998; Petronilli et al., 2009; Blanchet et al., 2014), 
representing photoactivation of mPTP.  The technique of photoactivation was used for the 
second approach of monitoring mPTP in vitro: the method we used was to load the cells 
with a high (1M) concentration of TMRM, a fluorescent lipophilic cation which partitions 
specifically in the mitochondria, dependent on ΔΨm.  During imaging, high laser power is 
used to excite TMRM, causing the local generation of free radicals, which cause mPTP 
opening (De Giorgi et al., 2002).  As TMRM accumulation is dependent on ΔΨm, it can be 
used to measure this; therefore, in this assay TMRM is used both as the trigger and the 
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measure of mPTP.  mPTP opening is marked by a sudden decrease in ΔΨm, represented by a 
sharp increase in TMRM fluorescence.  However, this technique also has issues: 
depolarization can be caused by a variety of events besides mPTP opening (e.g. increased 
ATP demand).  When this assay was tried (on a Zeiss Confocal LSM 500, and a Molecular 
devices ImageXpress MicroXL), it was found to be very difficult to attenuate the light 
exposure in order to give a sufficient delay in pore opening such that compounds could be 
assessed – the pore opened (represented by a sudden increase in TMRM fluorescence) 
within seconds of exposure, was found to be highly variable between different cell 
populations, and even within cell populations there was significant time delay between pore 
opening in different cells.  Therefore, neither of these assays produced sufficiently 
reproducible data to be used to investigate the effect of JW47 on pore opening in cells in 
vitro.   
 
 
Figure 2.9: a flowchart for the presumed mechanism of action of JW47.   
 
An alternative approach could be - rather than demonstrating that JW47 inhibits mPTP 
opening in vitro -  to investigate whether JW47 inhibits cell death, as cell death is the 
supposed consequence of mPTP opening.  If it could be demonstrated that JW47 inhibits cell 
death, this would nicely demonstrate the presumed mechanism by which it is able to 
improve symptoms of EAE (see Figure 2.9).  In order to test this, an ischemia-reperfusion 
assay could be used, in which cells are kept in anoxic conditions, typically using argon gas to 
displace oxygen, in order to mimic ischemia and produce cell death during reperfusion – for 
review see (White et al., 2000).  Alternatively, neurons could be treated with glutamate, in 
order to cause Ca2+ influx through voltage gated Ca2+ channels, and NMDA receptors, and 
cause Ca2+ induced cell death.  If using a glutamate assay, it would be necessary to use older 
neurons than have been used in this project, as glutamate sensitivity changes throughout 
development, with young (DIV6-8) neurons able to recover from glutamate stimulation, 
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whereas older (DIV11-17) neurons are more vulnerable to glutamate induced injury 
(Adamec et al., 1998; Vergun et al., 1999).  H2O2 could also be used to induce cell death.   
In in vivo work done by the Baker group, JW47 was found at nanomolar concentrations in 
the brain of EAE animals following a 10mg/kg dose, demonstrating it is able to enter the 
brain.  This does not demonstrate that it can cross the blood brain barrier however, as it has 
been found that the lesions formed in the brain in the EAE model of Multiple Sclerosis cause 
a local malfunction of p-glycoprotein, which is usually responsible for the extrusion of any 
solutes which manage to cross the BBB (Al-Izki et al., 2014).  This means that compounds are 
able to cross the BBB at the sites at which they are most necessary; further work would be 
needed to establish whether the compound can cross the BBB in other circumstances.  This 
could be established by removing the brains of healthy mice after treatment, and using 
mass spectrometry to investigate the presence of JW47.   
The assays of the basic mitochondrial function demonstrated that JW47 does have a toxic 
effect at high, supramaximal concentration (1M), at which it significantly reduces 
membrane potential, and appears to reduce state 3 and maximal respiration and ATP 
production, although these were not significantly affected.  Whilst this toxicity is clearly an 
issue, as toxic side effects will reduce the usefulness of the compound as a therapeutic 
pharmaceutical, the lack of toxic effect at 200nM or 40nM demonstrates that there is a wide 
margin for error between relevant concentrations and the threshold for toxicity.  The effects 
of the drug on membrane potential, respirometry, and ATP production can be easily linked, 
as ΔΨm is defined by the proton gradient across the IMM generated by oxidative 
phosphorylation; therefore if oxidative phosphorylation is reduced, as demonstrated by 
reduced oxygen consumption, it is logical that ΔΨm would decline also.  ATP production is 
the end product of oxidative phosphorylation so it is consistent that lower oxygen 
consumption would be accompanied by lower ATP production.  The effect of the compound 
on the P/O ratio could be investigated; this ratio is the amount of ATP produced by the 
movement of two electrons (from an oxygen atom) through the ETC.  ΔΨm was significantly 
affected in cells only (not in isolated mitochondria), suggesting the reduction in membrane 
potential may be due to off target effects on other cellular components, such as substrate 
supply.  Conversely, the reduction of mitochondrial membrane potential could also 
potentially contribute to the efficacy of the drug: specific Ca2+ uptake through MCU is 
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dependent on ΔΨm, so if ΔΨm is reduced then Ca2+ uptake would also reduce, therefore 
reducing the mitochondrial Ca2+ overload which leads to mPTP opening.  However, 
inhibition of mPTP was seen at concentrations of JW47 which do not cause mitochondrial 
depolarisation, so it is unlikely that this mechanism is in effect.  It would be interesting to 
investigate the toxic side effects of JW47 at high concentration further, using 
immunoprecipitation to investigate whether the drug binds to other components of the cell.    
Screening of the second round of compounds demonstrated that three compounds were as 
effective as JW47 at 40nM, and significantly more effective than JW47 at 8nM.  As full 
structural data is not yet available for these compounds it cannot be hypothesized why they 
are more efficacious.  Whilst toxicity studies have not been done with these compounds, it 
would be hoped that even if they share the same toxic side effects as JW47 at higher 
concentrations, their effective concentrations would be even further removed from the 
toxicity threshold, thereby making them even more suitable as potential therapeutic agents.  
It would be interesting to investigate whether they have similar side effects to JW47 as it 
would provide some insight into the cause of these effects, whether they are associated 
with regions that differ between these compounds and JW47, or the regions that have 
remained the same.   
In conclusion, JW47 was found to be a more efficacious inhibitor of mPTP than the classic 
inhibitor CsA, and was active at lower concentrations.  This is likely due to the mitochondrial 
localization caused by the use of the quinolinium ion.  JW47 was found to be non toxic to 
mitochondrial membrane potential, ATP production, or oxygen consumption in both 
isolated liver mitochondria and rat cortical neurons at nanomolar concentrations, but it 
significantly reduced membrane potential in neurons at 1M.  Future work should include 
screening the compounds in mitochondria isolated from brains in order to confirm they 
have the same effect, and experiments to confirm that JW47 can delay mPTP opening or 
reduce necrotic cell death in vitro, in order to investigate the mechanism by which JW47 is 
able to improve clinical symptoms of EAE.  The newest compounds need further 
investigation in order to find their optimal concentrations, and investigating for 
mitochondrial toxicity but are promising in terms of their higher efficacy in comparison to 
JW47.  Further work is also needed to investigate whether the compound can cross the BBB; 
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if so then JW47 and the range of new compounds have broad therapeutic potential for the 
treatment of neurodegenerative disease.   
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Chapter 3: Developing an Aequorin-
based Screening Approach to Identify 
Inhibitors of MCU 
Introduction 
 
Mitochondria as drug targets 
 
Mitochondrial dysfunction is implicated in an ever increasing number of major diseases, for 
example, in neurodegenerative disease mitochondrial dysfunction is a common feature, and 
in cancer cells, mitochondria play an important role in allowing cell survival and proliferation 
(Camara et al., 2010).  Increased understanding of the pathways that cause dysfunction 
opens the way to development of new pharmaceutical approaches which can specifically 
target mitochondrial functions, which presents a challenge in drug discovery: it is necessary 
to differentiate between the mitochondrial and cytosolic effects of drugs, as some effects 
seen on mitochondria may be downstream consequences of the effects of a drug on the 
cytosol.   
 
The MCU in particular is an interesting therapeutic target in diseases in which there is 
excessive cell death, such as neurodegenerative disease - as discussed in depth the 
introduction to this thesis, it has been proposed that inhibition of mitochondrial Ca2+ uptake 
may be protective against cell death, as mitochondrial Ca2+ overload is a critical checkpoint 
in cell survival.  Existing MCU inhibitors are difficult to work with, and all have off target 
effects (see below), so it is desirable to find other MCU-specific, small molecule, cell and 
BBB permeable inhibitors, both as an alternative experimental tool to using genetic 
manipulation to study MCU function, and as potential therapeutics to reduce mitochondrial 
Ca2+ overload induced cell death.  
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Existing MCU-targeting compounds  
 
For many years preceding the discovery of the molecular identity of MCU, ruthenium red 
(RuR) and ruthenium 360 (Ru360) - derivatives of ruthenium - have been used as inhibitors 
of the MCU.  RuR potently inhibits mitochondrial Ca2+ uptake in isolated mitochondria with 
no major off target effects, however in intact cells it has a wide selectivity and also targets 
(amongst others), VDAC, L-type plasmalemmal Ca2+ channels, Ry-R (Duchen, 1992; 
Lukyanenko et al., 2000).  An additional difficulty with the use of RuR in intact cells is its high 
charge, which makes it unlikely to cross the plasma membrane, although it has been 
reported to do so (McCormack and England, 1983).  Ru360 is reportedly a more potent 
inhibitor of MCU, and more readily enters intact cells, where it does not inhibit the RyR 
(Matlib et al., 1998), however it has been found that in many cell types, neither RuR or 
Ru360 are effective in intact cells and that cell type specific validation of their efficacy is 
needed (Hajnóczky et al., 2006).  In one of the original MCU identifying papers it was 
established that Ru360 acts directly on the channel protein: a point mutation of MCU at 
S259A confers resistance to Ru360 (Baughman et al., 2011).  Lanthanides are also able to 
inhibit mitochondrial Ca2+ uptake in isolated mitochondria, but not in intact cells (Mela, 
1969).  The drug KB-R7943 has also been demonstrated to inhibit the MCU, but 
simultaneously inhibits NCLX (Santo-Domingo et al., 2007); the polyamine spermine has 
historically been suggested as an MCU activator (Nicchitta and Williamson, 1984; 
McCormack, 1989), as has kaempferol, which is also known to have other cellular targets 
(Montero et al., 2004).  No drugs have yet been proposed to effect components of the MCU 
complex besides the MCU itself; this could be an interesting approach to modulating, rather 
than ablating, mitochondrial Ca2+ uptake.  
 
Ca2+ signalling can be used to identify mitochondrial specific inhibitors, as Ca2+ can be 
measured specifically in different cellular compartments by using targeted aequorin.  This 
provides the benefit, when searching for MCU specific inhibitors, of direct insight into the 
impact of compounds on mitochondrial Ca2+ uptake.   Therefore, an aequorin-based 
approach was used to develop a method of screening for mitochondrial-specific 
compounds.   
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Aequorin 
 
Aequorin is a 21kDa Ca2+ sensitive bioluminescent protein, first isolated from the jellyfish 
Aequorea Victoria in 1962 (SHIMOMURA et al., 1962).  It is a coelenterate protein which is 
inactive in its apoprotein form; it requires reconstitution with the hydrophobic prosthetic 
group coelenterazine, to which it binds covalently, in order to function as a Ca2+ indicator.  It 
was initially used as a purified protein which had to be microinjected into cells (Ridgway and 
Ashley, 1967; Allen and Blinks, 1978), thereby limiting its use to large and robust cells, and 
due to this it became a secondary technique to small molecule fluorescent Ca2+ indicator 
dyes.  However, the cloning of aequorin cDNA (Inouye et al., 1985; Prasher et al., 1985) 
opened the way to the more widespread use of aequorin, as it could then be transfected 
into a wider variety of cells.   
 
A further discovery which popularized the use of aequorin was the ability to target it to 
cellular compartments and organelles.  This was first demonstrated in 1992 (Rizzuto et al., 
1992), when the cDNA encoding subunit VIII of human cytochrome c oxidase was ligated to 
the aequorin cDNA in order to target aequorin to the mitochondria.  It has since been 
targeted also to the endoplasmic reticulum (Kendall et al., 1992a), the nucleus (Brini et al., 
1993) and the Golgi apparatus (Pinton et al., 1998), among others.  These cDNA constructs 
can then be transfected (or, when packaged in a viral vector, transduced) into cells in order 
to measure intracellular Ca2+ in specific compartments.  Mutant versions of both the 
aequorin protein and coelenterazine have also been made, in which the affinity for Ca2+ has 
been altered (Kendall et al., 1992b; Shimomura et al., 1993).   These mutant versions can be 
used in combination (mutant aequorin cDNA with mutant coelenterazine), or with wild type 
counterparts (wild type aequorin with mutant coelenterazine or vice versa).   
 
Aequorin measurements can be made using a cuvette in a spectrophotometer, or for higher 
throughput, in a plate reader able to measure luminescence.  A typical aequorin assay 
consists of a two-hour incubation with coelenterazine in order to form the active 
photoprotein, followed by a baseline measurement, an addition of (cell type appropriate) 
agonist to induce a Ca2+ response, and then a permeabilizing agent such as digitonin with a 
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saturating concentration of Ca2+.  The digitonin and excess Ca2+ is in order to provide a 
maximal light value (Lmax), which can then be used to calibrate the agonist-induced response 
into a micromolar Ca2+ concentration (see Figure 3.1); Lmax can also be used to assess the 
transfection efficiency of the experiment. 
 
 
Figure 3.1: An explanation of aequorin calibration, from  measurements made using wild type aequorin reconstituted 
with wild type coelenterazine, measured at 37C.  Note: under these conditions, the rate constant is 1.0 sec
-1
 (Allen and 
Blinks, 1978), and therefore is not included in the equations.   
 
The constants used to calibrate the measurements in a [Ca2+] value were derived using a 
model in which each of the aequorin protein’s Ca2+ binding site has two possible states, R 
and T (Allen et al., 1977).  It is assumed that Ca2+ only binds to the R state, and light is 
emitted when every site is in the R state, and therefore the equilibrium is in favour of the R 
state.  There are four constants used in the calibration of aequorin: n (the number of Ca2+ 
binding sites), KR (the Ca
2+ association constant), KTR (=[T]/[R]), and Rate (rate constant of 
aequorin consumption at saturating [Ca2+]).  These constants vary between the different 
 
1. A ratio is made using the formula: 
Ratio =((L1-MIN(L1:LX))/SUM(L1:LX))^(1/n) 
Where: 
L1 = first light measurement of the time course (in counts per second) 
LX = last light measurement of the time course (n counts per second) 
n = 2.99 
 
2. This is then calibrated into a micromolar Ca2+ value using the formula: 
[Ca2+] (M) =(Ratio+(Ratio* KTR)-1)/(KR -(Ratio*KR))*10^6 
Where: 
KTR = 120 
KR = 10366185 
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types of aequorin (wild type or mutant), and the different types of coelenterazine (wild type 
and mutant).  The KR constant also varies depending on the temperature at which the 
experiment is carried out (usually 37C) (Brini et al., 1995), so this is important to note 
during experiments.  
 
The major limitation of aequorin is its poor ability to emit light (Ottolini et al., 2014), which 
limits its use: it has to be expressed at a sufficiently high level to emit enough light to be 
measureable, and therefore can mostly only be used in easily transfectable cell lines, 
although recently GFP-aequorin conjugates have been produced to overcome this issue 
(Baubet et al., 2000).  Another factor which has to be considered is the consumption of 
aequorin through the experiment, which prevents its use in lengthy time courses (although 
it has been demonstrated to give continuous signals for up to 70 minutes (Woods et al., 
1986), and the necessity of a time consuming reconstitution with coelenterazine.  A final 
consideration is that due to the single wavelength of light emitted, signals from different 
compartments cannot be measured in parallel, as there is no way to distinguish the source 
of the light.  However, the advantages of aequorin make it an appropriate choice for large 
scale screening experiments: the specificity of the targeting allows measurements from 
whole population, and consequently the analysis is much simpler than single cell 
measurements where regions of interest (ROIs) have to be defined manually.  Additionally 
the calibration can be largely automated, using Excel templates or R code to make the 
process faster, which is especially advantageous for screening many compounds.  Lastly, 
aequorin has a large dynamic range, which makes it suitable for work with compounds 
which have unknown effects on Ca2+ signalling, and could produce a wide range of changes 
in [Ca2+].   
 
Designing an aequorin-based screening approach for inhibitors of MCU 
 
A useful approach to finding new inhibitors is to screen a compound library of drugs already 
in clinical use; therefore any drugs found to be MCU inhibitors would already be known to 
be safe for human use.  However this means it is necessary to design a screening approach 
which will be able to identify mitochondrial specific inhibitors, and this is what we aimed to 
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do in the work described in this chapter.  This project aimed to develop an aequorin based 
screening approach in order to screen the NINDS-2 compound library (see Appendix 2): 
compounds were screened initially using mitochondrial-targeted aequorin, and then with 
cytosolic aequorin, to ensure that changes in mitochondrial signal were not secondary to 
changes in the cytosolic calcium signal.  Different experimental approaches were used to 
confirm the results, and investigations were made of the compounds other effects on 
mitochondrial parameters.   
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Methods 
 
Tissue culture 
Tissue culture was carried out in a laminar flow cabinet in order to maintain a sterile 
environment and prevent contamination of the cells; before and after use the cabinet was 
cleaned with Virkon, and all items used for tissue culture were sprayed with 70% ethanol 
before being placed in the cabinet.  Lab coats and gloves were worn, and gloves were 
sprayed with 70% ethanol before placing hands in the cabinet.  After use, the cabinet was 
closed, the laminar airflow turned off, and sterilised with UV light.  Human embryonic 
kidney (HEK 293T) cells were cultured in Dulbecco’s Modified Eagles Medium (DMEM) with 
10% (v/v) Fetal Bovine Serum (FBS), in 10cm tissue culture treated sterile plates.  Cells were 
cultured in a 37°C incubator with 5% CO2 and 95% humidity.  HEK 293T cells were passaged 
every 2-3 days using trypsin: when cells were 80-90% confluent, media was removed, and 
cells were gently washed with PBS (5ml).  Trypsin (0.25% w/v, 2ml) was then added to the 
dish, and incubated for 1-2 minutes, until the cells began to lift from the plate.  DMEM + FBS 
(4ml) was then added to the plate to inactivate the trypsin and halt digestion, and the media 
was triturated to ensure the cells were all dislodged.  The cell suspension was then 
centrifuged at 500g for 5 minutes, in order to form a cell pellet free of all trypsin, and then 
resuspended in DMEM + FBS, counted if necessary, and plated as appropriate into a fresh 
10cm plate.  When it was necessary to plate a specific number of cells, 10l of cell 
suspension were mixed with 10l of trypan blue, and 10l of this mixture were pipetted 
onto a haemocytometer.  Four counts were then made – one of each shaded section (see 
Figure 3.2) – and an average count calculated.  This value was then multiplied by 2 (to 
account for the dilution with trypan blue), and then by 10000, in order to give an average 
number of cells/ml.   
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Figure 3.2: A haemocytometer.  Live cells in each shaded section were counted using a 20X microscope, and then an 
average cell number calculated.   
 
Transient Transfection with Aequorin cDNA 
HEK 293T cells were transfected using Fugene transfection reagent.  By splitting and 
counting the cells as described above, cells were plated into 6 well plates at a density of 1 
million cells/well.  After 24 hours, cells were transfected: per well to be transfected, 12l 
Fugene was added to 200l  Optimem and mixed.  4l DNA (1g/l) was then added and 
mixed, and the mixture incubated for 15 minutes at room temperature, during which time 
the cell media (DMEM + 10% FBS (v/v)) was replaced.  After incubation the transfection 
mixture was added dropwise to the cells.  Transfection reactions and media were removed 
after 24 hours, and cells were split, and plated into 96 well plates at a density of 50000 
cells/well.  Aequorin assays were carried out after a further 24 hours (48 hours after 
transfection). The mitochondrial aequorin construct is in the commercially available pcDNA3 
plasmid (with ampicillin resistance), and the cytosolic aequorin construct is in the VR1012 
plasmid (with kanomycin resistance (Hartikka et al., 1996)).  Both constructs are wild type, 
and the mitochondrial construct targeting sequence is subunit VIII of human cytochrome c 
oxidase, as described in (Rizzuto et al., 1992).   
Viral Transduction with Aequorin Adenovirus 
All viral work was carried out in a designated Biosafety Level III laboratory, using laminar 
flow cabinets and appropriate disposal methods.  HEK293T cells were transduced using wild 
type mitochondrial aequorin cDNA packaged in an adenoviral vector (kind gift from R. 
Rizzuto, Padova).  72 hours prior to assay, HEK293T cells at 80-90% confluency were split, 
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counted, and plated in opaque white 96 well plates at a density of 20000 cells/well.  This 
density was chosen as HEK293T cells will double in number approximately every 24 hours, 
but after addition of virus their growth slows dramatically; 20000 cells/well was found to 
produce an appropriate level of confluency on day of assay.  Extra wells were plated at the 
same density on a transparent 96 well plate in order to monitor the cell health and growth 
before and after addition of the virus.  24 hours after plating, cells were transduced with the 
viral aequorin: media was removed from the cells, and fresh DMEM containing the virus was 
added. After a further 24 hours, the media was removed from the cells, and replaced with 
fresh DMEM.  As the viral concentration was unknown, the volume of virus was titrated in 
order to ensure a sufficient expression level of the aequorin protein, and the optimum 
volume was found to be 2µl of the mitochondrial aequorin virus per well, and the optimum 
volume of cytosolic virus was 10µl/well.    
Aequorin Assays 
Transfected HEK293T cells were plated in opaque white 96 well plates at a density of 
50000cells/well, 24 hours prior to assay (transduced cells were plated as described above).  
Aequorin is expressed in an inactive form; to reconstitute the active protein, cells were 
incubated with the lipophilic prosthetic group coelenterazine (5µM) for 2 hours prior to 
assay at 37°C, in Krebs buffer (125mM NaCl, 5mM KCl, 1mM Na3PO4, 1mM MgSO4, 1g/l 
glucose, 20mM HEPES) plus 1mM CaCl2 or DMEM/HEPES buffer (1 bottle DMEM powder, 
4.5g/L glucose, 1mM sodium pyruvate, 2mM L-glutamine, 15mM HEPES), as specified.  
Coelenterazine was then removed and replaced with Krebs buffer or DMEM/HEPES as 
appropriate.  Cells were placed in a BMG Labtech Fluostar Optima plate reader to readjust 
to 37°C for at least 10 minutes (longer where drug treatments were required) and then 
assayed.  Standardly, cells were measured for 10 seconds before stimulation with ATP 
(100µM) and then a further 20 seconds before the addition of digitonin (1mM) and CaCl2 
(100mM) in dH2O, in order to produce Lmax.  For the high throughput screen these timings 
were reduced to ATP injection at 4 seconds, and digitonin at 13 seconds (total timecourse 
18 seconds).  Data were then calibrated using the appropriate constants (dependent on 
temperature and type of aequorin used), as described in Figure 3.1, or for the 18 second 
timecourse a ratio was made using the equation ratio = M/T, where M is the maximum ATP-
induced luminescence value, and T is the sum of all luminescence values after the digitonin 
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injection, see Figure 3.4.  For the initial high throughput screen, automated drug additions 
were carried out with the assistance of the Ketteler lab of the UCL Laboratory of Molecular 
and Cellular Biology, who also provided the NINDS-2 compound library.  Data were then 
analysed by B-score by Dr Janos Kriston-Vizi of the same lab, using the CellHTS2 analysis 
package, available from Bioconductor.   
Fluo4-am Assays 
Cytosolic Ca2+ responses to drugs were also assessed using Fluo4-AM, a cell permeant dye 
which, once diffused into the cell, is cleaved by cellular esterases into Fluo4 free acid and an 
AM group, leaving the charged Fluo4 trapped within the cell.  Cells were plated in an 
opaque black 96 well plate at 50 000 cells/well.  30 minutes prior to assay, cells were loaded 
with 5µM Fluo4-AM with 0.002% v/v pluronic acid and 1.4mM probenecid (to inhibit anionic 
transporters that may transport the dye from the cell) in Krebs buffer at 37°C, and drug 
concentrations as specified in results; cells were then washed and the buffer replaced with 
Krebs buffer + 200µM EGTA.  Fluorescence was measured with a BMG Labtech Fluostar 
Optima plate reader (Ex/Em 480/520); after 10 seconds baseline measurement, 100µM ATP 
was injected, followed by 2µM ionomycin after a further 20 seconds.  Measurements were 
calibrated by subtracting background counts, and then using the equation: [Ca2+] = Kd x 
(F/Fmax – 1/Rf)/(1 - F/Fmax), where the Kd is 350nM, Fmax is maximum fluorescence (post 
ionomycin addition) and Rf is 100 (Maravall et al., 2000).   
Measuring ΔΨm using an ImageXpress Micro-XL 
Cells were imaged on a Molecular Devices ImageXpress Micro-XL.  Cells were plated in clear 
bottomed black 96 well plates at a density of 50000/well, 24 hours before assay.   Cells were 
loaded for 30 minutes before assay with 25nM TMRM and 5µg/ml Hoechst in Krebs buffer 
at 37°C.  Ex/Em 377/50 and 531/540 and a 20X objective were used, and 9 sites were taken 
per well.  Basal levels were measured for 20 minutes before the addition of compounds.  
Fluorescence signals were then measured for a further 40 minutes before the addition of 
5µM FCCP to all wells, using the fluidics application, in order to give a minimum TMRM 
fluorescence value.  After acquisition, the mean cell integrated intensity of the TMRM was 
calculated for each well over the time course, using the MicroXpress High Content Image 
Acquisition and Analysis software.  Each time series was then expressed as a percentage of 
the average of its 20 minute baseline, and the minimum fluorescence value measured after 
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the addition of compound, before the addition of FCCP was used to assess the effect of the 
compound on membrane potential.     
Mitochondrial Isolation and Calcium Retention Capacity Assay 
Mitochondrial isolation and CRC assays were carried out as detailed elsewhere (Chapter 2, 
p66) in this thesis.   
Respirometry: Seahorse XF24 Extracellular Flux Analyzer 
Respirometry was carried out using a Seahorse XF 24 Extracellular Flux Analyzer as 
described elsewhere in this thesis (Chapter 2, p70).  HEK293T cells were plated 24 hours 
ahead of assay, at a density of 50000 cells/well.  Cells were incubated with the compounds 
(10M) for 30 minutes prior to assay (during the calibration of the fluorescent probes), and 
the drug additions were: oligomycin (5M), FCCP (2M), FCCP (2M), Antimycin A (5M).   
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Results 
 
Initial Screening of the NINDS-2 compound library 
 
HEK293T cells were transiently transfected with mitochondrial-targeted aequorin in order to 
assess the effect of the NINDS-2 compound library on mitochondrial calcium accumulation 
(see Appendix 2).  Cells were stimulated with 100µM ATP to generate a Ca2+ peak and then 
1mM digitonin and saturating CaCl2 to produce a maximal luminescence value. In order to 
screen large numbers of compounds, steps were taken to reduce assay time; this was due to 
a desire for efficiency (with a standard time course of 50 seconds, each 96 well plate would 
take 80 minutes, with 1040 compounds on 13 plates this would take 52 hours of assay time 
to screen the whole library in triplicate, not including reconstitution and other 
preparations), and additionally the observation that there was a time dependent effect on 
the magnitude of aequorin signals. 
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Figure 3.3: The time resolution of the signal for each well was reduced to enable high throughput screening.  A: Typical 
experiments run for 50 seconds, with ATP injected at 10 seconds and digitonin (DG) injected at 30 seconds.  B: The reduced 
temporal resolution gave a run of 18 seconds, with the ATP injection at 4 seconds and the digitonin at 13 seconds.   
 
 
One option to overcome this was to change the format in which the plate was read; instead 
of reading one well continuously for 50 seconds (well mode), it is possible to take one 
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measurement from each well and repeat this cycle multiple times (plate mode).  However, 
in plate mode, the lag time between cycles was found to be too long to capture the fast Ca2+ 
dynamics.  Therefore, it was decided to reduce the overall measurement time, in order to 
use well mode within reasonable time limits.  Initially, a 13 second measurement was 
trialled, with an ATP injection at 4 seconds, and no digitonin injection.  However, this was 
dismissed, as without an Lmax value, it cannot be said definitively that reductions in agonist-
induced response are due to the effect of the compounds, rather than lower aequorin 
expression.  Consequently it was decided to extend the timecourse to 18 seconds, in order 
to allow for an Lmax measurement (See Figure 3.3).   
 
 
 
Figure 3.4: An example of how the ratio values were calculated for the 18 second timecourse.  Using the luminescence 
values from the timecourse in Figure 3.3, a ratio was calculated between the maximum ATP induced luminescence value 
and the total digitonin-induced luminescence values.   
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This was found to be adequate to measure both responses.  However, as the digitonin peak 
does not return to baseline levels within this timecourse, the Lmax value is not a true Lmax as 
it doesn’t measure the total maximum light emitted in response to digitonin, and therefore 
cannot be used to calibrate the luminescence values into [Ca2+].  For the purposes of the 
screening however, it was not deemed necessary to calibrate into an actual [Ca2+], as long as 
the total luminescence is still taken into account; the effect of the compounds can be 
assessed by their effect relative to control compounds, rather than the absolute [Ca2+] 
produced.  Therefore a ratio was made, of the peak value after ATP stimulation divided by 
the total luminescence after digitonin injection (See Figure 3.4).   
 
The full drug library was then screened, using HEK293T cells transiently transfected with 
mitochondrial-targeted aequorin in order to assess the effect of the compounds.  Prior to 
assay, cells were treated with 10µM compounds or DMSO as a negative control; they were 
incubated with the compounds for 30 minutes at 37°C and then assayed in a BMG FluoStar 
plate reader.  
 
Out of 1040 compounds, 65 compounds were found which inhibited mitochondrial Ca2+ by 
more than two standard deviations from the mean (see Figure 3.5A).  Two standard 
deviations from the mean was arbitrarily selected for the purpose of keeping the number of 
compounds manageable, and the threshold could be raised or lowered as necessary.  It is 
also important to consider the total aequorin luminescence: compounds in which there was 
a significantly decreased total luminescence were likely to be raising Ca2+ concentration 
prior to the assay, and thus exhausting the aequorin supply, or it might indicate cell death 
induction by the compound. This would suggest they have off target effects, and are not 
suitable, therefore only compounds which did not deviate in total aequorin luminescence by 
more than two standard deviations from the mean were considered for further 
investigation.  The top 21 compounds which most strongly inhibited mitochondrial [Ca2+] 
without affecting total luminescence were selected for the next stage of the screen.   
 
It is notable that in the mitochondrial screen, the controls appear skewed to the upper left 
quadrant of the plot of peak [Ca2+] against total aequorin luminescence – this is due to the 
normalization method used to acquire these data.  The data were normalized by Dr Janos 
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Kriston-Vizi using B-score normalization (Brideau et al., 2003).  B-score is a sample-based 
normalization method recommended for high throughput screening (Malo et al., 2006), in 
which it is assumed that the majority of screened compounds will have no effect on 
phenotype, and the samples are therefore used as controls.  B-score is a measure of 
variability within each plate, and eliminates positional bias (Brideau et al., 2003).  
 
HEK293T cells were then transiently transfected with cytosolic aequorin in order to assess 
the effect of compounds on cytosolic [Ca2+].  In order to ensure mitochondrial specificity, 
successful compounds should have no effect on cytosolic [Ca2+] as it is likely that compounds 
which reduce cytosolic [Ca2+] are false positives: the reduced mitochondrial [Ca2+] in these 
instances would be a downstream effect of a reduced cytosolic [Ca2+] transient.  Therefore, 
in this secondary screen, compounds were selected for which the [Ca2+] signal did not differ 
from the controls (see Figure 3.5B).  This applied to only 3 of the 21 compounds screened.  
These were aminosalicylate sodium, cetylpyridinium chloride (also known as 
hexadecylpyridinium chloride) and desipramine hydrochloride (see Figure 3.6), hereafter 
designated as Drug A, H and D respectively.   
 
These compounds were found in different positions on the compound plates, suggesting 
that there was not a positional bias in the assay.  They have diverse uses: Drug A is an anti-
bacterial and tuberculostatic compound, Drug H is a topical anti-infective compound, and 
Drug D is an antidepressant (see Appendix 2).   
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Figure 3.5: Aequorin 
based screening of the 
NINDS-2 drug library.   
A: an initial screen of 
1040 compounds at 
10µM using 
mitochondrial targeted 
aequorin found 65 
compounds which 
inhibited mitochondrial 
calcium concentration by 
more than two standard 
deviation from the mean. 
The dotted box 
represents those 
compounds which inhibit 
mitochondrial [Ca
2+
] by 
more than four standard 
deviations, without 
affecting total 
luminescence. N =3.   
B: a secondary screen of 
the top 21 compounds  
(at 10M) selected from 
the initial screen, using 
cytosolic aequorin to find 
compounds which do not 
affect cytosolic [Ca
2+
].    
Three compounds were 
found to inhibit cytosolic 
[Ca
2+
] by less than two 
standard deviations from 
the mean.  N = 3.  
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Figure 3.6: Three compounds were identified as specific inhibitors of mitochondrial Ca
2+
 uptake.  These compounds were 
aminosalicylate sodium (Drug A), cetylpyridinium chloride (Drug H), and desipramine hydrochloride (Drug D).  Chemical 
structures own drawings (information from Sigma-Aldrich).   
 
 
Reconfirming screening results 
 
The next step was to reconfirm the actions of these compounds by other methods, to 
investigate whether the screen had been a robust method of detecting specific reductions in 
mitochondrial [Ca2+].  Initially, retroviral aequorin was used: as some cell lines do not 
transfect with a high enough efficiency to be practical, retroviral aequorin was used to 
transduce cells to investigate whether this could be an appropriate screening strategy for 
these cell lines.  FCCP (carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone) was used as 
a positive control for the mitochondrial aequorin and a negative control for the cytosolic.  
FCCP is a mitochondrial uncoupler which dissipates ΔΨm by equilibrating H+ ions across the 
mitochondrial membrane.  As a result of its effect on ΔΨm, FCCP inhibits mitochondrial 
calcium uptake through the MCU (which is ΔΨm dependent), but does not affect the agonist 
stimulated cytosolic [Ca2+] response, although it can cause an increase in resting cytosolic 
[Ca2+] (Luo et al., 1997).  It was found that Drugs D and H significantly reduced mitochondrial 
[Ca2+] responses in comparison to the DMSO control (see Figure 3.7A), but Drug A did not – 
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a contrast to the initial screening in which all these drugs significantly inhibited 
mitochondrial Ca2+ uptake.  
 
Drug D was also found to significantly inhibit cytosolic [Ca2+] responses in comparison to the 
DMSO control (see Figure 3.7B).  However, the cytosolic [Ca2+] responses shown in Figure 
3.7B are very unusual: they range from 2-9µM which is much higher than the standard 
cytosolic [Ca2+] response, which is in the nM range (Rizzuto and Pozzan, 2006).  This calls 
into serious doubt the validity of the cytosolic aequorin virus, and raises questions about 
whether the construct is truly cytosolic: these concentrations are much more typical of 
mitochondria.  Therefore, these results have been discounted, and an alternative approach 
was taken to confirm the effect of the compounds on cytosolic [Ca2+]: the fluorescent 
calcium indicator Fluo4-AM was used to measure cytosolic [Ca2+] in response to ATP 
stimulation (see Figure 3.7C), and it was found that none of the drugs were significantly 
different to DMSO control.    
 
A calcium retention capacity assay was also used on liver mitochondria isolated from adult 
C57/Black mice to investigate the effect of the compounds on mPTP opening (see Figure 
3.7D and 3.7E).  CsA was used as a positive control, as it is known to desensitize the pore to 
Ca2+, thereby delaying its opening.  It was found that Drugs A and D both inhibited pore 
opening, as the responses were not significantly different to CsA, but that Drug H 
potentiated pore opening in comparison to the DMSO control (0%), and was significantly 
different to CsA, Drug D and Drug A.  Inhibition of mPTP correlates with inhibition of MCU: it 
is logical that reduced mitochondrial Ca2+ uptake would be expected to delay mPTP opening, 
which is caused by mitochondrial Ca2+ overload, as was demonstrated in the MCU knock out 
mouse (Pan et al., 2013).  This contrasts with the data shown in Figure 3.7A, in which Drug A 
was found to not significantly reduce mitochondrial [Ca2+], whereas Drug H did.   
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Figure 3.7: Reconfirming the results of the initial screen.  A: Using the mitochondrial aequorin virus, FCCP (5M), Drug D 
and Drug H  significantly reduced mitochondrial [Ca
2+
].  N of 3.  B: Representative mitochondrial [Ca
2+
] trace using the 
mitochondrial aequorin virus.  C: Using the cytosolic aequorin virus, Drug D was found to significantly reduce [Ca
2+
], 
however these results were discounted due to doubt over the identity of aequorin construct.   N of 3.  D: Representative 
cytosolic [Ca
2+
] trace using the cytosolic aequorin virus.  E: None of the drugs affected cytosolic [Ca
2+
] when measured 
using the calcium indicator dye Fluo4-AM.  N of 3.  F: Representative cytosolic [Ca
2+
] trace using Fluo4-AM.  G: A CRC assay 
showed that only CsA (1M) was significantly different to DMSO (0%), but that Drug A and D had an inhibitory effect while 
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Drug H potentiated mPTP opening. N of 5.  H: A representative trace of the CRC assay.  * denotes significance as assessed 
by one way ANOVA * = p value <0.05, *** = p value < 0.005.  Drugs A, D and H were used at 10M for all these 
experiments.  Error Bars are SEM.   
 
 
Investigating the effect of compounds on other mitochondrial parameters 
 
In order to further investigate the mechanism of action of the three compounds, their effect 
on mitochondrial membrane potential (ΔΨm) was examined using the cationic fluorescent 
dye TMRM (Figure 3.8A).  As mitochondrial calcium uptake through the MCU is dependent 
on mitochondrial ΔΨm, any drugs which dissipate ΔΨm (visible as a reduction in TMRM) will 
reduce mitochondrial calcium uptake independently of any action on the MCU, as a 
downstream effect of the reduction in ΔΨm.  FCCP was used as a positive control.    
 
TMRM intensity was found to be significantly reduced in comparison to DMSO control in 
HEK293T cells treated with Drug H (see Figure 3.8B), whereas it was not significantly 
different in cells treated with Drug A or D.  This confirms that the inhibition of mitochondrial 
calcium uptake by Drugs A and D is not a consequence of inhibition of ΔΨm, but that Drug H 
may be working indirectly on MCU, via ΔΨm.  In all conditions FCCP ablated TMRM intensity 
when added after 40 minutes incubation with the compounds of interest, confirming loss of 
TMRM fluorescence corresponds to a drop in ΔΨm.   
 
The effect of the compounds on oxygen consumption was then investigated, using a 
Seahorse XF Flux Analyzer (Figure 3.8D).  Drugs A and D had no effect in comparison to 
DMSO, but Drug H significantly reduced basal oxygen consumption, although it had no 
effect on leak respiration, and no significant effect on maximal consumption, though it 
appeared reduced.  This suggests that the reduction of ΔΨm seen in Figure 8B may be due 
to inhibition of respiration, as ΔΨm is generated by the activity of the electron transport 
chain.   
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Figure 3.8: Drugs A and D act independently of mitochondrial membrane potential, and do not affect oxygen 
consumption.  A:  HEK293T cells stained with Hoechst and TMRM prior to drug addition.  B: TMRM fluorescence (relative 
to baseline) was significantly reduced by addition of Drug H in HEK293T cells, but not affected by addition of any other 
drugs in HEK293T cells.  N of 3.  C: Representative trace of TMRM intensity after 10µM drug addition in HEK293T cells.  D: 
Basal oxygen consumption was significantly reduced by Drug H (in comparison to DMSO), but not affected by Drugs A or D.  
N of 3.  Significance was assessed by one-way ANOVA,* denotes significance.  * = p value <0.05.  Error bars are SEM.   
A: 
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Summary 
 
Overall, it was demonstrated that an aequorin based screening approach can be used to find 
mitochondrial specific inhibitors of mitochondrial Ca2+ uptake: of the NINDS-2 compound 
library, the initial mitochondrial and cytosolic aequorin screens identified three compounds, 
Drug A, D and H, which inhibited mitochondrial [Ca2+] uptake and did not affect cytosolic 
[Ca2+] responses.  Screening with viral aequorin to verify the actions of these compounds 
was carried out, and revealed that Drug A had no effect on mitochondrial [Ca2+] uptake, and 
that the cytosolic aequorin construct was likely contaminated.  Fluo4-AM was found to be a 
simple alternative method for assessing impact on cytosolic [Ca2+], and reconfirmed that the 
compounds did not affect cytosolic [Ca2+], and a calcium retention capacity assay was found 
to be another possible approach.  Imaging with TMRM was shown to be an essential step to 
verify the specificity of inhibition, and Drug H was shown to significantly reduce ΔΨm, and 
therefore be indirectly reducing mitochondrial [Ca2+] uptake rather than directly inhibiting 
MCU.  Measurement of oxygen consumption cast further light on the mechanism of action 
of the compounds.    
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Discussion 
 
The initial screen using mitochondrial targeted aequorin was a successful approach, 
enabling the screening of a large library relatively easily and quickly (at the rate of 84 
compounds an hour, or the entire library in 13 hours).  A moderately high number of 
compounds were found to be of interest in this screen: 65 compounds were found to inhibit 
mitochondrial [Ca2+] by more than two standard deviations from the mean.  It would have 
been useful to have positive controls included in this part of the screen, however this was 
not possible due to the automated drug addition (necessary to maintain the efficiency of 
screening) and the lack of a suitable control – whilst FCCP has been used elsewhere in this 
study it does not directly inhibit the MCU, which would be desirable in an optimal control.   
 
Although there were 65 positive hits from the mitochondrial screen, only 21 were used for 
the next step; this was in order to keep the cost of screening low, whilst the screening 
method was still in development, these other compounds could be screened in future 
investigations.  From the top 21 mitochondrial Ca2+ inhibitors, only 3 were found not to have 
affected cytosolic [Ca2+] responses.  An alternative approach could have been to start the 
screen with a cytosolic screen and so eliminate all compounds which did affect cytosolic 
[Ca2+] before proceeding to the mitochondrial screen – this may have been a more efficient 
approach, as 85% of the compounds reduced cytosolic [Ca2+], and these compounds could 
be immediately eliminated from the screen.    
 
Another approach would be to screen all compounds with both mitochondrial and cytosolic 
aequorin simultaneously; whilst this approach would have been the most thorough it would 
also significantly increase the time necessary for screening, using the 96 well plate reader 
method.  Alternatively, a FLIPR device could be used for screening: this enables the 
simultaneous measurement of every well in a 96 well plate; therefore the original 50 
seconds timecourse could be used, and the screening of the entire library in triplicate would 
take only ~32 minutes of assay time, significantly reducing screening time.  This would be 
highly advantageous to increase the throughput of screening, and would be recommended 
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for any further library screens, however no luminescence-capable FLIPR was available for 
this project.   
 
When reconfirming the effect of the drugs using a virally transduced mitochondrial-targeted 
aequorin (Figure 3.7), it was found that only Drugs D and H were significantly different to 
the DMSO control, and that Drug A did not reduce mitochondrial [Ca2+] at all.  
 
There was clearly an issue with the results from the viral cytosolic aequorin: the [Ca2+] 
responses found in these experiments were much higher than would be expected in the 
cytosol, and therefore these data were completely discounted, as the method cannot be 
relied upon.  It is possible that the cytosolic virus may have been confused or contaminated 
with the mitochondrial virus during transit, as the [Ca2+] values are much more 
representative of mitochondrial [Ca2+]; in order to establish which aequorin this is, it could 
be tested with FCCP: if it is a mitochondria-targeted construct, FCCP should significantly 
decrease [Ca2+] due to its effects as an uncoupler, whereas if it is really a cytosolic construct 
FCCP should have no effect.  Another method of establishing the identity of the cDNA would 
be to sequence it to identify whether the mitochondrial COX targeting sequence is present.  
Alternatively, this could be due to low transduction efficiency: if a low level of aequorin was 
expressed, a large proportion may be used up in the initial agonist-induced response, 
meaning that the aequorin could be entirely consumed before the peak digitonin-induced 
response was reached, meaning it would not be representative of true Lmax, and therefore 
the calibration would be skewed.  
 
When assessed using Fluo4-AM, ATP-induced cytosolic Ca2+ signals did not differ between 
conditions.  Fluo4-AM could be an acceptable alternative for the initial cytosolic screen, 
especially for cells which do not easily transfect or transduce.  Although the timecourse of a 
Fluo4-AM experiment is too long (1 minute/well) to enable high throughput screening, this 
could be reduced, as was the aequorin timecourse, or a FLIPR could be used to measure all 
wells simultaneously.  If a FLIPR device could be acquired which was capable of measuring 
luminescence and fluorescence simultaneously, Fluo4-AM could even be used in the same 
cells as mitochondrial-targeted aequorin – Fluo4-AM is excited at 480nm and emits at 
510nm, whereas aequorin luminesces at 465nm -  in order to measure mitochondrial and 
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cytosolic Ca2+ together.  Another method of dual measurement, using luminescence and 
fluorescence, would be to simultaneously measure mitochondrial aequorin and TMRM in 
order to measure mitochondrial membrane potential and mitochondrial Ca2+ together.   
 
The CRC assay showed that Drug A and Drug D inhibited mPTP opening to a similar extent as 
CsA.  It would be expected that MCU inhibitors would inhibit mPTP opening, as they would 
reduce mitochondrial Ca2+ uptake, and therefore mitochondrial [Ca2+], which is the critical 
trigger for mPTP opening.  Interestingly however, Drug A has previously been shown in 
Figure 3.7A to not significantly reduce mitochondrial [Ca2+], and Drug H had been shown to 
significantly reduce it, whereas in this experiment Drug H was not inhibiting mPTP opening, 
and was in fact potentiating it.  These contrasting results suggest that Drug H could be 
having other effects which are causing the earlier opening of mPTP, as mitochondrial Ca2+ 
overload is not the only cause of mPTP opening; it was demonstrated that Drug H also 
significantly reduced mitochondrial membrane potential and oxygen consumption.  
Mitochondria can produce reactive oxygen species (ROS) such as superoxide, which is 
produced by the reduction by one electron of O2 (Murphy, 2009).  Superoxide flux is 
determined by both the availability of electron donors, and the local O2 concentration, 
which has been demonstrated to be altered by Drug H: this suggests that Drug H could be 
potentiating mPTP opening through production of ROS.  This could be tested by FACS or 
confocal imaging with a ROS sensitive dye, such as dihydroethidium (DHE), to investigate 
whether Drug H increases ROS production above basal levels.  This would not be necessary 
to include as part of an initial screen for mitochondria-specific inhibitors, but could be a 
useful secondary step for determining mechanism of action.   
 
Drug H was found to significantly reduce TMRM fluorescence (and therefore ΔΨm) in 
comparison to a DMSO control (Figure 3.8).  This demonstrates that Drug H is not acting 
directly on the MCU – it is indirectly inhibiting mitochondrial Ca2+ uptake by reducing 
mitochondrial membrane potential, upon which MCU mediated uptake relies.  This shows 
that this is an important step of the screening, to check the specificity of the compounds.  
 
The effect of the compounds on oxygen consumption was also investigated – ATP 
production via oxidative phosphorylation is the primary function of mitochondria, and 
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therefore it is important that any potential inhibitors do not affect oxygen consumption.  
Drugs A and D were found to have no significant affect on oxygen consumption, whereas 
Drug H significantly reduced basal levels in comparison to DMSO controls.  This is not a 
surprising result, as Drug H was found to significantly reduce ΔΨm, which is generated by 
the passage of protons across the inner membrane by the electron transport chain, 
therefore a reduction in basal oxygen consumption would directly account for the reduced 
ΔΨm.  This demonstrates that Drug H is conclusively not an MCU specific inhibitor.   
 
From the NINDS-2 library screened in this study, 3 drugs were found which in a preliminary 
screen significantly reduced mitochondrial [Ca2+] without affecting cytosolic [Ca2+] 
responses; using mitochondrial-targeted aequorin was a useful approach for determining 
drug specificity.  When reconfirmed using viral aequorin, Drug A was found to not inhibit 
mitochondrial [Ca2+], and when the effect of the compounds on ΔΨm was investigated, Drug 
H was found to significantly reduce membrane potential and oxygen consumption, and to 
potentiate mPTP opening. In this screen, Drug D was found to specifically inhibit 
mitochondrial Ca2+ without affecting cytosolic Ca2+ responses, although it was not a 
particularly potent inhibitor; this was reconfirmed using viral aequorin, Fluo4-AM, and the 
CRC assay.  It did not affect mitochondrial membrane potential or oxygen consumption, 
important measurements of mitochondrial health.  Further work would be to do dose 
response experiments, and to investigate the pharmacokinetics and methods of action of 
Drug D, in addition to more work on possible side effects, such as ROS production.  It would 
also be interesting to test these drugs in cells from the MCU knock out mouse to verify their 
specificity for the MCU.   
 
Finding an inhibitor of the MCU would provide an invaluable research tool and has 
considerable translational potential for pathologies involving calcium overload.  Overall, this 
screening approach appears to be a good preliminary method of screening large numbers of 
compounds before progressing to more in depth analysis of any positive hits, and could be 
used to screen other compound libraries in order to identify such inhibitors.  
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Chapter 4: Investigating the role of the 
MCU in vitro.   
Introduction 
 
The Mitochondrial Calcium Uniporter (MCU) 
Until recently, the molecular components of the mitochondrial calcium uniporter complex 
were unknown.  A variety of components have now been identified: MCU (Baughman et al., 
2011; De Stefani et al., 2011), MCUb (Raffaello et al., 2013), MICU1/2/3 (Perocchi et al., 
2010; Plovanich et al., 2013), EMRE (Sancak et al., 2013), MCUR1 (Mallilankaraman et al., 
2012a), and SLC25A23 (Hoffman et al., 2014).  Investigations into the role and function of 
these proteins have begun (see Chapter 1, “the mitochondrial Ca2+ uptake complex” p33-
47), but much work is still needed to fully understand the function of the individual proteins, 
the function of the entire complex in health and disease, the composition of the complex, 
and the manner of its regulation.  Investigating the role of each of the components is too 
large a task for one project, therefore it was decided to focus initially on MCU, as the central 
component of the pore and the MCU complex.   
To recap, in the original studies identifying MCU, MCU knockdown was found to cause no 
differences in mitochondrial volume or number, ΔΨm, or basal and uncoupled respiration, 
but to significantly reduce agonist stimulated mitochondrial Ca2+ uptake (Baughman et al., 
2011; De Stefani et al., 2011).  Overexpression was found to increase H2O2 mediated cell 
death, and the DIME motif was identified as being essential for Ca2+ uptake.  The knock out 
mouse did not have an overt phenotype, and the most notable difference (beyond ablation 
of mitochondrial Ca2+ uptake) was that the MCU -/- mice performed worse in high intensity 
exercise tests (Pan et al., 2013).  There have been contradicting reports on the effect of 
MCU knock out on cell death, with the original knockout mouse paper reporting there was 
no effect (Pan et al., 2013), and the latter conditional knockout showing protection (Kwong 
et al., 2015; Luongo et al., 2015).   
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Many more studies have been published in the intervening years since the identification of 
the gene CCDC109a as the MCU.  These studies have found a plethora of functions in which 
MCU is involved, in diverse areas and organisms.  For example, MCU knockdown has been 
found to increase autophagy (Mallilankaraman et al., 2012b), and to regulate metabolism in 
the heart, coupling energy supply and demand (Kwong et al., 2015; Luongo et al., 2015; Wu 
et al., 2015).  It has also been found to be involved in ROS mediated wound closure in C. 
elegans  (Xu and Chisholm, 2014), to play a role in NMDA induced toxicity – against which 
MCU knockdown is protective (Qiu et al., 2013) – and to be important for the development 
of the notochord and anteroposterior stages during gastrulation in zebrafish development 
(Prudent et al., 2013).  MCU also has an increasing number of roles in cancer cells: it has 
been found to mediate breast cancer cell progression via transcription factor HIF-1 
(Tosatto et al., 2016), to have a role in regulating passage into and out from senescence 
(Wiel et al., 2014), and in mediating cerastol-induced paraptosis (cell death characterized by 
extensive vacuolization) in breast cancer cells (Yoon et al., 2014).  Despite these discoveries, 
MCU function is still relatively uncharacterized, and further investigation is warranted, to 
confirm these data and to expand upon them.   
Protein function can be examined chemically, using drugs to inhibit or potentiate function, 
or genetically, by reducing or removing gene expression and therefore protein function.  
Due to the issues (lack of specificity and permeability) with the existing inhibitors of the 
MCU, as described elsewhere in this thesis (Chapter 3, p88), it was decided to investigate 
the function of the MCU genetically, by transfecting cells with constructs targeting the 
CCDC109a gene.   
Transfection 
Transfection is a powerful tool for the study of gene and protein function: it is a procedure 
which produces genetically altered cells through the use of transfection reagents which 
introduce foreign nucleic acids (DNA and RNA) to the cell.  The goal of transfection is to 
study the function of specific genes and the gene products, by either enhancing or inhibiting 
gene expression. Transfection is an alternative to the use of transgenic animals as it allows 
the study of gene function without the need for housing, breeding and sacrificing animals, 
thus complying with the replacement principle of using non animal methods to achieve the 
same scientific aims, although animals are still useful to demonstrate how genetic 
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alterations impact within a multicellular organism rather than the more simplistic cell 
culture model. 
Cells can be transfected either transiently or stably; stable transfections require a selection 
marker, usually an antibiotic resistance gene, and will continue to express transgenes in 
future generations of cells.  Transient transfections do not require selection and transgenes 
are only temporarily expressed, typically for up to 72 hours after transfection, although 
some methods provide longer expression.  Transiently transfected cells will not express the 
transgene in future generations (Kim and Eberwine, 2010), as the introduced nucleic acid is 
not integrated into the genome, so it will be diluted through mitosis, and degraded.  Both 
have their advantages and should be selected depending on the experimental requirements.   
DNA and RNA can be transfected into cells, although usually with opposite purpose: 
transfection with DNA is usually to express a new protein, or overexpress an existing 
protein, whereas transfection with RNA is often to prevent protein expression through gene 
knockdown with RNA interference (RNAi).  RNAi was first used in 1998 (Fire et al., 1998); it 
allows the knockdown of gene expression and has a variety of applications, such as the 
study of protein function, pathway analysis and drug target discovery.  RNAi can be used in a 
wide variety of cells, and also in vivo.  There are different types of RNAi including short 
interfering RNA (siRNA), and short hairpin RNA (shRNA), amongst others.   
siRNAs are double stranded RNAs (dsRNAs) of 21-25bp, with dinucleotide 3’ overhangs.  
They induce gene knockdown through the RNA-induced silencing complex (RISC): the 
antisense strand of the siRNA is incorporated into RISC and acts as a targeting sequence to 
identify the corresponding mRNA.  RISC then cleaves the matching mRNA and marks it for 
degradation, resulting in loss of protein expression, as no further protein encoded by that 
mRNA will be synthesized (for overview, (Sen and Blau, 2006)).  shRNA (contained in DNA 
vectors) is a subset of RNAi used for stable gene knockdown.  shRNA can be introduced to 
the cell through transfection or transduction, and can integrate into the host cell DNA.  They 
consist of two 19-22bp RNA sequences linked by a short “hairpin” loop of 4-11 nucleotides.  
After transcription, the shRNA is exported to the cytosol, where it is processed into siRNA by 
the enzyme Dicer, and is incorporated into RISC, which binds to the target sequence, and 
marks it for degradation (Paddison et al., 2002).  
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Methods of transfection  
Unfortunately, there is not one methodology which works for all cell types and nucleic acid 
types.  Multiple methods of transfection exist, and each of them need optimizing for 
different cell types in order to produce maximum transfection efficiency.  Optimization of 
the transfection method aims to achieve high and reproducible transfection efficiency with 
minimal cell toxicity.   
One of the main challenges in optimizing transfection is reducing toxicity to the cell: in order 
to deliver genetic material (most commonly to the nucleus, although other parts of the cell 
can also be targeted), it is generally necessary to disrupt the plasma membrane.  This can 
cause membrane leakiness and activate stress response pathways, which can impact cell 
health and sometimes lead to cell death. Many transfection reagents require a serum-free 
medium, which can also damage cell health.   
Transfection methods can be either chemical, physical, or biological.  Each method has 
advantages and disadvantages; these are summarised in Table 3.  This is not an exhaustive 
list: other methods also exist, such as direct injection of genetic material into cells, laser 
irradiation to disrupt the plasma membrane, and the use of nanoparticles for delivery into 
the cell.   
Transfection method Type of method Advantages Disadvantages 
 
Lipofection 
E.g.  Fugene, 
Lipofectamine, Viafect, 
Effectene 
Chemical: uses 
positively charged 
cationic liposomes 
which form complexes 
with negatively 
charged DNA, and are 
thus able to fuse to cell 
membranes. 
 
Easy to use 
Widely available  
Low cost 
Applicable to a wide 
range of immortalized 
cell lines 
Requires extensive 
optimization to find 
optimum lipofection 
agent:DNA ratio 
(Recillas-Targa, 2006) 
Calcium phosphate Chemical: forms a 
precipitate of 
positively charged 
Inexpensive Batch dependent 
efficiency (Graham and 
van der Eb, 1973) 
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calcium and negatively 
charged phosphate 
which binds DNA on its 
surface. 
 
Morpholino  Chemical: an oligomer 
with a backbone of 
morpholino rings, 
targets specific mRNA 
sequences and 
prevents translation by 
steric blocking.   
 
Does not require 
additional reagents 
Must be designed and 
synthesized specially  
Expensive 
(Summerton, 1999) 
Electroporation 
E.g. nucleofection 
Physical: uses an 
electrical pulse to 
permeabilize the cell 
membrane, allowing 
the transfer of genetic 
material inside the cell. 
   
Does not require 
vector 
Can be used in vivo 
Uses small amounts of 
DNA 
High rate of cell death 
Requires special 
equipment (Neumann 
et al., 1982) 
Viral transduction 
E.g. Lentiviral, 
retroviral 
Biological: viral vector 
carrying nucleic acid 
infects host cell, and 
NA is integrated into 
the nuclear genome, 
replicated and 
transcribed.   
 
High efficiency 
Can infect non dividing 
cells 
Biohazard, requires 
GM license and Level 2 
containment 
laboratories (Akkina et 
al., 1996) 
Can have high cell 
toxicity 
Table 3: a summary of the primary advantages and disadvantages of a range of transfection techniques.   
 
Transfecting primary cultures 
Primary cultures are cells isolated directly from tissue, which may initially contain more than 
one cell type, as opposed to cell lines, which are cells of one type which are either naturally 
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immortal (such as cancer cell lines) or have been genetically altered to inhibit genes 
involved in senescence (Stacey, 2006).   
Primary cells are a more relevant model than immortalized cell lines, as they more closely 
retain the characteristics of cells in vivo than immortalized cell lines, which are either cancer 
cell lines or cell lines with extreme genetic modifications.  However, primary cells are more 
labour intensive to prepare, and they can only be kept in culture for a limited time before 
entering senescence and dying – this is as described by the Hayflick Limit, which is the 
number of times which a population of human cells will divide, before entering senescence 
(HAYFLICK and MOORHEAD, 1961).  This is dependent on cell type, and is linked to the 
length of telomeres, which shorten after each cycle of cell division, and eventually induce 
apoptosis after reaching a specified length.  Primary cells are also more vulnerable, requiring 
specific media containing growth factors and cytokines, and requiring more expertise to 
culture than immortalized cell lines (ATCC, 2012).  With minor exceptions, primary neurons 
do not divide (Fishel et al., 2007), and therefore it is not possible to generate stably 
transfected neuronal lines (Zeitelhofer et al., 2009).  They can with difficulty be transiently 
transfected or transduced, but this is harder to achieve than in immortalized cell lines, and 
they are also more vulnerable to transfection-induced toxicity and cell death.   
HEK293T cells were selected for initial study: they are a widely used and easy to transfect 
cell line, and the MCU gene is highly expressed in the kidney (Mallilankaraman et al., 
2012a), making these kidney derived cells appropriate for the study of MCU function.  In this 
project, the properties of the MCU were investigated through the creation of a stable MCU 
knockdown cell line in HEK293T cells, created through the lipofection of HEK293T cells with 
shRNA constructs.  Mitochondrial and cytosolic [Ca2+], at rest and under stimulation, 
mitochondrial morphology and membrane potential, oxygen consumption, cell growth and 
cell death were then investigated.   
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Methods 
 
Tissue culture 
Tissue culture of HEK293T cells was carried out as described elsewhere (Chapter 3, p93) in 
this thesis.   
Transient Fugene Transfection 
Transient Fugene transfections were carried out as described elsewhere (Chapter 3, p94) in 
this thesis.  The shRNA constructs used were obtained from OpenBioSystems, and the 
sequences were as follows: 
Identified 
in text: 
OpenBioSystems 
Nomenclature: 
Sequence (mature 
antisense): 
Target GC Content 
#58 V3LHS_410058 TTTCATACACAATGATCCC 3’ UTR 36.8% 
#62 V3LHS_370862 TGAGTGTGAACTGACAGCG ORF 52.6% 
#86 V2LHS_37186 GACAATATTCACTAAGCCC ORF 52.6% 
Table 4: identities, sequences and details of the shRNA constructs used to create transient knockdown of MCU.   
Constructs were received as bacterial stabs, and were amplified by the Central Lab facility at 
UCL, run (at the time of use) by Mary Rahman.   
Stable Transfection 
HEK 293T cells were transfected using Fugene transfection reagent, as described in Chapter 
3.  However, 24 hours after transfection cells were split at low confluency into 10cm plates; 
this and all subsequent steps were simultaneously done with cells which had not been 
transfected.  After another 48 hours, media was removed and replaced with selection media 
(DMEM + 10% v/v FBS + 1µg/µl puromycin).  Once all non-transfected cells had died 
(approximately 5-7 days after the addition of selection media), single colonies were picked 
and grown in 96 well plates, and numbered according to the order in which they were 
picked.  Once confluent in a 96 well plate, they were transferred to and grown in 6 well 
plates.  Cells were maintained in selection media until freezing (3-6 passages), and then in 
DMEM + 10% v/v FBS only; cells were reselected with puromycin every 10-20 passages to 
ensure the population was still transfected.   
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Protein sample collection 
Protein samples were collected from cells grown in 6 well plates: tissue culture media was 
removed from cells and they were rinsed gently with PBS.  100l of RIPA buffer (150mM 
NaCl, 0.5% (v/v) sodium deoxycholic acid, 0.1% (v/v) SDS. 1% (v/v) Triton X-100, 50mM Tris 
pH 8.0, 1mM PMSF) were added per well and solubilised cells were collected using a rubber 
spatula; this was then transferred to an Eppendorf (on ice) and spun at 13200g for 10 
minutes at 4°C, then the protein containing supernatant was removed and stored, and the 
pellet discarded.  Samples were stored at -20°C until use.   
Western blot 
Protein samples were quantified using a Qiagen BCA protein quantification kit according to 
manufacturer’s instructions.  Samples were prepared with loading buffer and boiled as 
appropriate per antibody (for anti-MCU and anti-MCUb antibodies this was for 5 minutes at 
100C, for the oxphos cocktail antibody this was for 5 minutes at 55C).  10% NuPAGE gels 
were loaded with 15-50µg (usually 30µg) protein per well and run at 120V in MES running 
buffer until sufficient separation was achieved.  Blotting pads were pre-soaked in transfer 
buffer, and PVDF membranes were cut to size, activated in methanol, and then soaked in 
transfer buffer.  Transfer apparatus was then assembled, and gels were transferred onto a 
PVDF membrane using a semi-dry transfer at 20V; protein transfer was checked with 
Ponceau-S, and then membranes were blocked for one hour at room temperature in PBS-
Tween containing 5% (w/v) milk.  Primary antibodies were applied overnight at 4°C, at 
appropriate dilutions (see Materials); membranes were then washed 3X for 5 minutes each 
with PBS-Tween before application of a suitable horseradish peroxidase-conjugated 
secondary antibody for 1 hour at room temperature in PBS-Tween and 5% (w/v) milk.  
Membranes were washed 3X for 5 minutes each with PBS-Tween, then imaged on a BioRAD 
ChemiDoc system using BioRAD ECL.  Where a loading control was necessary, membranes 
were then further washed 3X for 5 minutes each with PBS-Tween before repeating the 
primary and secondary antibody steps with an appropriate loading control (usually beta-
actin).  Images were analysed using ImageJ, and relative intensities were normalized to 
loading controls.   
Aequorin assays 
Aequorin assays were carried out as detailed elsewhere (Chapter 3, p95) in this thesis.     
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Fluo4 Assays 
Responses to drugs were also assessed by measuring cytosolic [Ca2+] by the Fluo4 
fluorescent dye.  Cells were plated in an opaque black 96 well plate at 50 000 cells/well.  30 
minutes prior to assay, cells were loaded with 5µM Fluo4-AM with 0.002% (v/v) pluronic 
acid and 1.4mM probenecid in Krebs buffer at 37°C, and drug concentrations as specified in 
results; cells were then washed and the buffer replaced with Krebs buffer.  Fluorescence 
was measured with a BMG Labtech Fluostar Optima plate reader; after 10 seconds baseline 
measurement, 100µM ATP was injected, followed by 2µM ionomycin after a further 20 
seconds.  Measurements were calibrated by subtracting background counts, and then using 
the equation: [Ca2+] = Kd x (F/Fmax – 1/Rf)/(1 - F/Fmax), where the Kd is 350nM, Fmax is 
maximum fluorescence (post ionomycin addition) and Rf is 100 (Maravall et al., 2000).   
Respirometry: Oroboros 
Oxygen consumption rates were measured using an Oroboros Oxygraph-2K system. 
Confluent cells (grown in 10cm plates for 48 hours prior to assay) were trypsinized, counted, 
and diluted to 1 million cells/ml in DMEM/HEPES (as described in Chapter 3).  Prior to assay, 
electrode air calibration was performed were calibrated with DMEM/HEPES, as suggested 
by manufacturer’s protocol.  2ml of cell suspension were added to each chamber, and the 
O2 flow signal allowed to stabilise to the routine respiration rate.  Drugs were added to the 
chambers using Hamilton syringes at the following concentrations and order: histamine 
(100µM, to one chamber only), oligomycin (2.5µM), FCCP (titrated 1l at a time from 1mM 
stock, to produce maximal respiratory capacity), and antimycin A (2.5µM).  Data were then 
extracted and analysed using O2K cell analysis template, in order to give oxygen 
consumption per unit cells. For the galactose experiments, cells were grown in galactose 
media (DMEM powder (8.3g/L), pyruvate (1mM), galactose (5.5mM), glutamax, sodium 
bicarbonate (44mM), FBS (10% v/v), penicillin/streptomycin (1% v/v)), for a minimum of two 
weeks prior to measurement, and galactose media was used throughout the experiment (to 
calibrate the chambers, resuspend the cells).   
ImageXpress – measurement of mitochondrial membrane potential 
Cells were imaged on a Molecular Devices ImageXpress Micro-XL.  Cells were plated 24 
hours before assay, and loaded for 30 minutes before assay with 30nM TMRM and 5µg/ml 
Hoechst in Krebs buffer at 37°C.  Steady state TMRM intensities were measured for 20 
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minutes before the addition of 5µM FCCP to all wells.  The mean cell integrated intensity of 
TMRM was calculated for each well over the time course, using the MetaXpress High 
Content Image Acquisition and Analysis software, and averaged for each cell type. 
ImageXpress – measurement of transfection efficiency and cell death 
Cells were imaged on a Molecular Devices ImageXpress Micro-XL.  Cells were transfected 48 
hours before assay with cDNA for red fluorescent protein (RFP), as a marker of successful 
transfection, and loaded for 15 minutes before assay with Sytox Green (40nM), a marker of 
cell death and 5µg/ml Hoechst (to mark total cell number) in recording buffer at 37°C. 
Images were taken using a 20X objective, and excitation wavelengths 377nm (Hoechst), 
562nm (RFP) and 462 nm (Sytox Green). MicroXpress High Content Image Acquisition and 
Analysis software was used to analyse the images: multi-wavelength cell scoring was used to 
count the number of cells positive for each wavelength, and percentages were made of cell 
death (Sytox Green positive cells divided by total cells) and of transfection efficiency (RFP 
positive cells divided by total cells).  In all transfection methods, non-transfected cells were 
used as controls; % cell death in non-transfected cells was subtracted from % cell death in 
transfected cells, to give the % cell death caused specifically by transfection.   
ImageXpress – measurement of thapsigargin induced cell death  
Cells were plated into a 96 well plate at a density of 10000 cells/well.  24 hours after plating, 
media was removed and replaced with either DMEM + DMSO or DMEM + thapsigargin 
(1M) for half of the cells in the plate (48 hour treatment).  After a further 24 hours, media 
was removed and replaced with either DMEM + DMSO or DMEM + thapsigargin (1M) for 
the other half of the plate (24 hour treatment).  After another 24 hours, cells were imaged 
using the Molecular Devices ImageXpress XL: cells were loaded for 15 minutes before assay 
with Sytox Green (40nM), and 5µg/ml Hoechst in recording buffer at 37°C. Images were 
taken using a 20X objective, and excitation wavelengths 377nm (Hoechst), and 462 nm 
(Sytox Green).  MicroXpress High Content Image Acquisition and Analysis software was used 
to analyse the images: multi-wavelength cell scoring was used to count the number of cells 
positive for each wavelength, and a percentage was made of Sytox Green positive cells 
divided by total cells to indicate % cell death.   
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Mitochondrial morphology 
Cells were plated on glass coverslips (22mm) 24 hours in advance of imaging, at a density of 
1 million cells/coverslip.  30 minutes prior to imaging, cells were loaded in recording buffer 
with TMRM (25nM) and Hoechst (5g/ml).  Cells were imaged on a Zeiss 700 LSM using a 
63X oil objective, and single images were taken.  These images were visually scored, and 
each cell was awarded a score of 1-3, using the following criteria: for cells in which all of the 
mitochondria were fragmented, a score of 1 was given.  For cells in which all of the 
mitochondria were fused, a score of 3 was given, and for cells in which some mitochondria 
were fragmented, and some were fused, a score of 2 was given.  Images were compared to 
other images of fused and fragmented mitochondria (see for example Logan et. al., 2013, 
Figure 4) to identify which score was appropriate.    
4mtGCaMP6m experiments 
 
 
Figure 4.0: A simplified mechanism of 4mtGCaMP6m fluorescence.  A donor and acceptor are separated by a Ca
2+
 
responsive element (CRE).  Ca
2+
 binding to CRE causes conformational change and alters the FRET efficiency, leading to a 
change in the acceptor/donor emission ratio (Hill et al., 2014).     
 
48 hours prior to imaging, cells were transiently transfected with mitochondrial targeted 
4mtGCaMP6m cDNA (Logan et al., 2014) using Fugene (as described in Chapter 3).  24 hours 
after transfection, the cells were plated onto glass coverslips (22mm) at a density of 1 
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million cells/coverslip.  They were imaged using an Olympus TH4-200 microscope, controlled 
using Metafluor software, and using a 20X air objective.  Cells were imaged in recording 
buffer.  GCaMP was excited at 410nm and 480nm and images were collected every 5 
seconds.  A baseline was recorded for 30 seconds, followed by the addition of ionomycin 
(2M) and imaging for a further 60 seconds.  The background was subtracted from both 
wavelengths, and regions of interest drawn around cells showing fluorescence.  A ratio was 
made of the 480:410 fluorescence intensity (see Figure 4.0), and this was calibrated into a 
[Ca2+] using the equation:  
[Ca2+] = Kd x (F/Fmax – 1/Rf)/(1 - F/Fmax) 
Where Kd is 167, F is fluorescence value, and Fmax is the maximum fluorescence value in 
the time course.  These data were then averaged and significance tested by one-way 
ANOVA.   
Growth assay 
HEK293T cells were plated at a density of 5000 cells/well of a 96 well plate in DMEM.  4 
plates were prepared per experiment. After 24 hours the growth medium was replaced with 
fresh DMEM, and simultaneously, one plate was fixed with paraformaldehyde (PFA) to give 
a 0-hour time point.  24 hours later, another plate was fixed (24 hour timepoint), and this 
was repeated at 48 and 72 hours after medium change.  To fix the cells, 4% (v/v) 
paraformaldehyde was prepared in PBS.  DMEM was removed from the cells, and they were 
gently rinsed in PBS, which was removed and replaced with 100µl of 4% (v/v) PFA per well.  
This was incubated for 30 minutes at room temperature before being removed and replaced 
with PBS containing Hoechst (5µg/ml).  This was incubated for 10 minutes at room 
temperature, after which the cells were rinsed 3X with PBS, and stored in PBS at 4C until 
imaged.  Plates were imaged using the Molecular Devices ImageXpress XL, using a 10X 
objective and Ex/Em 377/447nm.  16 images were taken per well, to ensure that the entire 
surface area was imaged to give an accurate total cell count.  MicroXpress High Content 
Image Acquisition and Analysis software was used to analyse the images by creating a 
specification of nuclei size and intensity, in order to ensure recognition of all nuclei and 
avoid double counting.  These data were then averaged and tested for significance by one-
way ANOVA.   
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Fluorescence activated cell sorting (FACS) 
Cells were plated into a 24 well plate 48 hours prior to assay.  Cells were incubated with 
either DMSO or 1µM A23187 (a Ca2+ ionophore) in DMEM (no FBS) for 12 hours overnight.  
After incubation, media was removed and kept, and cells were trypsinized.  Trypsin was 
inactivated with DMEM + FBS, and the cells triturated and added to the previously removed 
media.  Control samples were run on an Accuri C-Flow Plus FACS machine with no dye in 
order to gate the whole cell population and exclude debris; this was done by measuring 
forward scattering versus side scattering.  Control samples were then run with 1µg/ml 
propidium iodide (PI) to determine where to establish the division between the live and 
dead cell populations.  Samples were then loaded with PI and run until 5000 events 
occurred within the gate.   
Immunocytochemistry 
DIV 7 primary neuronal cells grown in 96 well plates were fixed with 4% (v/v) 
paraformaldehyde in PBS and then permeabilized for 5 minutes with TritonX (0.2% v/v).  
Blocking was carried out in PBS + 3% (w/v) BSA for 1 hour at 25°C and then incubated at 4°C 
overnight with anti-MAP2 primary antibody (1 in 2000).  Cells were then washed 3X with 
PBS, and incubated with a 488 conjugated donkey anti-mouse antibody in PBS + 3% (w/v) 
BSA (1 in 4000) for 3 hours at 25°C.  Cells were then washed 3X with PBS, and then 
incubated with Hoechst (5g/ml) for 5 minutes.  Cells were again washed with PBS and then 
stored at 4°C.  Primary and secondary antibody specificity was ensured by inclusion of both 
no primary, and no secondary antibody controls.  To quantify staining, cells were imaged on 
a Molecular Devices ImageXpress MicroXL, using excitation/emission 377/460nm for 
Hoechst and 472/520nm for MAP2 staining, and data were analysed using the 
multiwavelength cell scoring application on MetaXpress software.   
Lipofectamine LTX transfection 
Neurons were prepared as described in Chapter 2 of this thesis, and grown in 96 well plates.  
Cells were transfected at DIV5.  To prepare the transfection mix, DNA (4g per well of a 6 
well plate) was added to Optimem (500l/well) and flicked to mix.  Lipofectamine Plus 
reagent (4l/well) was then added and gently mixed; this was then incubated at room 
temperature for 5 minutes.  Lipofectamine LTX reagent (4l/well) was then added and 
flicked to mix; this was then incubated at room temperature for 5 minutes, during which 
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time the media on the cells was changed to Neurobasal (Glutamax and B27 only).  After 
incubation the transfection mix was added dropwise to the cells and incubated overnight at 
37°C, 5% CO2, after which the media was removed and replaced.  Transfection efficiency 
was measured 48 hours after transfection.   
Calcium phosphate transfection 
Neurons were prepared as described in Chapter 2 of this thesis, and grown in 96 well plates.  
Cells were transfected at DIV5.  48 hours prior to assay, the transfection mixture was 
prepared: CaCl2 (10l of 2.5M stock) was mixed with DNA (8g) and mqH2O (100l), and 
then 2X HBS (100l, 280mM NaCl, 1.5mM Na2HPO4, 50mM HEPES, pH 7.12) was added by 
vortexing, and the mixture was incubated for 10 minutes at room temperature, during 
which time the cell media was removed and replaced with fresh media.  The transfection 
mixture was then added dropwise onto cells, and incubated overnight.  Media was 
removed, cells were washed with PBS, and fresh media was added.  Measurements given 
are per well of a 6 well plate.   
Viafect transfection 
Neurons were prepared as described in Chapter 2 of this thesis, and grown in 96 well plates.  
Cells were transfected at DIV5.  48 hours prior to assay, the transfection mixture was 
prepared: DNA:Viafect in a ratio of 1:3.  These were mixed together and incubated at room 
temperature for 25 minutes, then added dropwise directly onto cells (at 10l/well of a 96 
well plate); Viafect does not require removal of serum or media replacement (before or 
after transfection).  Cells were then incubated at 37C/5% CO2 until assay.   
Nucleofection 
Neurons were prepared as described in Chapter 2 of this thesis, and grown in 96 well plates.  
Cells were transfected at DIV5.  Primary cortical neurons were prepared as described 
elsewhere in this thesis (Chapter 2, p67).  96 well plates which had been coated with 
polylysine were pre-incubated (containing 100l neurobasal medium/well) in a 37C/5% 
CO2 incubator, as was additional neurobasal medium.  Prior to plating, cells were 
nucleofected with RFP cDNA using a Lonza nucleofector: 5x106 cells per sample were 
centrifuged at 500 g for 5 minutes at room temperature.  The supernatant was discarded, 
and the pellet was resuspended in 100µl room temperature Nucleofector Solution per 
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sample.  This cell suspension was then combined with 2µg of DNA, and the mixture was 
transferred into a Nucleofector cuvette.  On the nucleofector itself, the program O-003 (for 
primary rat neurons) was selected, and the cuvette was inserted into the Nucleofector, and 
the program run.  When the program finished, the cuvette was removed, and 500l of the 
pre-incubated neurobasal medium was added to the cuvette.  This was then transferred 
directly into the prepared 96 well plate, and the cells incubated at 37C/5% CO2.  After 4 
hours the medium was carefully replaced with fresh neurobasal medium in order to remove 
cell debris, and the medium was replaced again after a further 24 hours.  Cells were imaged 
to assess % transfection and % cell death 48 hours after nucleofection.   
Endoporter transfection 
Neurons were prepared as described in Chapter 2 of this thesis, and grown in 96 well plates.  
Cells were transfected at DIV5.  48 hours prior to assay, the media was completely removed 
and replaced with fresh neurobasal.  The endoporter was supplied with a fluorescent tag; 
this was used at the recommended concentration (5M).  In 500l of neurobasal medium, 
2.5l of the fluorescent tag were added, and mixed, followed by 3l of endoporter (again as 
recommended), and mixed again.  This was then added dropwise to the cells (at 50l per 
well of a 96 well plate).  Cells were imaged to assess % transfection and % cell death 48 
hours after transfection.   
Morpholino 
Neurons were prepared as described in Chapter 2 of this thesis, and grown in 96 well plates.  
Cells were treated at DIV5.  A 500µM morpholino stock was kept at RT.  2X solutions were 
prepared in Neurobasal medium (see Figure 4.10 for concentration range used), and 50% of 
the media of the neurons to be treated was removed, and replaced with an equal volume of 
2X morpholino.  After 24 hours, this media was removed and replaced, and after another 24 
hours cells were assayed.  The sequence of the morpholino used was 
GTCCACGTCATTAATGTTCTTCAGG, which targets the mouse MICU1 gene.  The morpholino 
was a kind gift of Dr Haiyan Zhou at the Institute of Child Health, and was of her own design 
(ordered from Gene Tools).   
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Results 
 
Transient transfections with MCU targeted shRNA 
 
HEK293T cells were transiently transfected with MCU shRNA knockdown constructs to 
investigate the effect of reduced levels of MCU protein.  
Firstly, the effect of the shRNA constructs on MCU protein level was assessed by Western 
blot.  As shown in Figure 4.1A, no significant difference was found in the MCU protein level 
between control cells (transfected with scrambled shRNA vector, or the vector alone pGIPZ) 
and MCU-knockdown cells.  This suggests the transfection efficiency of the knockdown 
construct may be too low to be able to see its functional effects.  To verify this, these cells 
were transiently transfected with either mitochondrial-targeted or cytosolic aequorin in 
order to assess whether there had been any functional consequence of the constructs on 
mitochondrial Ca2+ uptake.  Cells were transfected with a mitochondrial-targeted or 
cytosolic aequorin construct and assayed in a plate reader using stimulation with 100µM 
ATP to generate a Ca2+ signal, which was calibrated into [Ca2+] using a total luminescence 
value provided by the later addition of digitonin (not shown, see Methods).  As shown in 
Figure 4.1C and 4.1D, there was no difference in either mitochondrial or cytosolic Ca2+ 
signal, confirming the lack of knockdown.   
In transient transfections, transgenes are only expressed for up to 72 hours after 
transfection, therefore if the protein turnover for MCU is longer than this, a transient 
transfection may not impact the cell’s current proteome.  Therefore, it was decided to make 
a stable monoclonal MCU-knockdown cell line in order to produce a significant knockdown 
of MCU protein.  In stable cell lines, the transgene is continually expressed, and therefore 
will affect the cell’s protein population.  Knockdown construct #58 was chosen for the 
production of a stable cell line, as it had given the lowest level of MCU protein, despite not 
reaching significance.   
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Figure 4.1: HEK293T cells transiently transfected with MCU knockdown constructs do not show different MCU protein 
levels, or altered mitochondrial or cytosolic Ca
2+
 levels.  A: MCU knockdown construct #58 is most effective at reducing 
MCU protein levels compared to scrambled and pGIPZ controls; no significant difference between any conditions.  N of 3. 
B: a representative Western blot of the transient transfections.  C: peak Ca
2+
 concentration reached after stimulation with 
100µM ATP.  Transiently transfected cells were not significantly different to scrambled or pGIPZ controls.  N of 3.  D: 
representative trace of an ATP-induced Ca
2+
 response.  Significance was assessed by one-way ANOVA.  Error bars are SEM.   
 
Creating and characterizing a stable MCU knockdown cell line 
 
Next, cell lines stably expressing MCU shRNA knockdown were established using construct 
#58, as described in the methods, and monoclones selected, also as described in the 
methods.  Monoclonal cells are a group of cells which have all been replicated from a single 
common ancestor, meaning they are genetically identical to each other, and genetically 
distinct to monoclones derived from a different common ancestor; therefore it is of use to 
test more than one monoclone in case their genetic variation causes functional variation.  
MCU protein levels of several control (scr) and knockdown (KD) monoclones were assessed 
by Western blot (see Figure 4.2A and 4.2B), and it was found that three MCU-knockdown 
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monoclones – KD7, KD33 and KD36 – showed significantly lower MCU expression than 
scrambled controls and these were therefore selected for further testing.  
It was recently shown that altered MCU complex component expression can result in 
alterations to the protein levels of other complex components ((Kamer and Mootha, 2014), 
therefore protein levels of MCUb were also investigated in the MCU-knockdown 
monoclones (Figure 4.2C and 4.2D), and it was found that MCUb protein levels were not 
significantly affected in any of the monoclones; knockdown resulted in a change in the 
MCU:MCUb ratio of one order of magnitude: the average ratio for the SCR clones being 
1.09, and for the MCU KD clones being 0.11.   
 
Figure 4.2: MCU protein levels in HEK293T cells can be significantly reduced by stable transfection.  A: Relative levels of 
MCU protein in monoclones of HEK293T cells stably transfected with construct #58. * denotes significant difference in 
comparison to Scr 4 control as assessed by one-way ANOVa, p<0.05.  KD 7, KD 33, KD 35, and KD 36 were all also 
significantly different to Scr 34 control, p<0.05.  N of 3.  B:  a representative Western blot of the clones which were chosen 
for further study.  C; relative protein levels of MCUb in stably transfected MCU knockdown cells and scrambled controls.  N 
of 3.  D: a representative Western blot of MCUb protein levels. Error bars are SEM.   
< MCUb 
< -actin 
 133 
 
The effect of MCU knockdown in stable clones was then explored.  Initially, the effect of 
MCU knockdown on Ca2+ signalling was investigated: cells were again transiently transfected 
with mitochondrial-targeted or cytosolic aequorin construct and their response to 100µM 
ATP measured.  MCU knockdown significantly reduced mitochondrial Ca2+ peak 
concentration: all three knockdown clones had significantly lower peak mitochondrial Ca2+ 
concentrations than the two scrambled controls, with maximum [Ca2+] of 43-55% of control 
(see Figure 4.3), whereas cytosolic Ca2+ peak concentrations were unaffected.  Therefore, 
MCU knockdown specifically reduces mitochondrial Ca2+ uptake.   
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Figure 4.3: HEK293T cells stably transfected with MCU knockdown constructs show significantly reduced mitochondrial, 
but not cytosolic agonist-induced Ca
2+
 concentration in comparison to controls.  A: peak Ca
2+
 concentration reached after 
stimulation with 100µM ATP.  All three knockdown clones (KD 7, 33, 36) had significantly lower mitochondrial Ca
2+
 
concentrations in comparison to both scrambled controls (p value <0.001), whereas cytosolic Ca
2+
 concentrations were 
unchanged .  N of 3.  B: representative trace of an ATP-induced Ca
2+
 response.  Significance was assessed by one-way 
ANOVa, * denotes significance.  ** = p value <0.01.  Error bars are SEM.   
 
Next, mitochondrial membrane potential and morphology were examined.  Mitochondrial 
Ca2+ uptake is dependent on ΔΨm, so it is an important parameter to consider: it was found 
that MCU knockdown had no effect on membrane potential (Figure 4.4A), showing that the 
reduced mitochondrial Ca2+ uptake demonstrated in Figure 2 was not due to reduced 
mitochondrial membrane potential.  Mitochondrial morphology was scored per cell, as all 
fragmented (1), all fused (3), or a mixture of both (3) (see Figure 4.4C).  MCU knockdown 
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had no effect on morphology (Figure 4.4B), there was no difference in mitochondria 
morphology between the scrambled and MCU knockdown cells.   
 
 
 
 
 
 
 
 
 
 
Figure 4.4: Mitochondrial membrane potential and morphology were not affected.  A: Mitochondrial membrane 
potential was not affected by MCU knockdown.  N of 4.  B: Mitochondrial morphology was not affected by MCU 
knockdown .  Each cell was scored either 1 (all fragmented), 2 (some fragmented, some fused) or 3 (all fused) and an 
average taken for each clone of ~60 cells from a total of 3 images per clone (n of 3).  C: Representative image to 
demonstrate morphology scoring method.  Significance was assessed by one-way ANOVA.  Error bars are SEM.   
 
Basal mitochondrial [Ca2+] was measured using 4mtGCaMP6m, and basal cytosolic [Ca2+] 
was measured using the calcium indicator dye Fluo4-AM (Figure 4.5).  Basal Ca2+ 
concentrations in MCU knockdown clones were not significantly different from scrambled 
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clones in either experiment, although basal cytosolic Ca2+ concentrations were unusually 
high in all clones.  This shows that MCU knockdown does not result in lower resting 
mitochondrial [Ca2+], and that it is only reduces Ca2+ uptake when stimulated.   
 
 
Figure 4.5: Basal mitochondrial and cytosolic [Ca
2+
].  A: Basal mitochondrial [Ca
2+
] measured using GCaMP was not 
significantly different between control and knockdown cells.  N of 3. B: Basal cytosolic [Ca
2+
] measured using Fluo4-AM was 
not significantly different between control and knockdown cells.  N of 4.  Significance was assessed by one-way ANOVA.  
Error bars are SEM.   
 
In order to investigate the downstream consequences of MCU KD, Ca2+ stimulated 
respiration was examined in the stable MCU KD clones. Oxygen consumption of control and 
MCU knockdown cells was assessed in different respiratory states using an Oroboros O2K 
Oxygraph.  Routine (steady state) oxygen consumption was measured prior to any drug 
addition, once respiration had stabilised (Figure 4.6A and 4.6B).  Leak respiration was 
measured after the addition of oligomycin, an inhibitor of ATP synthase which allows 
assessment of the rate of proton leak through the membrane (Figure 4.6C and 4.6D); a high 
leak state is indicative of increased proton leak across the inner mitochondrial membrane, 
and can be due to a loss of membrane integrity.  Maximal electron transfer system (ETS), 
capacity was measured after the addition of the uncoupler FCCP (Figure 4.6E and 4.6F).  It 
was found that oxygen consumption did not differ significantly between MCU knockdown 
cells and SCR control cells in any respiratory state, with or without the addition of histamine.   
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Figure 4.6 (previous page): MCU knockdown does not affect the rate of respiration, or the protein level of electron 
transport chain protein complexes I-V.  Respiration with and without the addition of 100µM histamine: Routine 
respiration in glucose media. B: Routine respiration in galactose media.  C: Leak respiration in glucose media.  C: Leak 
respiration in galactose media. D: ETS respiration in glucose media.  E:  ETS respiration in galactose media.  In all conditions, 
and with both media, O2 flow does not differ between MCU knockdown cells and SCR controls, and the addition of 
histamine does not cause any significant differences.  G: Relative levels of protein of complexes I-V of the ETC was assessed 
by Western blot and there were no significant differences between MCU knockdown cells and SCR controls.  H: 
Representative Western blot of ETC complexes.  All panels are n of 3 (except H).  Significance assessed by one-way ANOVA.   
Error bars are SEM.   
 
The respirometry experiments were done in both glucose and galactose based media; many 
cell lines, and those derived from cancer tissues in particular, derive their ATP supply from 
glycolysis rather than oxidative phosphorylation (Bensinger and Christofk, 2012), and 
consequently, effects on OXPHOS of modifications to mitochondrial proteins may be harder 
to see in these models.  To overcome this, cells can be grown using galactose rather than 
glucose, which suppresses glycolysis and shifts the energy dependency toward oxidative 
phosphorylation (Reitzer et al., 1979; MacVicar and Lane, 2014).  However, there were still 
no significant differences between MCU knockdown cells and SCR controls in any respiratory 
state.  Protein levels of the ETC complexes were also assessed, and there was no detectable 
difference between samples from SCR control and MCU knockdown cells (Figure 4.6G and 
H).   
Cell growth was also measured: cells were plated at low density in 96 well plates, and cell 
number was recorded at 0, 24, 48 and 72 hours after a media change (24 hours after 
plating) in order to monitor the effect of MCU knockdown on growth. There were no 
differences in the growth rate between MCU knockdown cells and scrambled control cells at 
any time point (Figure 4.7). In support of this, another experiment, done by Dr Aleck Jones 
(not shown) demonstrated there were no significant differences in the rate at which the 
cells progressed through the cell cycle between SCR and KD clones.   
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Figure 4.7: Rates of cell growth in 
SCR and MCU KD cells.  A: Medium 
was changed at 0 hours, and cells 
were fixed and imaged at 0, 24, 48 
and 72 hours, and there were no 
significant difference sin cell number 
between SCR and KD cells.  N of 4.  
Significance was tested by one-way 
ANOVA.  Error bars are SEM.   
 
 
Next, cell death was investigated.  Firstly, to verify that increased [Ca2+] causes death in 
these cells, the calcium ionophore A23187 was used to raise intracellular [Ca2+] by enabling 
Ca2+ cations to equilibrate across the cell and mitochondrial membrane (Pressman, 1976), 
bypassing the MCU.  Cell death was significantly increased by the ionophore in all clones 
treated, and there was no significant difference between responses in scrambled controls 
and MCU knockdowns (as would be expected), as the Ca2+ overload is MCU independent 
(see Figure 4.8A).  This confirms that increased [Ca2+] causes cell death, and that this can be 
measured by FACS.   
Then, cells were tested using thapsigargin (TG), an inhibitor of SERCA which causes Ca2+ 
release from the ER, in order to produce mitochondrial Ca2+ overload in an MCU-dependent 
manner.   However, this approach was unsuccessful: after both 24 (Figure 4.8B) and 48 
hours (Figure 4.8C) treatment with TG (1M), only 1-4% cell death was apparent in both 
DMSO treated and TG treated cells, suggesting that TG treatment had no effect.  TG 
treatment did not trigger Ca2+ dependent cell death, and therefore it was not possible to 
determine at this time whether MCU knockdown is protective against cell death, when Ca2+ 
is transported into mitochondria by the MCU.  
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Figure 4.8: An MCU independent Ca
2+
 increase causes Ca
2+
 induced cell death.  A: Cells were treated with the Ca
2+
 
ionophore A23187 (1µM) for 12 hours overnight, and cells were assayed by FACS, using Propidium Iodide (PI) as a marker 
of cells death.  There is a significant increase in cell death in treated cells compared to untreated cells in all clones; but 
there is no difference in cell death between MCU knockdown clones and controls, as would be expected. N of 3.  B and C: 
Cells were treated with either DMSO or Thapsigargin (TG, 1µM) for 24 (B) or 48 (C) hours, and cells were imaged using 
Sytox Green as a marker of cell death, using the Molecular Devices Image Xpress.  No significant differences were found 
between treated and untreated, or SCR and MCU KD cells at either timepoint.  Both N of 3, * marks significance as tested 
by one-way ANOVA, ** = p value< 0.01.  Error bars are SEM.   
 
Summary 
 
Overall, transient transfection was shown to be insufficient to investigate the effect of MCU 
knockdown.  In stably transfected HEK293T monoclones, MCU knockdown was shown to 
significantly reduce stimulated mitochondrial Ca2+ levels, without affecting stimulated 
cytosolic Ca2+ concentration; and to have no effect on respiration or on levels of respiratory 
chain proteins, or cell growth.  The effect of MCU knockdown on cell death was not 
determined.   
HEK293Ts are a useful model system for preliminary studies, however they have limitations: 
as they are an immortalized, cancerous cell lines they are not always representative of how 
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normal cells would behave.  Therefore, it is useful to consider using other model systems, 
such as primary cells and animal models, in order to generate more physiologically relevant 
data.   
 
Transfecting primary neurons 
 
It was decided to investigate the role of MCU in primary neuronal cultures, by knocking 
down MCU expression; Ca2+ signalling is especially important in the brain, so MCU is of 
special interest in this model.  In addition to characterizing the effect of MCU knockdown in 
primary neuronal cultures on general mitochondrial properties, it would be of particular 
interest to investigate glutamate excitotoxicity and delayed calcium deregulation (DCD, see 
page 57) in neurons with reduced MCU expression.  For this purpose, a method for 
measuring DCD was developed and optimised (see Appendix 4, Figure A3).  
 
A:       B: 
 
 
 
 
 
 
 
 
Figure 4.9: 92.6% of cells were neurons.  A – cultures stained with Hoechst and MAP2.  B – Quantification of staining 
showed that 92.6% of cells stained with Hoechst were also stained with MAP2.  Error bars are SEM.   
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All transfection conditions were optimised using DIV 5-7 primary cortical neurons from E17 
rat embryos.  These were used as it is possible to get nearly entirely pure neuronal cultures 
without the use of cell division inhibitors such as cytarabine (AraC).  The percentage of 
neuronal cells within the cultures was investigated using microtubule associated protein 2 
(MAP2) staining; MAP2 is a neuron specific cytoskeletal protein which is not present in 
astrocytes and glial cells (NCBI Gene, 2015); cultures were on average 92.6% neuronal cells, 
see Figure 4.9.  
 
 
Figure 4.10: Assessment of efficiency and toxicity of different transfection techniques.   A: Transfection efficiency using a 
variety of transfection techniques.  B: Quantification of cell death using different transfection techniques.  C: Cell death 
increased proportionately to concentration of morpholino treatment. 
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As primary cells are more difficult to transfect, a variety of transfection techniques were 
tried, in order to provide maximum transfection efficiency.  To assess efficiency of 
transfection using different techniques, neurons were transfected with cDNA encoding red 
fluorescent protein (RFP), using the optimised technique for each transfection method.  
Transfection efficiency was calculated by measuring the total number of transfected cells as 
a percentage of total cells, and average efficiencies are shown in Figure 4.10A. The 
transfection procedures were found to be extremely variable between different 
experimental repeats, therefore the maximal transfection efficiency found in any 
experiment is also shown in Figure 4.10A, although this was generally not replicable.  It is 
clear that nucleofection was the most efficient transfection method, however this still only 
had an average efficiency of 3.8%, and a maximal efficiency of 4.5%. Additionally, all 
transfection procedures caused considerable cell death (Figure 4.10B); this ranged from 5-
60%, with calcium phosphate being the most toxic transfection method, and the endoporter 
the least.  Cell death increased with morpholino concentration (Figure 4.10C) and at the 
manufacturer recommended concentrations (200-500nM) was between 2-20%.   
The low transfection levels found with each of these techniques is not sufficient for whole 
cell-population studies, or for confocal imaging, and as time did not permit further 
optimization, further studies were not undertaken in primary neuronal cultures.   
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Discussion 
 
Considering the low level of protein knockdown in transiently transfected HEK293T cells, as 
demonstrated by Western blot in Figure 4.1A, it is not surprising that there was no 
significant difference in peak mitochondrial Ca2+ levels between MCU knockdown and 
control cells (Figure 4.1C).  Transfection efficiency of HEK 293T cells by Fugene has 
previously been found to be approximately 60% (data not shown), so it may have been 
expected that some knockdown would be apparent; in cells transfected with construct #58, 
there was some visible reduction in protein level, although this was not significant.  
Knockdown is also dependent on the efficacy of the knockdown constructs, explaining the 
disparity between the three different constructs.   This can depend on factors such as which 
splice variant (if there are more than one) the shRNA targets, whether the target site has 
previously been validated, if the construct contains sequences which could trigger 
premature termination, whether the target site overlaps any regions of single nucleotide 
polymorphisms (SNPs), amongst others (Moore et al., 2010).  These shRNA constructs were 
ordered from OpenBioSystems (see Methods for details), who do not publish their construct 
design strategy, however these constructs have not been previously confirmed.  An 
alternative approach to MCU knockdown could be to overexpress MCUb, the dominant 
negative isoform of MCU (Raffaello et al., 2013), as this would also result in reduced 
mitochondrial Ca2+ uptake, and allow examination of the effects of this on the cell.   
Stable transfection was markedly more successful at reducing levels of MCU protein; in 
Figure 4.2A the levels of MCU protein in clone numbers #7, #33, and #36 were reduced to 6-
8% of SCR control.   
MCUb protein levels (Figure 4.2C) were not significantly affected by MCU knockdown.  
MCUb has been shown to form an oligomer with MCU (Rafaello 2013), so it was interesting 
to investigate whether MCU knockdown would also cause a reduction in MCUb levels, to 
keep the ratio of MCU:MCUb the same. This did not happen, and the MCU:MCUb ratio 
changed significantly between the SCR (ratio of 1.09) and MCU KD (ratio of 0.11) clones.    
The mitochondrial Ca2+ peaks in response to ATP were also significantly reduced, see Figure 
4.3; however the peak [Ca2+] was only reduced to approximately 50% of scrambled control.  
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This is surprising considering the extent to which the protein level is reduced, as previous 
work suggests the effects of MCU knockdown increases with longer exposure to genetic 
modifying agents: it was previously found that in HeLa cells, MCU silencing by siRNA 
reduced mitochondrial [Ca2+] responses by 75% 72 hours after transfection, but only by 50% 
after 48 hours (De Stefani et al., 2011).  As in these cells, the knockdown is stable, it would 
be hoped that the functional knockdown would be more complete.  This could suggest that 
the other proteins of the MCU complex (or other mitochondrial proteins) are able to 
compensate for reduced expression of MCU in order to prevent loss of function; to test this 
theory it would be interesting to create multiple knockdown cells lines in which MCU and 
another component could be targeted, in order to see which, if any component causes the 
compensation for loss of MCU.  As the MCUb protein levels did not change with MCU 
knockdown, this is unlikely to be a compensatory component.  It would also be useful to 
investigate the mRNA levels using quantitative PCR (qPCR), to determine the extent to 
which the shRNA resulted in degradation of MCU mRNA.   
Mitochondrial membrane potential and morphology were not affected by MCU knockdown 
(Figure 4.4). Membrane potential is an important parameter to check, as mitochondrial Ca2+ 
uptake is dependent on it, therefore it is essential to know that it is unaffected in order to 
conclude that the reduction in mitochondrial Ca2+ uptake is specifically due to MCU 
knockdown.  For absolute verification of this, it would have been useful to measure 
membrane potential concurrently with Ca2+ signals, rather than separately.  Mitochondrial 
morphology changes in response to the cellular environment, and the bioenergetics 
demands of such conditions.  Previous studies have suggested that increased resting 
mitochondrial [Ca2] is associated with mitochondrial fragmentation (Logan et al., 2014), 
however no change was seen with MCU knockdown in this case.  This was supported by the 
finding that there was no change in resting mitochondrial or cytosolic [Ca2+] between SCR 
and MCU KD cells (Figure 4.5), unlike MICU1 -/- patient fibroblasts, in which mitochondria 
were fragmented, basal mitochondrial [Ca2+] was higher, and basal cytosolic [Ca2+] was 
lower than in controls (Logan et al., 2014). However, basal cytosolic Ca2+ was unusually high 
(300-600nM, compared to usual basal concentrations of ~100nM) in all clones, which calls 
these data into question.   
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MCU knockdown does not appear to have any effect on routine, leak or ETS respiration 
states, in either glucose or galactose-based media.  Moreover, the relative protein levels of 
the oxidative phosphorylation complexes were not affected by MCU knockdown (Figure 
4.6).  It might be expected that altered levels of mitochondrial Ca2+ may have some effect on 
respiration due to the stimulation of the dehydrogenases of the TCA cycle by mitochondrial 
Ca2+; this is somewhat supported by findings in the MCU knockout mouse in which basal 
metabolism was unaltered but there were differences in the phosphorylation and activity of 
pyruvate dehydrogenase (Pan et al., 2013).  This supports the unaltered basal rate seen 
here.  Pyruvate dehydrogenase phosphorylation and activity was not investigated in this cell 
line; but it would be interesting to study.   
The electron transfer system capacity (ETS) (in which an uncoupler is used to dissipate 
membrane potential in order to induce the maximal rate of respiration by the ETC) was not 
examined in the knockout mouse. It might be expected that there would be no difference in 
ETS between control and MCU knockdown: as the membrane potential is dissipated the 
MCU would cease to function even in control cells, unless there were differences in complex 
protein levels.  Histamine had no measurable effect on respiratory rate in control or MCU-
knock down cells.  Previously, in MICU1 knockdown cells, low (10µM) histamine increased 
respiration, whereas high (100µM) histamine did not (Mallilankaraman et al., 2012b); as my 
experiments used 100µM histamine it is possible some effect might be seen using a lower 
histamine concentration, although the differences seen by Mallilankaraman et. al., may be 
an effect of the altered uptake curve of MICU1, and therefore not apply.  
Cell growth was also examined; there was no difference between SCR and MCU KD cells in 
cell number, or in cell cycle progression (data not shown).  It was noted that the MCU 
knockout mouse was smaller than the wild type (Pan et al., 2013), although this is a 
common feature of knockout mice (Reed et al., 2008), and may therefore not necessarily be 
an MCU specific trait.  
Previous work has shown conflicting results over the role of MCU knockdown in protection 
from Ca2+ induced cell death: it has been found to be protective against NMDA induced 
excitotoxicity in neuronal cells (Qiu et al., 2013), and against ischaemia reperfusion injury in 
a conditional MCU knock out mouse (Kwong et al., 2015), although a different MCU 
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knockout mouse showed no protection against coronary ischaemia induced necrosis, 
contrary to expectations (Pan et al., 2013).   The ionophore A23187 raises intracellular [Ca2+] 
by enabling Ca2+ cations to equilibrate across the cell membrane (Pressman, 1976).  
Therefore, in cells treated with this compound, it would be expected that MCU knockdown 
would have no effect - as Ca2+ is being transported directly into the matrix bypassing the 
mitochondrial calcium transport machinery – but that cell death would result from the Ca2+ 
overload.  This is what was seen in the experiments in Figure 4.8: there was no effect of 
MCU knockdown on A23187 induced cell death, and it was found that increasing 
mitochondrial [Ca2+] does result in significant cell death.  Furthermore, the effect of MCU 
dependent mitochondrial [Ca2+] increases on cell death was investigated. This was tested 
using a (non-ionophore) drug to induce cytosolic [Ca2+] increase, thapsigargin.  As 
thapsigargin causes Ca2+ release from the ER, cytosolic [Ca2+] will rise, and therefore 
mitochondrial [Ca2+] should rise – in an MCU dependent manner - with risk of Ca2+ overload 
and resultant cell death (Rogers et al., 1995).  However, it was found that TG did not induce 
significant levels of cell death, and the level of cell death was not sufficient to establish 
whether MCU knockdown was protective, and so this question remains open.  This is 
unusual, as TG is well established as a treatment for causing Ca2+ induced cell death (Nath et 
al., 1997; Takadera and Ohyashiki, 1998), therefore it is likely that with optimization of this 
procedure, a sufficient level of cell death could be produced.   
Overall, MCU knockdown in HEK293T cells was found to have little effect, beyond reducing 
mitochondrial [Ca2+] when cells were stimulated.  There was no effect on MCUb protein 
level, mitochondrial membrane potential, morphology, basal mitochondrial or cytosolic 
[Ca2+], respiration, or cell growth, and the effect on cell death could not be determined.  
Therefore, it was decided that it could be interesting to examine the effects in a different 
type of cell: rather than using an immortalized human cancer cell line, primary neuronal 
cells were utilized.  Immortalized cell lines, whilst easy to grow and well characterized, are 
not representative of in vivo conditions, or even of normal cells, as they are typically taken 
from tumours, which are known to have altered mitochondrial properties (Vander Heiden et 
al., 2009).  Primary cells (cells cultured directly from the tissue of living animals) are more 
physiologically relevant than immortalized cell lines, although they are more difficult to 
culture and have a limited life span.  
 147 
The effect of MCU knockdown in primary cortical neurons has previously been examined 
(Qiu et al., 2013), however it would be interesting to expand on this work, and to examine 
the effect of other MCU complex components (such as MICU1, the absence of which causes 
severe learning difficulties in humans (Logan et al., 2014) in this model.  In order to do this, 
a variety of approaches were taken to transfect primary neurons.   
It is useful to quantify the percentage of cultures which are neurons, as glial cells transfect 
more easily, as they continue to undergo division in culture, unlike neurons.  Therefore, if 
there is a high percentage of non-neuronal cells in a culture, transfection efficiency is likely 
to increase, but will not actually be targeting the desired cells, so to ensure any effects of 
transfection are neuron-specific it is useful to have a high percentage of neuronal cells.  In 
Figure 4.9, immunocytochemistry using the antibody anti-MAP2 showed that 92.6% of cells 
were neurons.  However, as shown in Figure 4.10, all transfection methods tested were 
unsuccessful, with a maximum transfection efficiency of 4% across all techniques, and cell 
death of up to 60%.  This is not entirely surprising as neurons are notoriously difficult to 
transfect, however, it has previously been done with success (Jiang and Chen, 2006; 
Zeitelhofer et al., 2009; Qiu et al., 2013; Sariyer, 2013) and should be possible. Nevertheless, 
even when methods have been completely optimized and neurons have been successfully 
transfected, the transfection efficiency still tends to be lower than that of immortalized cell 
lines.   
An alternative to transfection is transduction, which uses a viral vector to infect cells with 
nucleic acids.  This has the advantage of being able to infect non-dividing cells and has a 
high efficiency, but can also cause high toxicity, so would still require further optimizing, as 
well as the construction of the virus, but this could be considered a future avenue.   
A possible alternative approach to the genetic modification of cells, would be to examine 
MCU protein function chemically, using desipramine hydrochloride (Drug D), identified in 
Chapter 3 as a potential MCU-specific inhibitor.  This would also be interesting to further 
examine the effects of Drug D in a different cell type (primary neuronal cultures) to that in 
which it was initially tested (HEK293T).  Another alternative approach, and possibly more 
physiologically relevant is to use tissue from a knockout animal (knockout animals can form 
compensatory mechanisms to overcome the issues caused by the loss of the knockout gene, 
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and therefore mask these effects, for reviews see (Barbaric et al., 2007; Liang and Li, 2009), 
thus making their physiological relevance debated).  Whilst there is confusion over the MCU 
knockout mouse – in C57 mice the knockout was embryonic lethal, but in CD1 mice the 
knockout was viable, although non-Mendelian inheritance of the knockout suggested a 
more complex picture (Murphy et al., 2014) - mice lacking other components of the MCU 
complex have been, and are being developed, although no work has yet been published.   
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Chapter 5: Investigating expression 
levels of the MCU complex during 
development 
 
Introduction 
 
Cellular protein levels are dynamic.  They can be up and down regulated, either by the 
up/down regulation of mRNA, or by post-translational modifications that can mark the 
translated protein for activation or destruction, depending on the cell’s needs (Doherty et 
al., 2009; Farkash-Amar et al., 2012; Han et al., 2014).  Housekeeping proteins (proteins 
which have an essential function in the cell, such as -actin, a cytoskeletal actin with a role 
in cell structure and integrity) tend to have a constant expression level at all stages of 
development and under all cellular conditions, making them useful measures of total 
protein content, although care has to be taken to select appropriate proteins (Ferguson et 
al., 2005).  Some proteins have constant expression levels, however, the majority of 
proteins will vary in expression level, dependent on factors such as cell type, developmental 
stage, cell environment and cellular health.   
Ca2+ signalling has long been known to play a role during development, beginning with the 
activation of the egg (Heilbrunn et. al., 1937).  During fertilization and the early stages of 
embryogenesis, Ca2+ signalling is intracellular, consisting of blips, quarks, puffs, (Ca2+ signals 
resulting from a single IP3 receptor, a single or group of ryanodine receptors, groups of IP3 
receptors respectively) and intracellular Ca2+  waves; for a review, see (Webb and Miller, 
2003).  During the blastula phase of embryo development when cell number is increasing 
and cell size is decreasing, the Ca2+ signalling shifts from intracellular to localized 
intercellular, due to the requirement for coordinated activity (Reinhard et al., 1995).  This 
then shifts again to pan-embryonic intercellular signalling as the embryo establishes the 
body axes and develops a polarized structure, which necessitates coordination on a whole 
embryo scale (Gilland et al., 1999), and then finally back to localized intercellular signalling 
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for organ and tissue formation (Webb and Miller, 2003).  Confirming the importance of Ca2+ 
regulation in these processes, in an MCU knock down zebrafish model, it was found that the 
maturation of the notochord, and development of the anteroposterior axis during 
gastrulation were disrupted (Prudent et al., 2013).   
In addition to the many different types of Ca2+ signalling during development, Ca2+ signalling 
also has many functions during development; it has been demonstrated to be involved with 
the axis specification (Kume et al., 2000; Palma et al., 2001), cell motility (Gilland et al., 
1999), and organogenesis: heart, muscle and kidney formation (Godin et al., 1998; Mesaeli 
et al., 1999; De Deyne, 2000), and the development of the nervous system (Leclerc et al., 
2003), such as synapse formation and axon growth (Lohmann, 2009).   
 
Figure 5.0: the cell cycle.  The cell division 
cycle has four stages: Gap 1 (G1), DNA 
synthesis (S phase), Gap 2 (G2) and mitosis 
(M).  There are checkpoints between each of 
these stages, which either allow or prevent 
the passage of cells to the next stage.    
 
 
 
 
 
Ca2+ signalling also has a role in cell growth and division in somatic cells, although this role is 
not entirely clear: it was first suggested that Ca2+ may play a role when it was identified that 
microtubules are Ca2+ sensitive (Hepler, 1989; Whitaker, 1997).    The cell division cycle has 
four stages: Gap 1 (G1), DNA synthesis (S phase), Gap 2 (G2) and mitosis (M), see Figure 5.0.  
This cycle is governed by a complex signalling network: prior to entering each stage, the cell 
pauses at checkpoints.  Checkpoints either allow or prevent passage of the cell into the next 
stage, by the flicking of a chemical switch, to ensure that any cells containing errors are not 
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allowed to progress (Whitaker, 2006).  Errors can occur due to the mis-segregation of 
chromosomes, mistakes made by DNA polymerase, and damage sustained during the life of 
the cell by oxidative stress or UV radiation.  The role of Ca2+ in this process is thought to be 
in triggering the chemical switch.  It has been demonstrated that in sea urchins there are 
Ca2+ signals  at these cell cycle checkpoints (Poenie et al., 1985) , and that microinjection of 
Ca2+  can induce entry into mitosis (Steinhardt and Alderton, 1988).   In frog embryos, 
injection of Ca2+ chelators prevents entry into mitosis (Han et al., 1992) and in mice, large 
Ca2+ signals coincide with mitosis (Tombes et al., 1992).   
As Ca2+ signalling is important to cell health, life and death, and mitochondria play an 
important role in cellular Ca2+ homeostasis, it would be expected that the components of 
the MCU complex would be widely expressed, in order to enable mitochondrial Ca2+ 
handling and control in cells.  This has been found to be true, as homologues of MCU are 
present in nearly all plants and metazoa, in some fungi and protozoa, and a few bacterial 
species (Bick 2012).  In metazoa, plants and protozoa, where MCU homologues exist, there 
are also MICU1 homologues, but in fungi this is not true: MCU-containing organisms 
typically do not express MICU1, suggesting they have alternative regulatory mechanisms.  
Interestingly, EMRE has been found to be metazoan-specific (Sancak et al., 2013).  Studies of 
different cell types and mouse tissues have found that MCU, MICU1, MICU2, EMRE and 
MCUR1 are ubiquitously expressed in mammalian tissues, at various levels: mRNA has been 
identified in the skeletal muscle, heart, kidney, liver, brain, lung, large intestine, small 
intestine, thymus, bone marrow, spleen, adipose tissue, pancreas, spinal cord and lymph 
nodes (De Stefani et al., 2011; Mallilankaraman et al., 2012a; Sancak et al., 2013), with the 
highest levels in skeletal muscle and kidney.  MCUb is also ubiquitously expressed, although 
at a different expression profile to MCU (Raffaello et al., 2013).   SLC25A23 mRNA was found 
in human tissue samples from brain, heart, skeletal muscle, liver and the small intestine 
(Bassi et al., 2005).   
Studies by the Allen Mouse Brain Atlas (Lein et. al., 2007) have explored the expression of 
MCU in different structures of the adult mouse brain: MCU was identified in the olfactory 
areas, hippocampal formation, thalamus, pons, medulla, (Allen Mouse Brain Atlas, 2015), 
and MICU1 and SLC25A23 were found in all areas examined: the isocortex, hippocampal 
formation, olfactory areas, cortical subplate, striatum, pallidum, thalamus, hypothalamus, 
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midbrain, pons, medulla, and cerebellum (Allen Mouse Brain Atlas, 2015). Data were not 
available for EMRE, MCUb, MICU2, MICU3, or MCUR1, and no data were available for the 
developing mouse brain for these proteins.   
However, all of the existing work on the expression of the MCU complex has been done 
using either tissue taken from adult mice, or HEK293T and HeLa cell lines.  As Ca2+ plays such 
an important role in development and growth, we aimed to perform a preliminary 
investigation to explore how the expression level and structure of the MCU complex varies 
during development.  Therefore, in this project, protein samples were prepared from the 
brains of rats at eight different developmental stages, ranging from embryonic to adult, and 
the protein levels of MCU, MCUb, MICU1, and MCUR1 were investigated.    
 153 
Methods 
 
Sample preparation 
Rats were sacrificed according to Home Office Schedule 1 procedure: rats of age P21 and 
below by cervical dislocation, confirmed by beheading, older rats by CO2, confirmed by 
beheading.  Scissors were then used to break open the skull, and the brain was removed 
using curved forceps.   
Brains were then placed into sample tubes, and roughly chopped with scissors into rice 
grain-size pieces, and snap frozen in liquid nitrogen to preserve protein stability.  Samples 
were then removed and thawed on ice.  RIPA buffer was added (as described in Chapter 4); 
volumes were adjusted according to sample size, between 200l-2ml) and the tissue was 
manually homogenized using a Potter-Elvehjem homogenizer.  Samples were then 
centrifuged for 10 minutes at 13200g at 4C.  The supernatant was transferred to a fresh 
tube, the protein concentration quantified, and then frozen at -20C until use.  Protein 
concentrations were calculated using protein standards of 0-2000g/ml in RIPA buffer, using 
a ThermoFisher Scientific BCA assay kit, according to manufacturer’s instructions.   
Western blot 
Western blots were carried out as previously described (Chapter 4).  50g protein sample 
were loaded for each blot and for all antibodies except GRP75, samples were boiled to 
denature prior to loading on the gel.  For GRP75 samples were heated to 55C for 5 minutes.  
After images of the blots were acquired on a BioRad ChemiDoc Imager, protein levels were 
quantified using ImageJ: the image was inverted in order to make bands more visible, and 
the rectangular selection tool was used to draw a rectangle which fully included all of one 
band.  This was fixed into a y position on the blot using the command “Select First Lane” 
(Control + 1).  Identical rectangles (in the same y axis position) were used to cover each 
band, and were each fixed into place using the command “Select Second Lane “(Control + 2).  
The command “Plot Lanes” (Control +3) was then used to open plots of the intensity of each 
area, and the straight line tool used to mark off the peak caused by the band within each 
plot.  The wand tool was then used to measure the area of each peak, and these data were 
recorded, and normalized to area of the B-actin band in the corresponding lane.    
 154 
Results 
 
Brain protein samples were prepared from rats at eight different developmental stages: two 
embryonic stages (E12.5 and E17), at birth and shortly after birth (p0 and p2), during 
childhood (p10 and p21), at sexual maturity (2.5 months old), and in older adults (6 months 
old) (Sengupta, 2013).   
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Figure 5.1: Monitoring expression of developmental and mitochondrial markers.  A: Relative PCNA protein levels in brain 
samples of different ages.  N of 3.  B: Relative GRP75 protein levels in brain samples of different ages.  N of 3.  C:  
Representative blot of PCNA and B-actin.  D: Representative blot of GRP75 and B-actin.  P0, P2, P10 and P21 refer to 
sample age in number of postnatal days.  2.5M and 6M refer to sample age in months.  Significance was assessed by one-
way ANOVA.    * denotes significance, * = p value <0.05, ** = p value < 0.01.  Error bars are SEM.   
 
Initially, to demonstrate the change in developmental stage between the samples, Western 
blots were carried out using an anti-proliferating cell nuclear antigen (PCNA) antibody 
(Figure 5.1A and 5.1C).   PCNA is an essential component of DNA replication machinery 
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(Kelman, 1997), and is only found in dividing cells, so can be used as a marker of 
development and proliferation.  Blots were also run using an anti-GRP75 antibody, a 
member of the heat shock protein 70 (HSP-70) family (Wadhwa et al., 1993), a family of 
heat shock proteins which act as molecular chaperones in the import of nuclear encoded 
mitochondrial proteins.  GRP75 is expressed solely in the mitochondrial matrix, and 
therefore can be used as a marker of mitochondrial content.   
It was found that levels of PCNA decreased as the age of the sample increased (Figure 5.1A): 
PCNA protein levels at E12.5 were significantly different to that at P0, P2, P10, P21, 2.5 and 
6 months, and PCNA protein at E17 was significantly different to that at P21, 2.5 and 6 
months.   By P21, PCNA was barely detectable, demonstrating that the range of sample ages 
chosen represents both the developing and developed brain.  GRP75 was found to remain 
relatively constant throughout development, with a non-significant trend to increase after 
P2 (Figure 5.1B); this can be used to normalize the expression levels of the MCU complex, in 
order to examine whether their expression level remains consistent with mitochondrial load 
throughout development, or increases or decreases relative to mitochondrial load.   
Then, the protein expression levels of components of the MCU complex were examined by 
Western blot: levels of MCU were found to increase significantly across development (Figure 
5.2A).  Relative MCU protein at E12.5 and E17 was significantly different to P10, and E12.5, 
E17 and P0 were all significantly different to P21, 2.5 months and 6 months.  However, 
when normalized to GRP75 (Figure 5.2B), there were no significant differences between any 
sample ages, suggesting that MCU expression increases only proportionally with 
mitochondrial content.   
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Figure 5.2: Level of MCU protein expression at different developmental stages.  A: Level of MCU protein normalized to B-
actin.  N of 3. B: Ratio of (B-actin normalized) MCU: (B-actin normalized) GRP75. N of 3. C: Representative Western blot of 
MCU protein.  P0, P2, P10 and P21 refer to sample age in number of postnatal days.  2.5M and 6M refer to sample age in 
months.  Significance was assessed by one-way ANOVA.    * denotes significance, * = p value <0.05, ** = p value < 0.01.  
Error bars are SEM.   
 
Levels of MCUb were next investigated and were found to progressively increase across 
development (Figure 5.3).  Relative MCUb protein expression at E17, P0 and P2 was 
significantly different to protein levels at 2.5 months and 6 months; protein levels at E17 
were also significantly different to P21.  Interestingly, protein levels at E12.5 were actually 
higher than protein levels at E17, P0 and P2, in contrast to the overall effect of increasing 
MCUb levels with age, and therefore, only differed significantly to protein at 6 months.  
However, when normalized to GRP75 (Figure 5.3B), there were no significant differences 
between any sample ages, suggesting that MCUb expression increases proportionally with 
mitochondrial content.   
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Figure 5.3: Level of MCUb protein expression at different developmental stages.  A: Level of MCUb protein normalized to 
B-actin.  N of 3.  B: Ratio of (B-actin normalized) MCUb: (B-actin normalized) GRP75.  N of 3.  C: Representative Western 
blot of MCUb protein.  P0, P2, P10 and P21 refer to sample age in number of postnatal days.  2.5M and 6M refer to sample 
age in months.  Significance was assessed by one-way ANOVA.    * denotes significance, * = p value <0.05, ** = p value < 
0.01.  Error bars are SEM.   
 
Levels of MICU1 expression were then investigated and it was found that they did not alter 
significantly across development (Figure 5.4A).  The MICU1 antibody was not highly specific, 
with several non-specific bands observed; to ensure the correct band was used for analysis, 
samples were included from MICU1-deficient patient fibroblasts and control fibroblasts 
(Logan et al., 2014), and only the band in which there was protein present in the control, 
and absent in the patient, was used.  There appeared to be a general trend of increasing 
MICU1 content with sample age, although as the standard error was very large, this 
apparent increase failed to be significant.  When normalized to GRP75 (Figure 5.4B), there 
were no significant differences between any sample ages, suggesting that MICU1 expression 
also increases only proportionally with mitochondrial content.   
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Figure 5.4: Level of MICU1 protein expression at different developmental stages.  A: Level of MICU1 protein normalized 
to B-actin.  N of 3.  B: Ratio of (B-actin normalized) MICU1: (B-actin normalized) GRP75.  N of 3.  C: Representative Western 
blot of MICU1 protein.  Lane P contains samples from MICU1 -/- patients, Lane C contains samples from control patients.  
P0, P2, P10 and P21 refer to sample age in number of postnatal days.  2.5M and 6M refer to sample age in months.  
Significance was assessed by one-way ANOVA and no differences were found.    Error bars are SEM.   
 
Levels of MCUR1 expression were then investigated and it was found that they did not alter 
significantly across development (Figure 5.5A). There appeared to be very low protein levels 
of MCUR1 in early development and around birth (E12.5, E17, P0 and P2), with a trend to 
increase after P10; however this was not significant, and when normalized to GRP75 (Figure 
5.5B), there were no significant differences between any sample ages, suggesting that 
MCUR1 also increases only proportionally with mitochondrial content.   
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Figure 5.5: Level of MCUR1 protein expression at different developmental stages.  A: Level of MCUR1 protein normalized 
to B-actin.  N of 3.  B: Ratio of (B-actin normalized) MCUR1: (B-actin normalized) GRP75.  N of 3.  C: Representative Western 
blot of MCUR1 protein.  P0, P2, P10 and P21 refer to sample age in number of postnatal days.  2.5M and 6M refer to 
sample age in months.  Significance was assessed by one-way ANOVA and no differences were found.    Error bars are SEM.   
 
Next, in order to compare the pattern of expression between the different proteins, each 
were plotted onto one graph, and a sigmoidal non-linear regression curve was added to 
them (Figure 5.6A).  This allowed comparison through the Km (the day at which half of the 
maximal protein level was reached) and the slope factor (a measure of the steepness of the 
curve, which gives measure of the rate at which maximal protein level is achieved).  The Km 
of GRP75 was 24.77 days post conception (Figure 5.6B), showing that half of the maximal 
mitochondrial content is achieved three days after birth.  The Km for MCU and MICU1 were 
very similar to this, of 24.43 and 21.09 respectively, whereas for MCUb and MCUR1 they 
were higher, of 40.16 and 36.05 respectively.  This could suggest that the regulatory 
subunits develop slightly later than MCU, the pore forming subunit, and MICU1, the 
essential gatekeeper.  The slope factor of GRP75 was 15.21, in contrast to the slope factor of 
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the MCU complex components, which varied from 1.33 (MICU1) to 4.86 (MCUR1).  A higher 
slope factor value represents a steeper curve, so this shows that the sigmoidal curve of 
GRP75 was considerably more steep than that of the MCU complex components, due to the 
abrupt increase in GRP75 expression levels between P2 and P10.  However, the error bars 
were extremely large, and the confidence intervals overlapped between all proteins, so no 
conclusions can be drawn from this.   
 
A: 
 
 
 
 
B: 
 
 
 
 
 
Figure 5.6: Comparing relative protein levels of MCU, MCUb, MICU1, MCUR1 and GRP75.  A: Relative protein levels of 
each of the examined components and GRP75.  B: Km and Slope Factor for each of the examined components and GRP75.  
Error bars are SEM.   
Summary 
 
Overall, it was found that none of the components of the MCU complex which were 
examined by Western blot changed significantly during development, in comparison to 
mitochondrial content.  Levels of MCU and MCUb protein both significantly increased during 
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development, but when normalized to GRP75 their increase was not significant.  MCU and 
MICU1 had very similar Km values to GRP75, whilst the Km of MCUb and MCUR1 were 
higher.  GRP75 had a considerably higher slope factor value than any of the MCU complex 
components.   
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Discussion 
 
Expression levels of GRP75, MICU1 and MCUR1 showed high standard errors, especially at 
the later stages of development, and therefore the apparent differences in expression levels 
failed to reach significance.  This is likely due to the limitations of Western blots in 
quantifying protein levels, and insufficient powering of the experiment to produce 
significant results: all experiments only had an n of 3.  With highly variable results between 
different samples, and semi-quantitative techniques such as Western blots (see below), 
these experiments have low power.   Power is the ability of an experiment to detect an 
effect, if an effect is present, and low powered experiments need higher sample numbers in 
order to assess whether there is an effect; this is exaggerated if the expected effect is only 
small.  Therefore, in these experiments, as the size of the effect (if present) is unknown, 
more replicates should be done in order to give the experiment sufficient power.   
Western blots are useful in order to examine what is happening at a protein level (which is 
more likely to give insight into protein function than the mRNA level), but are of limited use 
for quantification of proteins – they can provide relative protein levels but not absolute 
protein concentration (Mahmood and Yang, 2012).  This is because of variations in loading 
and transfer between different blots, and because the signal generated for detection is not 
linear, which will have contributed to the high level of variation seen between samples in 
these experiments.  Whilst relative protein level is sufficient for a comparison within blots of 
the same protein at different ages, it would be useful to quantify this more precisely; for this 
qPCR could be used to measure mRNA levels.  This would also be interesting to investigate 
whether there are differences between the mRNA and protein levels, which would give an 
indication of whether the proteins are regulated at an mRNA level, or by post-translational 
modification.   
It was found that the protein levels all of the examined components of the MCU complex 
had a trend of increase over time, with significant increase in MCU and MCUb protein 
expression levels between the earlier and later developmental stages studied.  However, 
expression levels of GRP75 also increased over development, although with large standard 
error, so there were no significant differences in mitochondrial content at any development 
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age.  A possible source of this variability is GRP75’s role as a heat shock protein: GRP75 
levels are variable in response to cellular stress, so if stress conditions were present in the 
tissues before isolation, then GRP75 levels may not be constant. It would be useful to 
consider other approaches to quantifying mitochondrial content to eliminate this high 
variability.  This could be done using antibodies with alternative markers of mitochondrial 
content, such as cytochrome c oxidase (COX), or by quantifying mitochondrial DNA copy 
number with qPCR.   
This large standard error contributed to the lack of significant effect found when MCU 
complex components were normalized to levels of GRP75: once normalized to 
mitochondrial content, there were no significant differences between the developmental 
stages of any of the components.  This would suggest that each complex increases 
proportionally to the mitochondrial content, rather than any component being especially 
highly expressed in different stages, which could indicate a more important role of the 
component at that stage. Interestingly, although the protein expression levels were not 
different, there were some differences in the expression dynamics, although due to large 
standard error and overlapping confidence intervals (resulting form the issues discussed 
above) these differences were not significant: the Km values of MCU and MICU1 were very 
similar to that of GRP75, whereas the Km values of MCUb and MCUR1 were higher by at 
least 50%.  This suggests that they have a slightly altered expression profile, with half-
maximal protein levels being reached 12-16 days later in development than MCU, MCUb 
and GRP75.  This could indicate that fine regulation of mitochondrial Ca2+ uptake develops 
slightly later than the basic ability to uptake Ca2+.  This could be supported by the less broad 
expression of MCU regulators: MCUb is present in vertebrates but not other lineages (such 
as plants, Nematoda and kinetoplastids) (Raffaello et al., 2013), whereas the conservation of 
MCUR1 between species has not been described.  Another regulatory component, EMRE, is 
metazoan specific (Sancak et al., 2013); this limited abundance of regulatory components is 
in contrast to MCU and MICU1 which are present in metazoan, plants and protozoa (and 
MCU-only in fungi).  The reduced abundance of the regulatory subunits between species 
suggests that MCU regulation might not be essential for earlier life, which could explain the 
later development of these components as suggested by the data presented here.   
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It would be useful to examine the other known components of the complex, EMRE and 
SLC25A23, however, antibodies were not available for these proteins.  In adult mice, protein 
expression was quite different between the components in different areas of the brain 
(Allen Mouse Brain Atlas, 2015), with some (MICU1 and SLC25A23) being ubiquitously 
expressed and others (MCU) being more area specific.  This could suggest that whole brain 
samples, as were used here, may not give an accurate view, at least for components which 
are not ubiquitously expressed.  Therefore, it would also be interesting to examine specific 
areas of the brain, in order to have a more thorough picture of component expression, and 
to be able to compare this to the published data for adult mice.   
Another interesting avenue to investigate could be to attempt to clarify the role of MCUR1 – 
it’s identity as part of the MCU complex has been contested by a recent paper suggesting it 
is a cytochrome c oxidase assembly factor (Paupe et al., 2015).  To do this, cytochrome c 
oxidase protein expression could also be measured, to see whether protein levels between 
this and MCUR1 correlate – if it is an assembly factor then it could reasonably be assumed 
that its expression levels would correlate with the expression level of the protein it helps to 
assemble.  While this would not be an absolute proof of the role of MCUR1, it would be 
another piece of evidence to support one theory or the other.   
Overall, it was found that protein levels of MCU and MCUb increased significantly during 
development, and protein levels of MICU1 and MCUR1 increased but were not significant.  
When normalized to GRP75 as a marker of mitochondrial content, there were no significant 
differences between developmental stages of any components.  This is likely due to 
insufficient powering of the experiment: due to the variability of samples between 
experiments, and the limitations of Western blotting, a higher n number is needed to 
overcome the difficulty in assessing whether there are any differences.  Additionally, it 
would be advantageous to consider other markers of mitochondrial content, as GRP75 may 
not be consistently expressed.  Expression profiles of MCU and MICU1 were found to differ 
to those of MCUR1 and MCUb, suggesting it is possible that regulatory proteins may 
develop later, however these are not reliable conclusions due to the high variability of these 
data.  Further work is needed to clarify how the MCU complex develops in the brain.    
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Chapter 6: Conclusions and Future 
Work 
 
The purpose of the work described in this thesis was to investigate mitochondrial Ca2+ 
uptake pathways, and the associated pathology, mPTP, as potential therapeutic targets.  
This is because Ca2+ is essential to mitochondrial and cellular function.  Mitochondrial Ca2+ 
uptake through the MCU (in response to increased cytosolic [Ca2+]) upregulates 
mitochondrial energetics, alters morphology and suppresses mitophagy, in addition to 
regulating the localization, timing and amplitude of cytosolic Ca2+ waves (see Introduction, 
p27-28 for further detail). During pathological conditions, excessive mitochondrial Ca2+ 
uptake resulting in matrix overload may cause cell death as a result of mPTP opening.  In 
order to examine the potential of mitochondrial Ca2+ uptake pathways as therapeutic 
targets, the following aims were followed:  
1. To investigate the efficacy of a group of novel compounds as inhibitors of the mPTP. 
2. To develop a novel screening approach to identify inhibitors of the MCU. 
3. To investigate the physiological and pathophysiological role of the MCU and 
associated proteins through genetic manipulation, and to explore the relative 
protein levels of MCU and associated proteins through development. 
Each chapter of the thesis has addressed one of these aims.   
 
Rather than focus on preventing or reducing mitochondrial Ca2+ uptake as a therapeutic 
strategy, in Chapter 2 I focused on inhibition of the mPTP – the downstream consequence of 
excessive mitochondrial Ca2+ uptake and matrix overload and the direct cause of cell death.  
mPTP represents a potentially exciting therapeutic target as it appears to serve as the final 
common path to cell death in a wide number of pathologies, regardless of the source or 
method of excess mitochondrial Ca2+ uptake.  In order to identify inhibitors of the mPTP, I 
screened derivatives of CsA, with an added quinolinium ion for mitochondrial targeting, and 
with edited side chains to remove CyPA binding capability and improve CyPD binding.  The 
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quinolinium targeting was found to be a successful approach, resulting in mitochondrial 
localization, and led to inhibition of mPTP at lower concentrations than CsA: the 
mitochondrial targeting has a concentrating effect on the compounds, so that therapeutic 
dose can be reduced, and off target effects avoided.  The most effective compound, JW47, 
was further investigated and found to be approximately 4X more potent than CsA, non toxic 
to mitochondrial membrane potential, ATP production, or oxygen consumption in both 
isolated liver mitochondria and rat cortical neurons at nanomolar concentrations, although 
it significantly reduced membrane potential in neurons at 1M.  Three further compounds 
were identified as effective inhibitors at even lower concentrations than JW47.  The work 
described in this chapter did not directly demonstrate that the compound prevents cell 
death: although the animal study conducted by Gareth Pryce in parallel (see Appendix 2) 
demonstrates that JW47 has potential therapeutic benefit, and the inference is that this is 
due to reduced cell death, this needs to be proved, and would be a useful addition to this 
study.  Work is continuing in the Duchen/Szabadkai lab on developing cell based mPTP 
assays with which to test JW47 and other compounds. In the animal study the effect of 
JW47 was not compared to that of CsA, which would also be a crucial piece of work to 
demonstrate that the advantages of quinolinium targeting translate to in vivo studies.  
Future work should seek to clarify these two issues, and additionally demonstrate that the 
compound is capable of crossing the BBB, which is essential for it to have therapeutic value 
in neurological disease.  The three second generation compounds identified as more 
efficacious than JW47 should also be investigated further, as their higher efficacy presents a 
chance to further minimize possible toxicity.  It is hoped that these compounds will undergo 
pre-clinical testing, with a view to progressing to clinical trial if safety parameters are met.   
 
In Chapter 3, I addressed the current lack of MCU specific inhibitors – if the MCU is to be 
considered a therapeutic target, it is necessary to develop inhibitors which are MCU specific 
and cell permeable, and therefore methods are needed with which to screen for such 
compounds.  Additionally, MCU specific, permeable inhibitors would be a useful research 
tool with which to further investigate the function of MCU.  In Chapter 3, I described the 
development of a novel aequorin-based screening approach as a methodology to identify 
MCU specific inhibitors.  I used the NINDS-2 compound library as a starting point, and used 
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mitochondrial-targeted aequorin to identify compounds affecting mitochondrial Ca2+ 
uptake, followed by a screen measuring cytosolic [Ca2+] to determine which of these 
compounds were specific to mitochondria.  Of the 1040 compounds screened, the initial 
mitochondrial and cytosolic aequorin screens identified three compounds, Drug A, D and H, 
which inhibited mitochondrial [Ca2+] but did not affect cytosolic [Ca2+].  The specificity of 
these compounds were reconfirmed using other approaches (viral aequorin, Fluo4-AM, and 
a calcium retention capacity assay), which revealed that Drug A may not significantly affect 
mitochondrial Ca2+ uptake, and that Drug H potentiated mPTP opening, demonstrating the 
importance of validation. ΔΨm and oxygen consumption were also measured, and Drug H 
was found to reduce both, suggesting Drug H is a non-specific inhibitor of MCU, and acts 
through another mechanism (e.g. through ROS production).  Overall this approach was 
successful, and one mitochondria specific compound, Drug D, was identified.  Positive 
controls (compounds known to reduce mitochondrial Ca2+ uptake) could not be included in 
the initial screen, due to a lack of permeable, MCU specific inhibitors, thus only a DMSO 
control was included.  If appropriate positive controls were available, they would be useful 
to give a comparative efficiency of any inhibitors identified.  In this work, I identified a 
pipeline that can be used to develop MCU specific inhibitors, with three hits in the initial 
screen. It would be interesting to develop this work both to identify further compounds and 
also to explore their potential therapeutic value.  In order to do this, future work would 
need to develop Drug D by further investigating its mechanism of action and possible side 
effects, establishing its Kd, and assessing the bioavailability, efficacy and safety in animals.  
An additional use of this screening approach which could develop from this work is the 
identification of activators of MCU; this could easily be done by reanalyzing the initial screen 
for compounds which increased mitochondrial Ca2+ concentration but which did not affect 
cytosolic [Ca2+].    
 
The work described in Chapters 4 and 5 then sought to investigate the MCU further as a 
therapeutic target by investigating its role in cell life, death and development.  In Chapter 4, 
an MCU knockdown cell line was created in HEK 293T cells, and its effects investigated.  
MCU knockdown was found to reduce mitochondrial [Ca2+] uptake when cells were 
stimulated, although only to around 50% of control, despite a high level of protein 
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knockdown.  There was no effect on MCUb protein level, mitochondrial membrane 
potential, morphology, basal mitochondrial or cytosolic [Ca2+], respiration, or cell growth, 
and the effect on cell death could not be determined.  To determine the use of the model in 
the possibility of MCU being a therapeutic target, it would be useful to explore the effect of 
MCU knockdown on cell death.  This would be crucial to carry out as future work, as the 
current literature on whether reduced MCU protein is protective against cell death has been 
controversial; work is continuing in the lab to develop better Ca2+ induced cell death assays.  
It could also be useful to combine this knockdown cell line with inhibitors of MCU in order to 
completely ablate the mitochondrial Ca2+ uptake, as it is possible the limited effects of MCU 
knockdown are due to the remaining 50% mitochondrial Ca2+ uptake – the cumulative effect 
of knockdown and inhibitors may give a more accurate picture of the role of MCU.  The 
inhibitor identified in Chapter 3, Drug D, could be used for this purpose, for example.  In 
Chapter 4, I also attempted to optimize transfection of neuronal cultures, in order to 
investigate the effects of knockdown of MCU (and other components) in a primary cell 
system, as this would be a more therapeutically relevant model to use than an immortalized 
cell line.  However, this was not successful, and would therefore be another avenue for 
future work.  In Chapter 5, the relative protein levels of the MCU complex components were 
analysed in the rat brain at 8 stages throughout development, from embryonic day 12 to 6 
month adults.  This demonstrated that although protein levels of all components examined 
– MCU, MICU1, MCUb and MCUR1 - increase in proportion with mitochondrial content 
throughout development, MCUb and MCUR1 have a considerably later half maximal value, 
suggesting the possibility that regulation of MCU develops later.   It would be useful to 
confirm the results by qPCR, as Western blots cannot provide absolute quantification, only 
relative.  However, qPCR gives information on mRNA level, and not protein expression level, 
which is more indicative of function.  It would also be of use to quantify the other protein 
components of the MCU complex, EMRE, MICU2/3 and SLC25A23, in order to provide 
further insight about the possible differential development of regulatory subunits.   
 
Overall, this work contributes to the literature by identifying several new inhibitors of mPTP, 
and examining one in detail, by introducing a mechanism by which to screen for MCU-
specific inhibitors, and by further investigating the role of MCU in HEK293T cells, and during 
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development.  This should help to provide further background about the properties of the 
MCU for future work to build upon, and offer new pharmacological tools to aid the study of 
the physiological and pathophysiological roles of the MCU and the mPTP in addition to their 
potential use as therapeutics.  It is crucial for the application of this research to establish the 
extent to which MCU is a therapeutic target, and to directly link inhibition of mPTP to a 
reduction in cell death, however, it is clear that mitochondrial Ca2+ transport pathways have 
an important role in cell life and death, and it is important to continue to investigate their 
therapeutic potential.   
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Figure A1 (previous page): Fluorescein-tagged quinolinium co-localised with mitochondria labelled 
with TMRM in DIV10 rat cortical neurons.  A: Colocalization in Cell 1.  i) Fluorescein-tagged 
quinolinium (488nm).  Selected cell is highlighted in white box, yellow line represents line profile to 
be plotted.  ii) Line profile plot of fluorescein-tagged quinolinium.  iii) TMRM labelled mitochondria 
(555nm).  Selected cell is highlighted in white box, yellow line represents line profile to be plotted.  
iv) Line profile plot of TMRM labelled mitochondria.  B: Colocalization in Cell 2.  i) Fluorescein-tagged 
quinolinium (488nm).  Selected cell is highlighted in white box, yellow line represents line profile to 
be plotted.  ii) Line profile plot of fluorescein-tagged quinolinium.  iii) TMRM labelled mitochondria 
(555nm).  Selected cell is highlighted in white box, yellow line represents line profile to be plotted.  
iv) Line profile plot of TMRM labelled mitochondria.  C: Colocalization in Cell 3.  i) Fluorescein-tagged 
quinolinium (488nm).  Selected cell is highlighted in white box, yellow line represents line profile to 
be plotted.  ii) Line profile plot of fluorescein-tagged quinolinium.  iii) TMRM labelled mitochondria 
(555nm).  Selected cell is highlighted in white box, yellow line represents line profile to be plotted.  
iv) Profile plot of TMRM labelled mitochondria.  ImageJ was used to produce line profile intensity 
plots, using the command “Plot Profile.”  In each panel, the intensity profile of the fluorescein tagged 
quinolinium matches the intensity profile of the TMRM labelled mitochondria.   
Appendix 2 
 
 
Figure A2: In an experimental autoimmune encephalomyelitis (EAE) mouse model, JW47 
significantly prevented deterioration of motor skills and improved neurological clinical score.   
A: In mice treated with JW47 (1mg/kg), rotarod performance (time before falling from a rotating bar) 
was significantly higher than in mice treated with vehicle only. N of 12 (vehicle) and 13 (compound).  
B: Treatment with JW47 (1mg/kg) significantly reduced neurological scoring after a relapse (with 
higher numbers indicating increased severity) in comparison to vehicle treated mice.  N of 12 
(vehicle) and 13 (compound).  *denotes significance, p value <0.001.  Error bars are SEM.   
Experiments done by, and data used with permission of Dr Gareth Pryce, Queen Mary University.   
M
e
a
n
 R
o
to
ro
d
 A
c
ti
v
it
y
 (
s
e
c
s
)
Day 27
(pre-treatment)
Day 45
(post-treatment)
0
50
100
150
200
Vehicle JW47
***
Time Post EAE Induction (Days)
M
e
a
n
 N
e
u
ro
lo
g
ic
a
l S
c
o
re
30 35 40 45
0
1
2
3
4
Vehicle JW47
* * * * *
A B
 195 
Appendix 3 
 
Table A1: The NINDS-2 Compound Library 
Compound Plate Position Molecular 
Weight 
Therapeutic Use 
CARBINOXAMINE MALEATE 001 A02 406.87 anti-histaminic 
AMIKACIN SULFATE 001 A03 781.77 anti-bacterial 
CETYLPYRIDINIUM CHLORIDE 001 A04 340.00 anti-infective (topical) 
AZATHIOPRINE 001 A05 277.27 immunosuppressant anti-neoplastic, 
anti-rheumatic 
beta-CAROTENE 001 A06 536.89 provitamin A 
CHLORTHALIDONE 001 A07 338.77 diuretic, anti-hypertensive 
CEFOTAXIME SODIUM 001 A08 477.45 anti-bacterial 
CHLOROTHIAZIDE 001 A09 295.72 diuretic, anti-hypertensive 
CHLORZOXAZONE 001 A10 169.57 muscle relaxant (skeletal) 
BETHANECHOL CHLORIDE 001 A11 196.68 cholinergic 
ACETAZOLAMIDE 001 B02 222.25 carbonic anhydrase inhibitor, diuretic, 
anti-glaucoma 
AMILORIDE HYDROCHLORIDE 001 B03 266.09 Na+ channel inhibitor, diuretic 
AMPHOTERICIN B 001 B04 924.10 antifungal 
BACITRACIN 001 B05 1422.73 anti-bacterial 
BETAMETHASONE 001 B06 392.47 glucocorticoid, anti-inflammatory 
CARBACHOL 001 B07 182.65 cholinergic, miotic 
CEPHALOTHIN SODIUM 001 B08 418.43 anti-bacterial 
CHLOROXYLENOL 001 B09 156.61 anti-bacterial, topical and urinary 
antiseptic 
CICLOPIROX OLAMINE 001 B10 268.36 antifungal 
CLOXACILLIN SODIUM 001 B11 457.87 anti-bacterial 
ACETOHYDROXAMIC ACID 001 C02 75.07 urease inhibitor, antiurolithic, anti-
bacterial 
POTASSIUM p-
AMINOBENZOATE 
001 C03 175.23 ultraviolet screen 
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AMPICILLIN SODIUM 001 C04 371.39 anti-bacterial 
BACLOFEN 001 C05 213.67 muscle relaxant (skeletal) 
CLONIDINE HYDROCHLORIDE 001 C06 266.56 anti-hypertensive 
CARBAMAZEPINE 001 C07 236.28 analgesic, anticonvulsant 
CEPHAPIRIN SODIUM 001 C08 445.45 anti-bacterial 
CHLOROTRIANISENE 001 C09 380.88 estrogen 
CINOXACIN 001 C10 262.22 anti-bacterial 
CLOXYQUIN 001 C11 179.61 anti-bacterial, antifungal 
AMOXICILLIN 001 D02 365.41 anti-bacterial 
6-AMINOCAPROIC ACID 001 D03 131.18 hemostatic 
AMPROLIUM 001 D04 315.25 coccidiostat 
BENSERAZIDE 
HYDROCHLORIDE 
001 D05 293.71 decarboxylase inhibitor 
BISACODYL 001 D06 361.40 cathartic 
CARBENICILLIN DISODIUM 001 D07 422.37 anti-bacterial 
ACETYLCYSTEINE 001 D08 163.20 mucolytic 
CHLORPHENIRAMINE (S) 
MALEATE 
001 D09 390.87 anti-histaminic 
CLEMASTINE 001 D10 459.97 anti-histaminic 
COLCHICINE 001 D11 399.45 anti-mitotic, antigout agent 
ADENOSINE 001 E02 267.25 anti-arrhythmic, cardiac depressant  
AMINOGLUTETHIMIDE 001 E03 232.28 aromatase inhibitor, anti-neoplastic, 
testosterone suppressant 
ACETAMINOPHEN 001 E04 151.17 analgesic, antipyretic 
BENZETHONIUM CHLORIDE 001 E05 448.09 anti-infective (topical) 
BITHIONOL 001 E06 400.02 anthelmintic, antiseptic 
ANTHRALIN 001 E07 226.23 antipsoriatic 
CHLORAMPHENICOL 
HEMISUCCINATE 
001 E08 423.21 anti-bacterial, antirickettsial, inhibits 
protein synthesis 
CHLORPROMAZINE 001 E09 318.87 antiemetic, anti-psychotic 
CLIDINIUM BROMIDE 001 E10 432.36 anti-cholinergic 
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COLISTIMETHATE SODIUM 001 E11 1735.82 anti-bacterial 
COTININE 001 F02 176.22 antidepressant 
AMINOSALICYLATE SODIUM 001 F03 175.12 anti-bacterial, tuberculostatic 
ANTIPYRINE 001 F04 188.23 analgesic 
BENZOCAINE 001 F05 165.19 anesthetic (topical) 
BUSULFAN 001 F06 246.30 anti-neoplastic, alkylating agent 
CARISOPRODOL 001 F07 260.34 muscle relaxant (skeletal) 
CHLORAMPHENICOL 001 F08 323.13 anti-bacterial, antirickettsial, inhibits 
protein synthesis 
CHLORPROPAMIDE 001 F09 276.74 anti-diabetic 
CLINDAMYCIN 
HYDROCHLORIDE 
001 F10 461.45 anti-bacterial, inhibits protein synthesis 
ALLOPURINOL 001 F11 136.11 antihyperuricemia, antigout,  
antiurolithic 
ALVERINE CITRATE 001 G02 473.57 anti-cholinergic 
AMITRIPTYLINE 
HYDROCHLORIDE 
001 G03 313.87 antidepressant 
APOMORPHINE 
HYDROCHLORIDE 
001 G04 303.79 emetic 
BENZTHIAZIDE 001 G05 431.94 diuretic, anti-hypertensive 
CAFFEINE 001 G06 194.19 CNS stimulant 
CEFADROXIL 001 G07 363.39 anti-bacterial 
CHLOROCRESOL 001 G08 142.59 anti-infectant 
CHLORTETRACYCLINE 
HYDROCHLORIDE 
001 G09 515.35 anti-bacterial, antiamebic, Ca chelator, 
hepatotoxic; inhibits protein synthesis 
CLOFIBRIC ACID 001 G10 214.65 anti-hyperlipoproteinemic 
CORTISONE ACETATE 001 G11 402.49 glucocorticoid 
AMANTADINE 
HYDROCHLORIDE 
001 H02 187.71 anti-viral, anti-parkinsonian; treatment 
of drug-induced extrapyrimidal 
reactions 
AMODIAQUINE 
DIHYDROCHLORIDE 
001 H03 428.79 anti-malarial 
ATROPINE 001 H04 387.46 anti-cholinergic, mydriatic 
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BENZTROPINE 001 H05 405.52 anti-cholinergic 
1R-CAMPHOR 001 H06 152.24 analgesic, anti-infective, antipruritic 
CEFAZOLIN SODIUM 001 H07 476.49 anti-bacterial 
CHLOROQUINE 
DIPHOSPHATE 
001 H08 515.87 anti-malarial, antiamebic, anti-
rheumatic, intercalating agent 
CAPREOMYCIN SULFATE 001 H09 766.80 anti-bacterial, tuberculostatic 
CLOMIPHENE CITRATE 001 H10 598.10 gonad stimulating principle 
CRESOL 001 H11 108.14 anti-infectant 
CROMOLYN SODIUM 002 A02 512.34 antiasthmatic, antiallergy 
DEFEROXAMINE MESYLATE 002 A03 656.80 chelating agent (Fe & Al) 
DIBUCAINE HYDROCHLORIDE 002 A04 379.93 anesthetic (local) 
DIHYDROSTREPTOMYCIN 
SULFATE 
002 A05 681.68 anti-bacterial, tuberculostatic 
DISULFIRAM 002 A06 296.54 alcohol antagonist 
ESTRADIOL 002 A07 272.39 estrogen 
ETHOPROPAZINE 
HYDROCHLORIDE 
002 A08 348.94 anti-parkinsonian, anti-cholinergic 
FUSIDIC ACID 002 A09 516.72 anti-bacterial 
GUANETHIDINE SULFATE 002 A10 296.39 anti-hypertensive, mitotic agent 
HOMATROPINE 
METHYLBROMIDE 
002 A11 370.29 anti-cholinergic (opthalmic) 
CYCLIZINE 002 B02 266.39 H1 antihistamine 
SODIUM DEHYDROCHOLATE 002 B03 424.52 choleretic 
DICLOFENAC SODIUM 002 B04 318.14 anti-inflammatory 
DIMENHYDRINATE 002 B05 469.98 antiemetic 
DOPAMINE HYDROCHLORIDE 002 B06 189.64 cardiotonic, anti-hypotensive 
ESTRADIOL CYPIONATE 002 B07 396.58 estrogen 
EUGENOL 002 B08 164.21 analgesic (topical), antiseptic, antifungal 
GALLAMINE TRIETHIODIDE 002 B09 891.54 muscle relaxant (skeletal) 
HALAZONE 002 B10 270.09 anti-infectant 
HYDRALAZINE 
HYDROCHLORIDE 
002 B11 196.64 anti-hypertensive 
 199 
CYCLOPENTOLATE 
HYDROCHLORIDE 
002 C02 327.85 mydriatic 
DEMECLOCYCLINE 
HYDROCHLORIDE 
002 C03 501.32 anti-bacterial 
DICLOXACILLIN SODIUM 002 C04 492.32 anti-bacterial 
DIOXYBENZONE 002 C05 244.25 ultraviolet screen 
DYCLONINE HYDROCHLORIDE 002 C06 325.88 anesthetic (topical) 
ESTRADIOL VALERATE 002 C07 356.51 estrogen 
FLUDROCORTISONE ACETATE 002 C08 422.50 mineralocorticoid 
GEMFIBROZIL 002 C09 250.34 anti-hyperlipoproteinemic 
HALOPERIDOL 002 C10 375.87 antidyskinetic, anti-psychotic 
HYDROCHLOROTHIAZIDE 002 C11 297.74 diuretic 
CYCLOPHOSPHAMIDE 
HYDRATE 
002 D02 279.10 anti-neoplastic, alkylating agent 
DESIPRAMINE 
HYDROCHLORIDE 
002 D03 302.85 antidepressant 
DICUMAROL 002 D04 336.30 anti-coagulant 
DIPHENHYDRAMINE 
HYDROCHLORIDE 
002 D05 291.82 anti-histaminic 
DYPHYLLINE 002 D06 254.25 bronchodilator 
ESTRIOL 002 D07 288.39 estrogen 
FLUOCINONIDE 002 D08 494.54 anti-inflammatory, glucocorticoid 
GENTAMICIN SULFATE 002 D09 575.68 anti-bacterial 
HETACILLIN POTASSIUM 002 D10 427.57 anti-bacterial 
HYDROCORTISONE ACETATE 002 D11 404.51 glucocorticoid, anti-inflammatory 
CYCLOSERINE 002 E02 102.09 anti-bacterial (tuberculostatic) 
DEXAMETHASONE ACETATE 002 E03 434.51 glucocorticoid, anti-inflammatory 
DIENESTROL 002 E04 266.34 estrogen 
DIPHENYLPYRALINE 
HYDROCHLORIDE 
002 E05 317.86 anti-histaminic 
TRISODIUM 
ETHYLENEDIAMINE 
TETRACETATE 
002 E06 361.22 chelating agent, antioxidant 
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ESTRONE 002 E07 270.37 estrogen 
FLUOROURACIL 002 E08 130.08 anti-neoplastic, pyrimidine 
antimetabolite 
GENTIAN VIOLET 002 E09 407.99 anti-bacterial, anthelmintic 
HEXACHLOROPHENE 002 E10 406.91 anti-infective (topical) 
HYDROFLUMETHIAZIDE 002 E11 331.29 anti-hypertensive, diuretic 
CYTARABINE 002 F02 243.22 anti-neoplastic, anti-viral, 
antimetabolite 
DEXAMETHASONE SODIUM 
PHOSPHATE 
002 F03 516.42 glucocorticoid, anti-inflammatory 
DIETHYLCARBAMAZINE 
CITRATE 
002 F04 391.42 anthelmintic 
DIPYRIDAMOLE 002 F05 504.64 coronary vasodilator 
EMETINE 002 F06 553.58 inhibits RNA, DNA and protein synthesis 
ETHAMBUTOL 
HYDROCHLORIDE 
002 F07 277.24 anti-bacterial (tuberculostatic) 
FLURBIPROFEN 002 F08 244.27 anti-inflammatory, analgesic 
GLUCOSAMINE 
HYDROCHLORIDE 
002 F09 215.64 antiarthritic 
HEXYLRESORCINOL 002 F10 194.28 anthelmintic, topical antiseptic 
HYDROXYPROGESTERONE 
CAPROATE 
002 F11 428.62 progestogen 
DANAZOL 002 G02 337.47 anterior pituitary suppressant 
DEXTROMETHORPHAN 
HYDROBROMIDE 
002 G03 352.32 antitussive 
DIFLUNISAL 002 G04 250.20 analgesic, anti-inflammatory 
PYRITHIONE ZINC 002 G05 319.70 anti-bacterial, antifungal, antiseborrheic 
ADRENALINE BITARTRATE 002 G06 333.30 adrenergic agonist, bronchodilator, 
antiglaucoma agent 
ETHINYL ESTRADIOL 002 G07 296.41 estrogen, plus progestogen as oral 
contraceptive 
FURAZOLIDONE 002 G08 225.16 anti-bacterial 
GUAIFENESIN 002 G09 198.22 expectorant 
HISTAMINE 002 G10 184.07 H receptor agonist, induces edema in 
mammalian tissues; gastric secretion 
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DIHYDROCHLORIDE stimulant 
HYDROXYUREA 002 G11 76.06 anti-neoplastic, inhibits ribonucleoside 
diphosphate reductase 
DAPSONE 002 H02 248.31 anti-bacterial, leprostatic, dermatitis 
herpetiformis suppressant 
DIBENZOTHIOPHENE 002 H03 184.26 keratolytic 
DIGOXIN 002 H04 780.96 cardiac stimulant 
DISOPYRAMIDE PHOSPHATE 002 H05 437.48 anti-arrhythmic 
ERGONOVINE MALEATE 002 H06 441.49 oxytocic, 5HT antagonist 
ETHIONAMIDE 002 H07 166.25 anti-bacterial, tuberculostatic 
FUROSEMIDE 002 H08 330.75 diuretic, anti-hypertensive 
GUANABENZ ACETATE 002 H09 291.14 anti-hypertensive 
HOMATROPINE BROMIDE 002 H10 356.26 anti-cholinergic (opthalmic) 
HYDROXYZINE PAMOATE 002 H11 763.29 anxiolytic, anti-histaminic 
DIGITOXIN 003 A02 764.96 inotropic, cardiotonic 
ISONIAZID 003 A03 137.14 anti-bacterial, tuberculostatic 
LEVONORDEFRIN 003 A04 183.21 vasoconstrictor 
MEDROXYPROGESTERONE 
ACETATE 
003 A05 386.54 contraceptive 
METHOCARBAMOL 003 A06 241.25 muscle relaxant (skeletal) 
MICONAZOLE NITRATE 003 A07 479.15 antifungal (topical) 
NEOSTIGMINE BROMIDE 003 A08 303.20 cholinergic 
NORETHYNODREL 003 A09 298.43 progestogen, in combination with 
estrogen as oral contraceptive 
ORPHENADRINE CITRATE 003 A10 461.52 muscle relaxant (skeletal), anti-
histaminic 
PENICILLAMINE 003 A11 149.21 chelating agent (Cu), anti-rheumatic 
HYOSCYAMINE 003 B02 289.38 anti-cholinergic, analgesic 
ISOPROPAMIDE IODIDE 003 B03 480.44 anti-cholinergic 
LINCOMYCIN 
HYDROCHLORIDE 
003 B04 443.01 anti-bacterial 
MEDRYSONE 003 B05 344.50 glucocorticoid 
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METHOTREXATE 003 B06 454.45 anti-neoplastic, anti-rheumatic, folic 
acid antagonist 
MINOXIDIL 003 B07 209.25 anti-hypertensive, antialopecia agent 
NIACIN 003 B08 123.11 antihyperlipidemic, vitamin (enzyme 
cofactor) 
NORFLOXACIN 003 B09 319.34 anti-bacterial 
OXACILLIN SODIUM 003 B10 423.43 anti-bacterial 
BENZYL PENICILLIN 
POTASSIUM 
003 B11 372.49 anti-bacterial 
IBUPROFEN 003 C02 206.29 anti-inflammatory 
ISOPROTERENOL 
HYDROCHLORIDE 
003 C03 247.72 bronchodilator 
MAFENIDE HYDROCHLORIDE 003 C04 222.69 anti-bacterial 
MEGESTROL ACETATE 003 C05 384.52 progestogen, anti-neoplastic 
METHOXSALEN 003 C06 216.20 antipsoriatic, pigmentation agent 
MOXALACTAM DISODIUM 003 C07 564.44 anti-bacterial 
NIFEDIPINE 003 C08 346.34 antianginal, anti-hypertensive 
NORGESTREL 003 C09 312.46 progestogen 
OXYBENZONE 003 C10 228.25 ultraviolet screen 
PHENAZOPYRIDINE 
HYDROCHLORIDE 
003 C11 249.70 analgesic 
IMIPRAMINE 
HYDROCHLORIDE 
003 D02 316.88 antidepressant 
ISOSORBIDE DINITRATE 003 D03 236.14 antianginal 
MAPROTILINE 
HYDROCHLORIDE 
003 D04 313.87 antidepressant 
MEPENZOLATE BROMIDE 003 D05 420.35 anti-cholinergic 
METHSCOPOLAMINE 
BROMIDE 
003 D06 398.30 anti-cholinergic 
NAFCILLIN SODIUM 003 D07 436.47 anti-bacterial 
NITROFURANTOIN 003 D08 238.16 anti-bacterial 
NORTRIPTYLINE 003 D09 263.39 antidepressant 
OXYMETAZOLINE 003 D10 296.84 adrenergic agonist, nasal decongestant 
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HYDROCHLORIDE 
PHENELZINE SULFATE 003 D11 234.28 antidepressant 
INDAPAMIDE 003 E02 365.84 diuretic, anti-hypertensive 
ISOXSUPRINE 
HYDROCHLORIDE 
003 E03 337.85 vasodilator 
MECAMYLAMINE 
HYDROCHLORIDE 
003 E04 203.76 anti-hypertensive 
MERCAPTOPURINE 003 E05 152.18 anti-neoplastic, purine antimetabolite 
METHYLDOPA 003 E06 211.22 anti-hypertensive 
NALOXONE HYDROCHLORIDE 003 E07 363.84 narcotic antagonist 
NITROFURAZONE 003 E08 198.14 anti-infective (topical) 
NOSCAPINE HYDROCHLORIDE 003 E09 449.89 antitussive 
OXYQUINOLINE 
HEMISULFATE 
003 E10 243.24 anti-infectant 
PHENINDIONE 003 E11 222.25 anti-coagulant 
INDOMETHACIN 003 F02 357.80 anti-inflammatory, antipyretic, analgesic 
KANAMYCIN SULFATE 003 F03 582.59 anti-bacterial 
MECHLORETHAMINE 003 F04 156.06 anti-neoplastic, alkylating agent 
METAPROTERENOL 003 F05 211.26 bronchodilator 
METOCLOPRAMIDE 
HYDROCHLORIDE 
003 F06 336.26 antiemetic 
NAPHAZOLINE 
HYDROCHLORIDE 
003 F07 246.74 adrenergic agonist, nasal decongestant 
NITROMIDE 003 F08 211.14 anti-bacterial, coccidiostat 
NOVOBIOCIN SODIUM 003 F09 634.62 anti-bacterial 
OXYTETRACYCLINE 003 F10 496.91 anti-bacterial 
1S,2R-
PHENYLPROPANOLAMINE 
HYDROCHLORIDE 
003 F11 187.67 decongestant, anorexic 
INDOPROFEN 003 G02 281.31 analgesic, anti-inflammatory 
KETOCONAZOLE 003 G03 531.44 antifungal 
MECLIZINE HYDROCHLORIDE 003 G04 463.88 antiemetic 
METHENAMINE 003 G05 140.19 anti-bacterial (urinary) 
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METOPROLOL TARTRATE 003 G06 417.46 anti-hypertensive, antianginal 
NAPROXEN(+) 003 G07 230.27 anti-inflammatory, analgesic, antipyretic 
NOREPINEPHRINE 003 G08 169.18 adrenergic agonist, anti-hypotensive 
NYLIDRIN HYDROCHLORIDE 003 G09 335.88 vasodilator (peripheral) 
PAPAVERINE 
HYDROCHLORIDE 
003 G10 375.86 muscle relaxant (smooth), cerebral 
vasodilator 
PHENYTOIN SODIUM 003 G11 274.26 anticonvulsant, antieleptic 
IODOQUINOL 003 H02 396.96 antiamebic 
LEUCOVORIN CALCIUM 003 H03 511.51 antianemic, antidote to folic acid 
antagonists 
MECLOFENAMATE SODIUM 003 H04 318.14 anti-inflammatory, antipyretic 
METHIMAZOLE 003 H05 114.17 antihyperthyroid 
METRONIDAZOLE 003 H06 171.16 anti-protozoal 
NEOMYCIN SULFATE 003 H07 712.73 anti-bacterial 
NORETHINDRONE ACETATE 003 H08 340.47 Oral contraceptive (in combination with 
estrogen) 
NYSTATIN 003 H09 926.12 antifungal, binds to membrane sterols 
PARACHLOROPHENOL 003 H10 128.56 topical anti-bacterial (topical) 
PHYSOSTIGMINE SALICYLATE 003 H11 413.48 cholinergic, anticholinesterase, miotic 
PILOCARPINE NITRATE 004 A02 271.28 antiglaucoma agent, miotic 
DEXPROPRANOLOL 
HYDROCHLORIDE  
004 A03 295.81 anti-hypertensive, antianginal, anti-
arrhythmic 
RIFAMPIN 004 A04 822.96 anti-bacterial (tuberculostatic) 
STREPTOZOSIN 004 A05 265.22 anti-neoplastic, alkylating agent 
SULFATHIAZOLE 004 A06 255.32 anti-bacterial 
TOLBUTAMIDE 004 A07 270.35 anti-diabetic 
TRIFLUOPERAZINE 
HYDROCHLORIDE 
004 A08 480.43 anti-psychotic 
TRYPTOPHAN 004 A09 204.23 antidepressant, nutrient; LD50(rat) 1634 
mg/kg ip  
ACRIFLAVINIUM 
HYDROCHLORIDE 
004 A10 259.74 anti-infective, intercalating agent 
PENTAMIDINE ISETHIONATE 004 A11 592.69 anti-protozoal, inhibits nucleic acid & 
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protein synthesis 
PIPERAZINE 004 B02 86.14 anthelmintic 
PSEUDOEPHEDRINE 
HYDROCHLORIDE 
004 B03 201.70 decongestant 
ROXARSONE 004 B04 263.04 anti-bacterial 
SULFACETAMIDE 004 B05 214.24 anti-bacterial 
SULINDAC 004 B06 356.42 anti-inflammatory 
TOLNAFTATE 004 B07 307.42 antifungal 
TRIHEXYPHENIDYL 
HYDROCHLORIDE 
004 B08 337.94 anti-cholinergic, anti-parkinsonian 
TUAMINOHEPTANE SULFATE 004 B09 213.30 adrenergic agonist 
BROXYQUINOLINE 004 B10 302.95 anti-infectant, disinfectant 
PHENACETIN 004 B11 179.22 analgesic, antipyretic 
PRAZIQUANTEL 004 C02 312.42 anthelmintic 
PYRANTEL PAMOATE 004 C03 594.69 anthelmintic 
SALICYL ALCOHOL 004 C04 124.14 anesthetic (local), anti-inflammatory 
SULFADIAZINE 004 C05 250.28 anti-bacterial 
TETRACYCLINE 
HYDROCHLORIDE 
004 C06 480.91 anti-bacterial, antiamebic, antirickettsial 
TRANYLCYPROMINE SULFATE 004 C07 231.27 antidepressant 
TRIMEPRAZINE TARTRATE 004 C08 448.54 antipruritic 
TYROTHRICIN 004 C09 1272.48 topical anti-bacterial (topical) 
CARNITINE HYDROCHLORIDE 004 C10 197.66 anti-hyperlipoproteinemic, gastric/ 
pancreatic secretion stimulant 
PHENYLMERCURIC ACETATE 004 C11 336.74 antifungal 
PRIMAQUINE DIPHOSPHATE 004 D02 455.34 anti-malarial 
PYRIMETHAMINE 004 D03 248.72 anti-malarial 
SCOPOLAMINE 
HYDROBROMIDE 
004 D04 384.27 anti-cholinergic, treatment of motion 
sickness 
SULFAMERAZINE 004 D05 264.31 anti-bacterial 
THEOPHYLLINE 004 D06 180.17 bronchodilator 
TRIACETIN 004 D07 218.21 antifungal (topical) 
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TRIMETHOBENZAMIDE 
HYDROCHLORIDE 
004 D08 424.93 antiemetic 
URSODIOL 004 D09 392.58 anticholelithogenic; LD50(rat) 890 
mg/kg ip 
HEXESTROL 004 D10 270.37 estrogen, anti-neoplastic (hormonal) 
PREGNENOLONE 004 D11 316.49 glucocortcoid, anti-inflammatory 
PROCHLORPERAZINE 
EDISYLATE 
004 E02 564.15 antiemetic, anti-psychotic, treatment of 
vertigo 
QUINACRINE 
HYDROCHLORIDE 
004 E03 472.89 anthelmintic, anti-malarial, intercalating 
agent 
SISOMICIN SULFATE 004 E04 545.61 anti-bacterial, binds to ribosomes 
SULFAMETHAZINE 004 E05 278.33 anti-bacterial 
THIABENDAZOLE 004 E06 201.25 anthelmintic 
TRIAMCINOLONE ACETONIDE 004 E07 434.51 anti-inflammatory 
TRIMETHOPRIM 004 E08 290.32 anti-bacterial 
VANCOMYCIN 
HYDROCHLORIDE 
004 E09 1484.76 anti-bacterial 
HEXETIDINE 004 E10 339.61 antifungal 
AZELAIC ACID 004 E11 188.23 antiacne, antiproliferative agent 
PROMAZINE 
HYDROCHLORIDE 
004 F02 320.89 anti-psychotic 
QUINIDINE GLUCONATE 004 F03 520.58 anti-arrhythmic, anti-malarial 
SPECTINOMYCIN 
HYDROCHLORIDE 
004 F04 405.28 anti-bacterial 
SULFAMETHOXAZOLE 004 F05 253.28 anti-bacterial, antipneumocystis 
THIMEROSAL 004 F06 404.81 anti-infective, preservative 
TRIAMCINOLONE DIACETATE 004 F07 478.52 anti-inflammatory 
TRIOXSALEN 004 F08 228.25 melanizing agent, antipsoriatic 
VIDARABINE 004 F09 267.25 anti-viral 
IPRONIAZID SULFATE 004 F10 277.30 monoamine oxidase inhibitor, 
antidepressant 
THEOBROMINE 004 F11 180.17 diuretic, bronchodilator, cardiotonic 
PROMETHAZINE 004 G02 320.89 anti-histaminic 
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HYDROCHLORIDE 
QUININE SULFATE 004 G03 422.50 anti-malarial, skeletal muscle relaxant 
SPIRONOLACTONE 004 G04 416.58 diuretic 
SULFAPYRIDINE 004 G05 249.29 anti-bacterial 
THIOGUANINE 004 G06 167.19 anti-neoplastic, purine antimetabolite 
TRIAMTERENE 004 G07 253.27 diuretic 
TRIPROLIDINE 
HYDROCHLORIDE 
004 G08 314.86 anti-histaminic 
XYLOMETAZOLINE 
HYDROCHLORIDE 
004 G09 280.84 adrenergic agonist, nasal decongestant 
MERBROMIN 004 G10 750.66 anti-bacterial 
AJMALINE 004 G11 326.44 anti-arrhythmic (Class Ia): inhibits 
glucose uptake by mitochondria, & PAF 
blocker 
PROPANTHELINE BROMIDE 004 H02 448.40 anti-cholinergic 
RESORCINOL 004 H03 110.11 keratolytic, antiseborheic 
STREPTOMYCIN SULFATE 004 H04 679.66 anti-bacterial (tuberculostatic) 
SULFASALAZINE 004 H05 398.40 anticolitis and Crohn's disease 
TIMOLOL MALEATE 004 H06 432.50 betaadrenergic blocker 
TRICHLORMETHIAZIDE 004 H07 380.66 diuretic, anti-hypertensive 
TROPICAMIDE 004 H08 284.36 anti-cholinergic (opthalmic) 
ZOMEPIRAC SODIUM 004 H09 291.74 analgesic, anti-inflammatory 
OCTOPAMINE 
HYDROCHLORIDE 
004 H10 189.64 adrenergic agonist 
HYDROQUINIDINE 004 H11 326.44 anti-arrhythmic, anti-malarial 
KETOTIFEN FUMARATE 005 A02 425.51 antiasthmatic 
MYCOPHENOLIC ACID 005 A03 320.35 anti-neoplastic 
KYNURENIC ACID 005 A04 189.17 nutritient in vitamin B deficiency 
diseases 
NEOHESPERIDIN 
DIHYDROCHALCONE 
005 A05 612.59 sweetener 
KINETIN 005 A06 215.22 auxin, plant growth regulator, plant cell 
division promotor 
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ALTHIAZIDE 005 A07 383.90 diuretic 
PALMATINE CHLORIDE 005 A08 387.87 anti-bacterial, uterine contractant 
DROPROPIZINE 005 A09 236.32 antitussive 
BERBAMINE 
HYDROCHLORIDE 
005 A10 681.66 anti-hypertensive, skeletal muscle 
relaxant 
PROTOPORPHYRIN IX 005 A11 562.67 hepatoprotectant 
YOHIMBINE HYDROCHLORIDE 005 B02 390.91 alpha adrenergic blocker, mydriatic, 
antidepressant 
OLEANDOMYCIN PHOSPHATE 005 B03 785.87 anti-bacterial 
LIDOCAINE HYDROCHLORIDE 005 B04 270.81 anesthetic (local), anti-arrhythmic 
QUERCITRIN 005 B05 448.39 antihemmorrhagic 
NARINGIN 005 B06 580.55 antihaemorrhagic, anti-inflammatory 
BERBERINE CHLORIDE 005 B07 371.82 anti-arrhythmic, alpha2 agonist, 
cholinesterase, anticonvulsant, anti-
inflammatory, anti-bacterial, antifungal, 
antitrypanosomal, anti-neoplastic, 
immunostimulant; LD50(mouse) 329 
mg/kg po  
PIPERINE 005 B08 285.35 analeptic, anti-bacterial 
ETODOLAC 005 B09 287.36 anti-inflammatory 
FENDILINE HYDROCHLORIDE 005 B10 351.92 coronary vasodilator 
NALBUPHINE 
HYDROCHLORIDE 
005 B11 393.91 analgesic, narcotic antagonist 
BENFLUOREX 
HYDROCHLORIDE 
005 C02 387.83 anti-hyperlipoproteinemic 
OUABAIN 005 C03 584.67 anti-arrhythmic, cardiotonic, 
hypertensive, Na/K ATPase inhibitor 
ACETYL TYROSINE ETHYL 
ESTER 
005 C04 251.28 chymotrpsin substrate 
ESERINE 005 C05 275.35 anticholinesterase, miotic, 
antiglaucoma, cognition activator 
BUTAMBEN 005 C06 193.25 anesthetic (local) 
CANRENOIC ACID, 
POTASSIUM SALT 
005 C07 396.58 aldosterone antagonist, diuretic 
AESCULIN 005 C08 340.29 anti-inflammatory 
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FENOTEROL HYDROBROMIDE 005 C09 384.27 betaadrenergic agonist 
METHACYCLINE 
HYDROCHLORIDE 
005 C10 478.89 anti-bacterial 
MEBHYDROLIN 
NAPHTHALENESULFONATE 
005 C11 564.68 H1 antihistamine 
SULFANILAMIDE 005 D02 172.21 anti-bacterial 
AMINOPTERIN 005 D03 440.42 anti-neoplastic, anti-rheumatic, folic 
acid antagonist 
ACETYLTRYPTOPHANAMIDE 005 D04 245.28 antidepressant, nutrient 
XANTHURENIC ACID 005 D05 205.17 caspase activatir, guanylyl cyclase 
stimulant 
CEFACLOR 005 D06 367.81 anti-bacterial 
HARMALOL HYDROCHLORIDE 005 D07 236.70 anthelmintic, narcotic agent 
PROTOVERATRINE B 005 D08 809.96 anti-hypertensive, emetic; LD50(mouse) 
0.21 mg/kg sc 
FENBUFEN 005 D09 254.29 anti-inflammatory 
PUROMYCIN 
HYDROCHLORIDE 
005 D10 544.44 anti-neoplastic, anti-protozoal 
MEBEVERINE 
HYDROCHLORIDE 
005 D11 466.02 muscle relaxant (smooth) 
STRYCHNINE 005 E02 334.42 central stimulant 
ARECOLINE HYDROBROMIDE 005 E03 236.11 anthelmintic (Cestodes), hypotensive, 
cathartic 
N-ACETYLPROLINE 005 E04 157.17 anti-rheumatic 
LOBELINE HYDROCHLORIDE 005 E05 373.93 antiasthmatic, respiratory stimulant 
IODIPAMIDE 005 E06 627.95 radioopaque agent 
HARMALINE 005 E07 214.27 CNS stimulant, anti-parkinsonian agent 
18alpha-GLYCYRRHETINIC 
ACID 
005 E08 470.70 anti-inflammatory 
1R,9S-HYDRASTINE 005 E09 383.40 uterine hemostatic, antiseptic 
PICROTOXININ 005 E10 292.29 convulsant, GABA receptor antagonist, 
ichthyotoxin 
MECLOCYCLINE 
SULFOSALICYLATE 
005 E11 695.06 anti-bacterial 
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QUERCETIN 005 F02 302.24 capillary protectant, antioxidant. anti-
neoplastic, anti-HIV; LD50(mouse) 159 
mg/kg po  
CAPTOPRIL 005 F03 217.29 anti-hypertensive 
CITROPTEN 005 F04 206.20 photosensitizing agent 
HECOGENIN 005 F05 430.63 anti-inflammatory 
THYROXINE 005 F06 776.88 antihypercholesterimic, thyromimetic 
HARMINE 005 F07 212.25 anti-parkinsonian, CNS stimulant 
FLUMEQUINE 005 F08 261.26 anti-bacterial 
FENOFIBRATE 005 F09 360.84 antihyperlipidemic 
MEFEXAMIDE 005 F10 316.83 stimulant (central) 
PROGLUMIDE 005 F11 334.42 anti-cholinergic 
VALPROATE SODIUM 005 G02 166.20 anticonvulsant 
CIMETIDINE 005 G03 252.34 anti-ulcerative 
CHRYSIN 005 G04 254.24 diuretic 
CALCEIN 005 G05 622.55 chelating agent (Ca, Mg) 
ALLOXAN 005 G06 142.07 specific cytotoxin (pacreatic islet 
betacell) 
MIMOSINE 005 G07 198.18 depilatory agent 
FLUPHENAZINE 
HYDROCHLORIDE 
005 G08 510.45 H1 antihistamine 
FENOPROFEN 005 G09 242.28 anti-inflammatory 
PROBUCOL 005 G10 516.86 antihyperlipidemic 
MINAPRINE HYDROCHLORIDE 005 G11 371.31 psychotropic 
MOLSIDOMINE 005 H02 242.24 antianginal 
CLOZAPINE 005 H03 326.83 anti-psychotic 
NARINGENIN 005 H04 272.26 anti-ulcer, gibberellin antagonist 
GUANIDINE CARBONATE 005 H05 121.10 striated muscle stimulant 
ALLANTOIN 005 H06 158.12 wound healing agent 
NORHARMAN 005 H07 168.20 plant growth inhibitor; mutagen 
FAMOTIDINE 005 H08 337.45 H2 antihistamine 
 211 
FENBENDAZOLE 005 H09 299.35 anthelmintic 
MEBENDAZOLE 005 H10 295.30 anthelmintic 
MEMANTINE 
HYDROCHLORIDE 
005 H11 215.77 muscle relaxant (skeletal) 
3-
AMINOPROPANESULPHONIC 
ACID 
006 A02 139.17 anti-bacterial; GABA agonist 
NEFOPAM 006 A03 253.35 analgesic 
SUXIBUZONE 006 A04 438.48 analgesic, antipyretic, anti-inflammatory 
ESTRADIOL METHYL ETHER 006 A05 286.42 estrogen 
RETINOL 006 A06 286.46 vitamin A 
FOSFOSAL 006 A07 218.10 analgesic, anti-inflammatory 
CEFUROXIME SODIUM 006 A08 446.37 anti-bacterial 
BEZAFIBRATE 006 A09 361.83 antihyperlipidemic 
CYCLOCREATINE 006 A10 143.15 regulator of creatine biosynthesis 
1,2-DIMETHYLHYDRAZINE 
HYDROCHLORIDE 
006 A11 133.02 anti-neoplastic 
5-AMINOPENTANOIC ACID 
HYDROCHLORIDE 
006 B02 153.61 GABAb antagonist 
PIRENZEPINE 
HYDROCHLORIDE 
006 B03 424.33 anti-ulcerative 
SUPROFEN 006 B04 260.31 anti-inflammatory 
ESTRADIOL ACETATE 006 B05 314.43 estrogen 
LAPACHOL 006 B06 242.28 anti-neoplastic, antifungal 
MESNA 006 B07 164.18 mucolytic 
METAMPICILLIN SODIUM 006 B08 383.40 anti-bacterial 
LIOTHYRONINE SODIUM 006 B09 672.96 thyroid hormone 
alpha-CYANO-3-
HYDROXYCINNAMIC ACID 
006 B10 189.17 inhibit mitochondrial pyruvate transport 
ATRACTYLOSIDE POTASSIUM 006 B11 803.01 oxidative phosphorylation inhibitor 
ATENOLOL 006 C02 266.34 beta adrenergic blocker 
PRAMOXINE 
HYDROCHLORIDE 
006 C03 329.87 anesthetic (topical) 
 212 
ACETAMINOSALOL 006 C04 271.28 analgesic, antipyretic 
5-FLUORO-5'-DEOXYURIDINE 006 C05 246.20 anti-neoplastic, pyrimidine 
antimetabolite 
KETOPROFEN 006 C06 254.29 anti-inflammatory 
TRETINON 006 C07 300.44 keratolytic 
LOMEFLOXACIN 
HYDROCHLORIDE 
006 C08 387.82 anti-bacterial 
CEPHALORIDINE 006 C09 415.49 anti-bacterial 
PERILLIC ACID (-) 006 C10 166.22 inhibits posttranslational cys 
isoprenylation, blocks G-protein 
GUVACINE HYDROCHLORIDE 006 C11 163.61 muscarinic agonist, GABA uptake 
inhibitor 
CARBETAPENTANE CITRATE 006 D02 525.60 antitussive 
MEPHENESIN 006 D03 182.22 muscle relaxant (skeletal) 
ACETANILIDE 006 D04 135.17 analgesic, antipyretic 
ESTRIOL BENZYL ETHER 006 D05 378.52 estrogen 
LISINOPRIL 006 D06 405.50 ACE inhibitor 
BRETYLIUM TOSYLATE 006 D07 414.36 inhibitor of norepinephrine release 
FOSFOMYCIN 006 D08 176.12 anti-bacterial 
5-CHLOROINDOLE-2-
CARBOXYLIC ACID 
006 D09 195.61 NMDA receptor antagonist (gly) 
QUINOLINIC ACID 006 D10 167.12 differentiates between cerebral and 
forebrain NMDA receptors 
TINIDAZOLE 006 D11 247.27 anti-protozoal 
AMINOPYRIDINE 006 E02 94.12 K channel blocker 
SULFAPHENAZOLE 006 E03 314.37 anti-bacterial 
TODRALAZINE 
HYDROCHLORIDE 
006 E04 268.70 anti-hypertensive, peripheral 
vasodilator 
ESTRADIOL-3-SULFATE, 
SODIUM SALT 
006 E05 374.43 estrogen 
ACETYL-L-LEUCINE 006 E06 173.21 anti-vertigo 
FOSCARNET SODIUM 006 E07 191.95 anti-viral 
CEFAMANDOLE NAFATE 006 E08 512.50 anti-bacterial 
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7-CHLOROKYNURENIC ACID 006 E09 223.62 NMDA receptor antagonist (gly) 
ANTHRAQUINONE 006 E10 208.22 irritant 
CYCLOLEUCINE 006 E11 129.16 NMDA receptor antagonist (gly) 
NEROL 006 F02 154.25 weak estrogen receptor blocker 
RANITIDINE 006 F03 314.41 H2 antihistamine 
ESTRIOL METHYL ETHER 006 F04 302.42 estrogen 
TOLFENAMIC ACID 006 F05 261.71 anti-inflammatory, analgesia 
BUMETANIDE 006 F06 364.42 diuretic 
FOLIC ACID 006 F07 441.41 hematopoietic vitamin 
PRALIDOXIME MESYLATE 006 F08 232.26 cholinesterase reactivator 
4-NAPHTHALIMIDOBUTYRIC 
ACID 
006 F09 283.29 aldose reductase inhibitor 
CARBOPLATIN 006 F10 371.26 anti-neoplastic, convulsant 
AMINOCYCLOPROPANECARB
OXYLIC ACID 
006 F11 101.11 NMDA partial agonist (gly) 
NICERGOLINE 006 G02 484.40 vasodilator 
SULOCTIDIL 006 G03 337.57 peripheral vasodilator 
ESTRADIOL PROPIONATE 006 G04 328.46 estrogen 
ZAPRINAST 006 G05 271.28 cGMP phosphodiesterase inhibitor 
CARBENOXOLONE SODIUM 006 G06 614.74 anti-inflammatory, antisecretory, anti-
ulcer 
TRANEXAMIC ACID 006 G07 157.21 hemostatic 
OFLOXACIN 006 G08 361.38 anti-bacterial 
INDOLE-2-CARBOXYLIC ACID 006 G09 161.16 NMDA receptor antagonist (gly) 
AZACITIDINE 006 G10 244.21 anti-neoplastic, pyrimidine 
antimetabolite 
5-NITRO-2-
PHENYLPROPYLAMINOBENZO
IC ACID [NPPB] 
006 G11 300.32 chloride channel blocker 
PIMOZIDE 006 H02 461.56 anti-psychotic 
RONIDAZOLE 006 H03 200.16 anti-protozoal 
ESTRONE ACETATE 006 H04 312.41 estrogen 
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GALANTHAMINE 
HYDROBROMIDE 
006 H05 368.27 anticholinesterase, analgesic, 
antiAlzheimer 
CARPROFEN 006 H06 273.72 anti-inflammatory, analgesic 
CEFOXITIN SODIUM 006 H07 449.44 anti-bacterial 
PIROMIDIC ACID 006 H08 288.31 anti-bacterial 
N- (9-
FLUORENYLMETHOXYCARBO
NYL)-L-LEUCINE 
006 H09 353.42 anti-inflammatory 
AZASERINE 006 H10 173.13 anti-neoplastic, amino acid antagonist 
N-FORMYLMETHIONYL-
LEUCYLPHENYLALANINE 
006 H11 437.56 chemotactic peptide 
N-
FORMYLMETHIONYLPHENYLA
LANINE 
007 A02 324.40 chemotactic peptide 
ANISINDIONE 007 A03 252.27 anti-coagulant 
LYSYLPHENYLALANYLTYROSIN
E 
007 A04 456.55 TAN inhibitor 
ABRINE (L) 007 A05 218.26 insecticide, anti-inflammatory, 
antiopthalmic 
MONENSIN SODIUM 
(monensin A is shown) 
007 A06 690.90 anti-bacterial 
ACEXAMIC ACID 007 A07 173.21 wound healing agent 
AMBROXOL HYDROCHLORIDE 007 A08 414.57 expectorant 
DEQUALINIUM CHLORIDE 007 A09 527.59 anti-infectant 
PYRIDOSTIGMINE BROMIDE 007 A10 261.12 cholinergic 
BETA-PROPIOLACTONE 007 A11 72.06 anti-infective 
METHIONYL-
LEUCYLPHENYLALANINE 
ACETATE 
007 B02 469.60 chemotactic peptide 
CYCLOSPORINE 007 B03 1202.64 immunosuppressant 
S-METHYL-L-THIOCITRULLINE 
ACETATE 
007 B04 205.28 nitroc oxide synthase inhibitor 
HARMOL HYDROCHLORIDE 007 B05 234.69 MAO inhibitor 
MORIN 007 B06 302.24 P450 and ATPase inhibitor 
FLOXURIDINE 007 B07 246.20 anti-neoplastic, antimetabolite 
 215 
GLUCONOLACTONE 007 B08 178.14 chelating agent 
MENTHOL(-) 007 B09 156.27 analgesic (topical), antipruritic agent 
ISOXICAM 007 B10 335.34 anti-inflammatory 
PAROMOMYCIN SULFATE 007 B11 713.72 anti-bacterial, antiamebic 
LEUCINE ENKEPHALIN 007 C02 555.64 opioid neuromodulator 
TROLEANDOMYCIN 007 C03 813.99 anti-bacterial 
S-(1,2-
DICARBOXYETHYL)GLUTATHI
ONE  
007 C04 437.43 anti-inflammatory, antiallergy, mast cell 
degranulation inhibitor 
VINBURNINE 007 C05 294.40 cerebral vasodilator, muscle stimulant 
BENZYL ISOTHIOCYANATE 007 C06 149.22 anti-neoplastic, anti-bacterial, 
antifungal 
ALTRETAMINE 007 C07 210.28 anti-neoplastic 
TIOXOLONE 007 C08 168.17 antiseborrhoic 
THIAMPHENICOL 007 C09 356.23 anti-bacterial 
LABETALOL HYDROCHLORIDE 007 C10 364.88 adrenergic blocker 
LEVAMISOLE 
HYDROCHLORIDE 
007 C11 240.76 immunomodulator 
LYSYL-TYROSYL-LYSINE 
ACETATE 
007 D02 497.60 Induces nicks at apurinic and 
apyrimidinic sites in circular DNA 
L-LEUCYL-L-ALANINE 007 D03 202.26 ubiquitin blocker, neurite growth 
inhibitor 
N-HISTIDYL-2-
AMINONAPHTHALENE 
(betaNA) 
007 D04 280.33 beta-glucosidase inhibitor 
RHAPONTIN 007 D05 420.42 antifungal, antioxidant 
BIOTIN 007 D06 244.31 vitamin B complex 
AMINOHIPPURIC ACID 007 D07 194.19 renal function diagnosis 
BACAMPICILLIN 
HYDROCHLORIDE 
007 D08 501.99 anti-bacterial 
TENOXICAM 007 D09 337.38 anti-inflammatory 
NIFENAZONE 007 D10 308.34 analgesic, anti-inflammatory 
6alpha-
METHYLPREDNISOLONE 
007 D11 416.52 glucocorticoid 
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ACETATE 
SPAGLUMIC ACID 007 E02 304.26 neurotransmitter; mGluR3 receptors 
Tfa-VAL-TYR-VAL-OH 007 E03 475.47 elastase (human) inhibitor 
1-
BENZYLOXYCARBONYLAMINO
PHENETHYL  CHLOROMETHYL 
KETONE 
007 E04 331.80 peptidase inhibitor, esterase inhibitor 
ELLAGIC ACID 007 E05 302.20 hemostatic, anti-neoplastic, 
antimutagenic 
DINITOLMIDE 007 E06 225.16 anti-protozoal 
MEFLOQUINE 007 E07 378.32 anti-malarial 
BEPRIDIL HYDROCHLORIDE 007 E08 403.01 anti-arrhythmic 
CETRIMONIUM BROMIDE 007 E09 364.46 anti-infectant 
HALCINONIDE 007 E10 454.97 glucocorticoid, anti-inflammatory 
HYDROCORTISONE BUTYRATE 007 E11 432.56 glucocorticoid, anti-inflammatory 
Ng-METHYL-L-ARGININE 
ACETATE 
007 F02 248.28 NO synthesis inhibitor 
PHENETHYL CAFFEATE (CAPE) 007 F03 284.31 anti-neoplastic, anti-inflammatory, 
immunomodulator, NFkB blocker 
PHENYLALANYLTYROSINE 007 F04 328.37 TAN inhibitor 
GLUTATHIONE 007 F05 307.33 antioxidant 
NICOTINYL TARTRATE 007 F06 259.22 vasodilator 
ADIPHENINE 
HYDROCHLORIDE 
007 F07 347.89 muscle relaxant (smooth) 
CARMUSTINE 007 F08 214.05 anti-neoplastic, alkylating agent 
CHLOROXINE 007 F09 214.05 chelating agent 
HYCANTHONE 007 F10 356.49 anthelmintic, hepatotoxic 
MITOXANTHRONE 
HYDROCHLORIDE 
007 F11 517.41 anti-neoplastic 
PIRACETAM 007 G02 142.16 antinauseant 
VALYLTRYPTOPHAN 007 G03 303.36 ACE inhibitor 
RESVERATROL 007 G04 228.25 antifungal, anti-bacterial 
MONOCROTALINE 007 G05 325.36 anti-neoplastic, insect sterilant 
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AMINOHYDROXYBUTYRIC 
ACID 
007 G06 119.12 antiepileptic 
ALEXIDINE HYDROCHLORIDE 007 G07 581.73 anti-bacterial 
CEFTRIAXONE SODIUM 007 G08 598.55 anti-bacterial 
CLOFOCTOL 007 G09 365.35 anti-bacterial 
NIMESULIDE 007 G10 308.31 anti-inflammatory 
URETHANE 007 G11 89.09 anti-neoplastic, cytotoxic 
PIPERIDOLATE 
HYDROCHLORIDE 
007 H02 359.90 antispasmodic 
GLYCYLLEUCYLPHENYLALANI
NE 
007 H03 335.41 immunostimulant 
CAMPTOTHECIN 007 H04 348.36 anti-neoplastic 
SALICIN 007 H05 286.28 analgesic, antipyretic 
ARTEMISININ 007 H06 282.34 anti-malarial 
QUINAPRIL HYDROCHLORIDE 007 H07 474.99 anti-hypertensive, ACE inhibitor 
TRAZODONE 
HYDROCHLORIDE 
007 H08 408.33 antidepressant 
LASALOCID SODIUM 007 H09 612.79 anti-bacterial 
MEPHENTERMINE SULFATE 007 H10 261.34 vasoconstrictor 
THIOTEPA 007 H11 189.22 anti-neoplastic, alkylating agent 
CHLOROACETOXYQUINOLINE 008 A02 221.64 antifungal 
NIMODIPINE 008 A03 418.45 vasodilator 
3,5-DINITROCATECHOL (OR-
486) 
008 A04 200.11 catechol O-methyltransferase inhibitor 
ESTRONE HEMISUCCINATE 008 A05 370.45 estrogen 
SODIUM beta-NICOTINAMIDE 
ADENINE DINUCLEOTIDE 
PHOSPHATE 
008 A06 765.40 cofactor in aryl & steroidal 
hydroxylation 
PROPAFENONE 
HYDROCHLORIDE 
008 A07 377.92 anti-arrhythmic 
CONVALLATOXIN 008 A08 550.65 cardiotonic 
PHYSCION 008 A09 284.27 anti-bacterial, cathartic 
GLICLAZIDE 008 A10 323.42 anti-diabetic 
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PRISTIMERIN 008 A11 464.65 anti-neoplastic, anti-inflammatory 
EXALAMIDE 008 B02 221.30 antifungal 
SALINOMYCIN, SODIUM 008 B03 773.00 anti-bacterial 
N- (3-
TRIFLUOROMETHYLPHENYL)P
IPERAZINE HYDROCHLORIDE 
(TFMPP) 
008 B04 266.70 5HT agonist 
AZITHROMYCIN 008 B05 749.00 anti-bacterial 
PACLITAXEL 008 B06 853.93 anti-neoplastic 
PERICIAZINE 008 B07 365.50 anti-psychotic 
BAICALEIN 008 B08 270.24 anti-viral (HIV) 
SENNOSIDE A 008 B09 862.76 cathartic 
TRIMEDLURE 008 B10 232.75 arthropod pheromone 
TETRANDRINE 008 B11 622.77 analgesic, anti-neoplastic, anti-
hypertensive, lymphotoxin 
ETANIDAZOLE 008 C02 214.18 anti-neoplastic, hypoxic cell 
radiosensitizer 
ACYCLOVIR 008 C03 225.21 anti-viral 
3-METHYL-1-PHENYL-2-
PYRAZOLIN-5-ONE (MCI-186) 
008 C04 174.20 antioxidant, lipoxygenase inhibitor 
AZADIRACHTIN 008 C05 720.73 anti-feedant, insecticide 
BUTACAINE 008 C06 306.45 anesthetic (local) 
SPERMIDINE 
TRIHYDROCHLORIDE 
008 C07 254.63 ornithine decarboxylase inhibitor 
GOSSYPOL 008 C08 518.57 anti-spermatogenic, anti-neoplastic, 
anti-HIV 
PHENOTHRIN 008 C09 350.46 ectoparasiticide 
MELOXICAM 008 C10 351.41 anti-inflammatory 
ISOLIQUIRITIGENIN 008 C11 256.26 aldose reductase inhibitor, anti-
neoplastic, anti-inflammatory 
MIZORIBINE 008 D02 259.22 immunosuppressant 
NITRENDIPINE 008 D03 360.37 anti-hypertensive 
METHIOTHEPIN MALEATE 008 D04 472.63 5HT1&2 receptor antagonist 
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CEVADINE 008 D05 591.75 anti-hypertensive 
TRYPTAMINE 008 D06 160.22 psychotropic 
LOVASTATIN 008 D07 404.55 antihyperlipidemic, HMGCoA reductase 
inhibitor 
LUPININE 008 D08 169.27 anti-feedant, anti-inflammatory, 
oxytoxic 
SILDENAFIL 008 D09 474.59 impotency therapy 
NIMUSTINE 008 D10 272.70 anti-neoplastic 
DELTALINE 008 D11 451.56 anti-arrhythmic 
NAFRONYL OXALATE 008 E02 473.57 vasodilator 
CIPROFLOXACIN 008 E03 331.35 anti-bacterial, fungicide 
RAUWOLSCINE 
HYDROCHLORIDE 
008 E04 390.91 alpha2 adrenergic antagonist 
CLOPIDOGREL SULFATE 008 E05 419.91 platelet aggregation inhibitor 
IOPANIC ACID 008 E06 570.94 radioopaque agent 
METHOXYAMINE 
HYDROCHLORIDE 
008 E07 83.52 hydroxymethyltransferase inhibitor 
SALSOLINE 008 E08 193.25 anti-hypertensive, antihistamine 
TETRACHLOROISOPHTHALON
ITRILE 
008 E09 265.91 antifungal 
PINOCEMBRIN 008 E10 256.26 anti-inflammatory 
BOVINOCIDIN (3-
nitropropionic acid) 
008 E11 119.08 anti-neoplastic 
SEMUSTINE 008 F02 247.73 anti-neoplastic 
SAFROLE 008 F03 162.19 anesthetic (topical) and antiseptic, 
pediculicide 
1-PHENYLBIGUANIDE 
HYDROCHLORIDE 
008 F04 213.67 5HT3 receptor agonist 
LORATADINE 008 F05 382.89 H1 antihistamine 
LANSOPRAZOLE 008 F06 369.37 anti-ulcerative 
AGMATINE SULFATE 008 F07 228.27 NMDA blocker, alpha-2 adrenergic 
agonist; NO synthase inhibitor 
CYTISINE 008 F08 190.25 anti-inflammatory, respiratory stimulant 
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DIHYDROJASMONIC ACID 008 F09 212.29 plant growth regulator 
VENLAFAXINE 008 F10 277.41 antidepressant 
ATOVAQUONE 008 F11 366.85 antipneumocystic, anti-malarial 
SPIRAMYCIN 008 G02 843.07 anti-bacterial 
OXOTREMORINE 
SESQUIFUMARATE 
008 G03 322.36 muscarinic agonist 
VERATRIDINE 008 G04 703.83 anti-hypertensive 
SELAMECTIN 008 G05 769.98 antiparasitic, antimite 
OXYPHENCYCLIMINE 
HYDROCHLORIDE 
008 G06 380.92 anti-cholinergic 
2-THIOURACIL 008 G07 128.15 thyroid depressant 
EMODIC ACID 008 G08 300.23 cathartic, purgative 
TANNIC ACID 008 G09 1701.23 nonspecific enzyme/receptor blocker 
BUPROPION 008 G10 276.21 antidepressant 
CHLOROGUANIDE 
HYDROCHLORIDE 
008 G11 290.20 anti-malarial 
RESORCINOL MONOACETATE 008 H02 152.15 antiseborrheic, antipruritic 
N-AMINOHEXYL-5-CHLORO-
1-
NAPTHALENESULFONAMIDE 
HYDROCHLORIDE  
008 H03 377.34 calmodulin antagonist, PDE and kinase 
inhibitor 
CELECOXIB 008 H04 381.38 antiarthritic, cyclooxygenase2 inhibitor 
ATORVASTATIN CALCIUM 008 H05 582.71 antihyperlipidemic, HMGCoA reductase 
inhibitor 
PENTOLINIUM TARTRATE 008 H06 538.60 anti-hypertensive, ganglionic blocker 
CLEBOPRIDE MALEATE 008 H07 489.96 antiemetic, antispasmodic 
BETULINIC ACID 008 H08 442.69 anti-neoplastic 
FORMESTANE 008 H09 300.44 anti-neoplastic, aromatase inhibitor 
TETRAHYDROPALMATINE 008 H10 355.44 analgesic, hypnotic, papaverine-like 
CHLORANIL 008 H11 245.88 antipsoriatic 
N-ACETYLASPARTIC ACID 009 A02 175.14 analeptic, neurostimulant 
2,3-DIHYDROXY-6,7-
DICHLOROQUINOXALINE 
009 A03 231.04 NMDA receptor antagonist (gly) 
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LEVOFLOXACIN 009 A04 361.38 anti-bacterial 
MOXIFLOXACIN 
HYDROCHLORIDE 
009 A05 465.96 anti-bacterial 
ALMOTRIPTAN 009 A06 335.47 5HT 1B/2D receptor agonist 
ROSUVASTATIN 009 A07 481.55 antihyperlipidemic 
TROXERUTIN 009 A08 742.69 vasoprotectant 
HUPERZINE A 009 A09 242.32 anticholinesterase, cognition enhancer 
CROTAMITON 009 A10 203.29 antipruritic, scabicide 
AMITRAZ 009 A11 293.42 pesticide, carcinogen 
N,N-
HEXAMETHYLENEAMILORIDE 
009 B02 311.78 Na/H+ antiporter inhibitor, diuretic 
ROFECOXIB 009 B03 314.36 COX2 inhibitor, anti-inflammatory, 
antiarthritic 
CANDESARTAN CILEXTIL 009 B04 610.68 angiotensin 1 receptor antagonist 
PIOGLITAZONE 
HYDROCHLORIDE 
009 B05 392.91 anti-diabetic 
OLMESARTAN MEDOXOMIL 009 B06 558.60 Angiotensin II inhibitor prodrug, anti-
hypertensive 
TEGASEROD MALEATE 009 B07 417.47 5HT4 receptor agonist, peristaltic 
stimulant 
GINKGOLIC ACID 009 B08 346.51 cytotoxic, apoptosis inducer, 
antitubercular 
SILIBININ 009 B09 482.45 hepatoprotective agent, antioxidant 
BENZANTHRONE 009 B10 230.27 hepatotoxic, P450 suppressant 
PURPURIN 009 B11 256.22 xanthin oxidase inhibitor, irritant 
ZOXAZOLAMINE 009 C02 168.58 muscle relaxant, antirrheumatic 
HYDROQUINONE 009 C03 110.11 antioxidant 
ROSIGLITAZONE 009 C04 357.43 anti-diabetic 
PICROPODOPHYLLOTOXIN 009 C05 414.42 anti-neoplastic; 10% cytotoxicity of 
podophyllotoxin 
CEFTIBUTEN 009 C06 410.43 anti-bacterial 
DERACOXIB 009 C07 397.38 anti-inflammatory, antiarthritic, COX-2 
inhibitor 
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CANRENONE 009 C08 340.47 aldosterone antagonist; antifibrogenic 
ICARIIN 009 C09 676.68 hepatoprotective 
ZOLMITRIPTAN 009 C10 287.36 antimigraine, 5HT[1B/1D] agonist 
GENETICIN 009 C11 692.72 anti-bacterial 
ACRISORCIN 009 D02 388.51 antifungal 
OXCARBAZEPINE 009 D03 252.28 anti-psychotic 
LOSARTAN 009 D04 422.92 anti-hypertensive, AT1 angiotensin II 
antagonist 
DIHYDROJASMONIC ACID, 
METHYL ESTER 
009 D05 226.32 plant growth regulator 
CEFDINIR 009 D06 395.42 anti-bacterial 
CILOSTAZOL 009 D07 369.47 phosphodiesterase inhibitor 
APRAMYCIN 009 D08 539.59 anti-bacterial; LD50(iv) 
280mg/kg(mouse) 
SERTRALINE 
HYDROCHLORIDE 
009 D09 342.70 antidepressant, 5HT uptake inhibitor 
DIALLYL SULFIDE 009 D10 114.21 anitbacterial, antifungal, anti-neoplastic, 
antihypercholesterolaemic, 
hepatoprotectant 
SECNIDAZOLE 009 D11 185.18 antiameobic, antitrichomonas 
PHENYLBUTYRATE SODIUM  009 E02 186.19 antihyperlipidemic 
BETAMIPRON 009 E03 193.20 sweetener 
GATIFLOXACIN 009 E04 375.40 anti-bacterial 
BENAZEPRIL 
HYDROCHLORIDE 
009 E05 460.96 ACE inhibitor, anti-hypertensive 
VALSARTAN 009 E06 435.53 Angiotensin II inhibitor, anti-
hypertensive 
AVOCADYNE 009 E07 284.44 anti-bacterial, antifungal 
MADECASSIC ACID 009 E08 504.71 wound healing 
ALFLUZOCIN 009 E09 389.46 alpha(1)-adrenergic blocker 
CARBADOX 009 E10 262.23 anti-bacterial 
PEFLOXACINE MESYLATE 009 E11 429.47 anti-bacterial, antiproliferative 
CRUSTECDYSONE 009 F02 480.65 insect molting hormone 
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CARVEDILOL TARTRATE 009 F03 556.57 betaadrenergic blocker 
MIGLITOL 009 F04 207.23 alpha-glucosidase inhibitor, anti-
diabetic 
FAMCICLOVIR 009 F05 321.34 anti-viral 
SIBUTRAMINE 
HYDROCHLORIDE 
009 F06 316.32 anorexic, antidepressant, uptake 
inhibitor (5HT, norepinephrine, 
dopamine) 
AVOCADYNONE ACETATE 009 F07 324.46 anti-bacterial, antifungal 
IMIDACLOPRID 009 F08 254.68 nicotinyl AChR agonist; antiparasitic 
TRANDOLAPRIL 009 F09 430.55 anti-hypertensive, ACE inhibitor 
OXFENDAZOLE 009 F10 315.35 anthelmintic 
ASPARTAME 009 F11 294.31 sweetener 
METAXALONE 009 G02 221.26 muscle relaxant (skeletal) 
NATEGLINIDE 009 G03 317.43 anti-diabetic 
ORLISTAT 009 G04 495.75 reversible lipase inhibitor, antiobesity 
AMLODIPINE BESYLATE 009 G05 567.06 Ca channel blocker 
TORSEMIDE 009 G06 348.43 diuretic, inhibits Na/K/2Cl carrier system 
SPARTEINE HYDROIODIDE 009 G07 362.30 oxytocic 
PALMATINE 009 G08 368.41 uterine contractant, anti-bacterial, anti-
arrhythmic, inotropic, 
adrenocorticotropic, anticholinesterase, 
analgesic 
TELITHROMYCIN 009 G09 824.04 anti-bacterial 
PERILLYL ALCOHOL 009 G10 152.24 anti-neoplastic, apoptosis inducer; skin 
irritant, LD50(rat) 2100 mg/kg po 
TRIADIMEFON 009 G11 293.76 antifungal, P450 inhibitor 
CLARITHROMYCIN 009 H02 747.97 anti-bacterial 
IRBESARTAN 009 H03 428.54 angiotensin 2 receptor antagonist 
VALDECOXIB 009 H04 314.37 anti-inflammatory, COX-2 inhibitor 
EZETIMIBE 009 H05 409.44 sterol absorption inhibitor 
PERINDOPRIL ERBUMINE 009 H06 441.62 anti-hypertensive, ACE inhibitor 
CITICOLINE 009 H07 488.33 cognition enhancer, phosphocholine 
cytidyltransferase activator 
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SINOMENINE 009 H08 329.40 weak abortifacient, 
immunosuppressant, analgesic, anti-
inflammatory; LD50 (po) 580 mg/kg; (ip) 
285 mg/kg(mouse) 
OXAPROZIN 009 H09 293.33 anti-inflammatory 
3-ISOBUTYL-1-
METHYLXANTHINE (IBMX) 
009 H10 222.25 phosphodiesterase inhibitor 
CHLOROPHYLLIDE Cu 
COMPLEX Na SALT 
009 H11 682.15 anti-neoplastic 
BIFONAZOLE 010 A02 310.40 antifungal, calmodulin antagonist 
INDOLE-3-CARBINOL 010 A03 147.18 anti-neoplastic 
3,3'-DIINDOLYLMETHANE 010 A04 246.31 apoptosis inducer 
7-NITROINDAZOLE 010 A05 163.14 NO synthetase inhibitor 
PRAVASTATIN SODIUM 010 A06 446.52 antihyperlipidemic, HMGCoA reductase 
inhibitor 
CAPSANTHIN 010 A07 584.89 anti-neoplastic 
ASTEMIZOLE 010 A08 458.58 H1 antihistamine (nonsedating) 
GLYBURIDE 010 A09 494.01 antihyperglycemic 
JUGLONE 010 A10 174.16 anti-neoplastic, antifungal 
ACETOSYRINGONE 010 A11 196.20 insect attractant, plant hormone 
DIBENZOYLMETHANE 010 B02 224.26 anti-neoplastic 
RIFAXIMIN 010 B03 785.90 anti-bacterial, RNA synthesis inhibitor 
AZAPERONE 010 B04 327.41 tranquilizer, neuroleptic, alpha 
adrenergic blocker 
RIBOFLAVIN 010 B05 376.37 Vitamin B2; Vitamin cofactor; LD50(rat) 
560 mg/kg ip 
PEONIFLORIN 010 B06 482.49 anti-inflammatory, antispasmodic, anti-
hypertensive, antidiuretic  
COLCHICEINE 010 B07 385.42 anti-mitotic 
N-ACETYLNEURAMIC ACID 010 B08 309.28 immunomodulator, adjuvant 
NICOTINE DITARTRATE 010 B09 462.41 nicotinyl acetylchloline receptor agonist, 
ectoparasiticide 
ANISODAMINE 010 B10 305.38 anti-cholinergic, antispasmodic 
POMIFERIN 010 B11 420.47 antioxidant 
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TYLOSIN TARTRATE 010 C02 916.12 anti-bacterial 
CEPHARANTHINE 010 C03 606.73 anti-neoplastic, hepatoprotectant, 
radiopropective 
TRANILAST 010 C04 327.34 antiallergic, mast cell degranulation 
inhibitor, angiogenesis blocker 
CURCUMIN 010 C05 368.39 antiedemic, anti-inflammatory, bile 
stimulant; anti-bacterial, antifungal, 
lipo/cyclooxygenase inhibitor 
N-CHLOROETHYL-N-ETHYL-2'-
METHYLBENZYLAMINE 
HYDROCHLORIDE 
010 C06 248.20 inhibits dopamine & norepinephrine 
accumulation in brain 
KOJIC ACID 010 C07 142.11 chelator, anti-bacterial, skin whitening 
agent 
VESAMICOL HYDROCHLORIDE 010 C08 295.86 acetylcholine transport blocker 
(vesicular) 
1-METHYLXANTHINE 010 C09 166.14 diuretic, adenosine antagonist 
VULPINIC ACID 010 C10 322.32 anti-inflammatory, anti-bacterial, plant 
growth inhibitor  
CELASTROL 010 C11 450.62 anti-neoplastic, antiinflamatory, NO 
synthesis inhibitor, chaperone stimulant 
SARAFLOXACIN 
HYDROCHLORIDE 
010 D02 421.83 anti-bacterial 
CARBIMAZOLE 010 D03 186.23 antithyroid 
SECURININE 010 D04 217.27 GABAA receptor blocker, CNS stimulant 
RILUZOLE 010 D05 234.20 anticonvulsant, glutamate release 
inhibitor 
PREGABALIN 010 D06 159.23 anticonvulsant 
ISOBUTYLMETHYLXANTHINE 010 D07 222.25 phosphodiesterase inhibitor 
MEXAMINE 010 D08 226.71 5HT agonist 
NIPECOTIC ACID 010 D09 129.16 GABA uptake inhibitor 
USNIC ACID 010 D10 344.32 anti-bacterial 
DEGUELIN(-) 010 D11 394.43 anti-neoplastic, anti-viral, insecticide 
6-AMINONICOTINAMIDE 010 E02 137.14 anti-neoplastic, apoptosis inducer 
CHLORMADINONE ACETATE 010 E03 404.94 progestin, antiandrogen 
VALERYL SALYCILATE 010 E04 222.24 COX-1 inhibitor 
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CEFDITORIN PIVOXIL 010 E05 620.73 anti-bacterial 
2,6-DI-t-BUTYL-4-
METHYLPHENOL 
010 E06 220.36 antioxidant 
DESMETHYLDIHYDROCAPSAI
CIN 
010 E07 293.41 analgesic (topical), depletes Substance P 
HYDROXYTACRINE MALEATE 010 E08 330.34 cholinesterase inhibitor, anti-
parkinsonian 
PENTETRAZOL 010 E09 138.17 analeptic, circulation stimulant 
PHLORIDZIN 010 E10 436.42 induces experimental glucosuria, anti-
feedant 
RUTILANTINONE 010 E11 428.40 coccidiostat 
PROTHIONAMIDE 010 F02 180.27 anti-bacterial 
4'-
DEMETHYLEPIPODOPHYLLOT
OXIN 
010 F03 400.39 anti-neoplastic 
ELAIDYLPHOSPHOCHOLINE 010 F04 433.62 anti-neoplastic 
MODAFINIL 010 F05 273.36 analeptic 
CHAULMOSULFONE 010 F06 777.22 antilepretic 
KAINIC ACID 010 F07 213.24 glutamate receptor agonist, 
anthelmintic 
9-AMINO-1,2,3,4-
TETRAHYDROACRIDINE 
HYDROCHLORIDE 
010 F08 234.73 anticholinesterase, K channel blocker 
1- (2-
METHOXYPHENYL)PIERAZINE 
HYDROCHLORIDE 
010 F09 228.72 5HT1 receptor agonist 
SPARTEINE SULFATE 010 F10 332.47 oxytocic 
ROTENONE 010 F11 394.43 acaricide, ectoparasiticide, anti-
neoplastic, mitochondrial poison 
CARMOFUR 010 G02 257.27 anti-neoplastic 
MILTEFOSINE 010 G03 407.58 anti-neoplastic 
L-PHENYLALANINOL 010 G04 151.21 anti-ulcer 
TOPIRAMATE 010 G05 339.37 anticonvulsant, antimigraine, GABA-A 
agonist, AMP/kinate glutamate receptor 
antagonist,  carbonic anhydrase 
inhibitor 
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CREATININE 010 G06 113.12 metabolic enhancer 
PODOFILOX 010 G07 414.42 anti-neoplastic, inhibits microtubule 
assembly, and human DNA 
topoisomerase II; anti-mitotic agent 
N-
HYDROXYMETHYLNICOTINA
MIDE 
010 G08 152.15 cholagogue 
HYDROCORTISONE 010 G09 362.47 glucocorticoid, anti-inflammatory 
ISORESERPINE 010 G10 608.69 anti-hypertensive 
GAMBOGIC ACID 010 G11 628.77 anti-inflammatory, cytotoxic, inhibits 
HeLa cells in vitro; LD50(rat) 88 mg/kg ip 
CLOPIDOL 010 H02 192.05 coccidiostat, antiplatelet 
OXICONAZOLE NITRATE 010 H03 492.15 antifungal 
AZELASTINE HYDROCHLORIDE 010 H04 418.37 H1 antihistamine (nonsedating); 
leucotriene synthesis blocker 
GEMIFLOXACIN MESYLATE 010 H05 485.49 anti-bacterial 
PAEONOL 010 H06 166.18 anti-bacterial 
EDROPHONIUM CHLORIDE 010 H07 201.70 acetylcholinesterase inhibitor 
LEVODOPA 010 H08 197.19 anti-parkinsonian 
PIMPINELLIN 010 H09 246.22 GABA receptor antagonist, phototoxin 
BERGAPTEN 010 H10 216.20 antipsoriatic, anti-inflammatory 
AKLAVINE HYDROCHLORIDE 010 H11 606.08 anti-bacterial, anti-neoplastic 
TETRACAINE 
HYDROCHLORIDE 
011 A02 300.83 anesthetic (local) 
METHYLTHIOURACIL 011 A03 142.18 antithyroid agent 
SULFAMETHIZOLE 011 A04 270.33 anti-bacterial 
ROSOLIC ACID 011 A05 290.32 diagnostic aid 
NICARDIPINE 
HYDROCHLORIDE 
011 A06 516.00 vasodilator 
AZOBENZENE 011 A07 182.23 acaricide 
TETRAHYDROZOLINE 
HYDROCHLORIDE 
011 A08 236.75 adrenergic agonist, nasal decongestant 
OXYPHENBUTAZONE 011 A09 324.38 anti-inflammatory 
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SULFINPYRAZONE 011 A10 404.49 uricosuric 
ACEBUTOLOL 
HYDROCHLORIDE 
011 A11 372.90 anti-hypertensive, antianginal, anti-
arrhythmic 
FLUNARIZINE 
HYDROCHLORIDE 
011 B02 477.43 vasodilator 
SULCONAZOLE NITRATE 011 B03 460.77 antifungal 
FLURANDRENOLIDE 011 B04 436.53 anti-inflammatory 
ENALAPRIL MALEATE 011 B05 492.53 ACE inhibitor, anti-hypertensive 
THIORIDAZINE 
HYDROCHLORIDE 
011 B06 407.04 anti-psychotic 
PROPYLTHIOURACIL 011 B07 170.23 antihyperthyroid 
SULFISOXAZOLE 011 B08 267.31 anti-bacterial 
MELATONIN 011 B09 232.28 sleep induction, modifies circadian 
rhythm 
FLUTAMIDE 011 B10 276.22 antiandrogen 
RITODRINE HYDROCHLORIDE 011 B11 323.82 muscle relaxant (smooth) 
ESTRADIOL DIACETATE 011 C02 356.47 estrogen 
CEFMETAZOLE SODIUM 011 C03 493.52 anti-bacterial 
THIOTHIXENE 011 C04 443.63 anti-psychotic 
PYRAZINAMIDE 011 C05 123.12 anti-bacterial, tuberculostatic 
AMINOPHENAZONE 011 C06 203.25 antipyretic, analgesic 
ACETYLTRYPTOPHAN 011 C07 246.27 antidepressant 
SUPROFEN METHYL ESTER 011 C08 274.34 anti-inflammatory 
GLAFENINE 011 C09 372.81 analgesic 
SULPIRIDE 011 C10 341.43 dopamine receptor antagonist, anti-
psychotic 
ECONAZOLE NITRATE 011 C11 444.70 antifungal 
CEFOPERAZONE SODIUM 011 D02 667.66 anti-bacterial 
TOLAZOLINE 
HYDROCHLORIDE 
011 D03 196.68 adrenergic blocker 
PYRVINIUM PAMOATE 011 D04 769.91 anthelmintic 
VINCAMINE 011 D05 354.45 vasodilator 
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ACETYLGLUTAMIC ACID 011 D06 189.17 excitatory aminoacid 
AMINACRINE 011 D07 194.24 local antiseptic 
ETHAVERINE 
HYDROCHLORIDE 
011 D08 431.96 antispasmodic 
SPIPERONE 011 D09 395.48 anti-psychotic 
FLUNISOLIDE 011 D10 434.51 anti-inflammatory 
NARASIN 011 D11 765.05 anti-bacterial, anti-viral 
TOLMETIN SODIUM 011 E02 279.27 anti-inflammatory 
SALICYLAMIDE 011 E03 137.14 analgesic 
gamma-AMINOBUTYRIC ACID 011 E04 103.12 anti-hypertensive 
ACETYLGLUCOSAMINE 011 E05 221.21 antiarthritic 
DROPERIDOL 011 E06 379.44 neuroleptic 
SULFAMETER 011 E07 280.31 anti-bacterial 
EBSELEN 011 E08 274.18 antioxidant, lipoxygenase inhibitor, 
inhibits oxidation of LDL 
SNAP (S-NITROSO-N-
ACETYLPENICILLAMINE) 
011 E09 220.25 muscle relaxant (smooth) 
TRIAMCINOLONE 011 E10 394.44 glucocorticoid 
SULFABENZAMIDE 011 E11 276.32 anti-bacterial 
QUINALIZARIN 011 F02 272.22 anti-viral, HIV-1 integrase inhibitor 
BUDESONIDE 011 F03 430.55 anti-inflammatory 
FLUFENAMIC ACID 011 F04 281.24 anti-inflammatory, analgesic 
SULFAMETHOXYPYRIDAZINE 011 F05 280.31 anti-bacterial 
FUREGRELATE SODIUM 011 F06 275.24 thromboxane synthetase inhibitor 
6,7-DICHLORO-3-HYDROXY-2-
QUINOXALINECARBOXYLIC 
ACID 
011 F07 259.05 NMDA and kainate receptor antagonist 
CINEOLE 011 F08 154.25 anthelminthic, antiseptic, expectorant 
DOXYCYCLINE 
HYDROCHLORIDE 
011 F09 480.91 anti-bacterial 
ACONITINE 011 F10 645.75 anesthetic (gastric), antipyretic, and 
cardiotoxin 
CORALYNE CHLORIDE 011 F11 399.88 cytostatic, intercalating agent 
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PATULIN 011 G02 154.12 anti-bacterial 
SACCHARIN 011 G03 183.19 sweetener 
XYLAZINE 011 G04 220.34 analgesic 
ACETYLCARNITINE 011 G05 225.67 cholinergic 
5-FLUOROINDOLE-2-
CARBOXYLIC ACID 
011 G06 179.15 NMDA receptor antagonist (gly) 
TARGININE HYDROCHLORIDE 011 G07 224.69 NO synthase inhibitor 
TIAPRIDE HYDROCHLORIDE 011 G08 364.89 neuroleptic 
CITIOLONE 011 G09 159.21 hepatoprotectant 
METHAZOLAMIDE 011 G10 236.27 carbonic anhydrase inhibitor 
HEXAMETHONIUM BROMIDE 011 G11 362.19 anti-hypertensive, ganglionic blocker 
RAMIFENAZONE 011 H02 281.79 analgesic, antipyretic, anti-inflammatory 
PERPHENAZINE 011 H03 403.98 anti-psychotic 
ETHYLNOREPINEPHRINE 
HYDROCHLORIDE 
011 H04 233.70 bronchodilator 
ROSMARINIC ACID 011 H05 360.32 anti-inflammatory, antithrombotic, 
antiplatelet, cytostatic, anti-viral 
AMYGDALIN 011 H06 457.44 anti-inflammatory, experimatal anti-
neoplastic 
AZLOCILLIN SODIUM 011 H07 483.48 anti-bacterial 
CYCLOBENZAPRINE 
HYDROCHLORIDE 
011 H08 311.86 muscle relaxant (skeletal) 
METHYLBENZETHONIUM 
CHLORIDE 
011 H09 462.12 anti-infectant 
DIPYRONE 011 H10 333.34 analgesic, antipyretic 
2- (2,6-
DIMETHOXYPHENOXYETHYL)
AMINOMETHYL-1,4-
BENZODIOXANE 
HYDROCHLORIDE (WB 4101) 
011 H11 381.86 alpha1a adrenergic blocker 
NIGERICIN SODIUM 012 A02 746.96 anti-bacterial 
THIOCTIC ACID 012 A03 206.33 hepatoprotectant 
TENIPOSIDE 012 A04 656.67 anti-neoplastic 
CISPLATIN 012 A05 300.06 anti-neoplastic, convulsant 
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BENDROFUMETHIAZIDE 012 A06 421.42 diuretic 
ENOXACIN 012 A07 320.33 anti-bacterial 
MIDODRINE 
HYDROCHLORIDE 
012 A08 290.75 anti-hypertensive, vasoconstrictor 
NABUMETONE 012 A09 228.29 anti-inflammatory 
CLOBETASOL PROPIONATE 012 A10 466.98 glucocorticoid, anti-inflammatory 
CACODYLIC ACID 012 A11 138.00 antieczema, dermatologic, herbicide 
DIRITHROMYCIN 012 B02 835.09 anti-bacterial 
ZIDOVUDINE [AZT] 012 B03 267.25 RT transferase inhibitor, anti-viral 
AKLOMIDE 012 B04 200.58 anti-protozoal, coccidiostat 
BROMHEXINE 
HYDROCHLORIDE 
012 B05 412.60 expectorant 
ETHISTERONE 012 B06 312.46 progestogen 
NADOLOL 012 B07 309.41 betaadrenergic blocker 
D-PHENYLALANINE 012 B08 165.19 antidepressant 
ANDROSTERONE SODIUM 
SULFATE 
012 B09 392.49 menstrual regulation 
CLOPERASTINE 
HYDROCHLORIDE 
012 B10 366.33 antitussive 
TULOBUTEROL 012 B11 264.20 bronchodilator, beta adrenergic agonist 
MEPIVACAINE 
HYDROCHLORIDE 
012 C02 282.82 anesthetic (local) 
N (g)-NITRO-L-ARGININE 012 C03 219.20 NO synthase inhibitor 
BUCLADESINE 012 C04 469.39 vasodilator 
BROMOPRIDE 012 C05 344.25 antiemetic 
FIPEXIDE HYDROCHLORIDE 012 C06 425.32 psychostimulant 
NALTREXONE 
HYDROCHLORIDE 
012 C07 341.41 morphine antagonist 
RETINYL PALMITATE 012 C08 524.88 provitamin, antixerophthalamic 
NAPROXOL 012 C09 216.28 antinflammatory, analgesic, antipyretic 
CYPROTERONE 012 C10 374.91 antiandrogen 
HYDROXYCHLOROQUINE 
SULFATE 
012 C11 433.96 anti-malarial, lupus suppressant 
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NILUTAMIDE 012 D02 317.23 antiandrogen 
p-CHLOROPHENYLALANINE 012 D03 199.64 Irreversible inhibitor of tryptophan 
hydrxylase 
PRIDINOL 
METHANESULFONATE 
012 D04 391.53 anti-cholinergic 
VINPOCETINE 012 D05 350.46 cerebral vasodilator, antimotion 
PERHEXILINE MALEATE 012 D06 393.57 coronary vasodilator 
NOMIFENSINE MALEATE 012 D07 354.41 antidepressant, dopamine uptake 
inhibitor 
BENZALKONIUM CHLORIDE 012 D08 354.02 anti-infective (topical) 
AMCINONIDE 012 D09 502.59 glucocorticoid, anti-inflammatory 
KETOROLAC TROMETHAMINE 012 D10 376.41 anti-inflammatory 
BROMPHENIRAMINE 
MALEATE 
012 D11 435.32 H1 antihistamine 
d[-Arg-2]KYOTORPHAN 
ACETATE 
012 E02 397.43 analgesic 
AMIPRILOSE 012 E03 341.84 immunomodulator, anti-inflammatory 
TRIMIPRAMINE MALEATE 012 E04 410.52 antidepressant 
METHAPYRILENE 
HYDROCHLORIDE 
012 E05 297.85 H1 antihistamine 
NORCANTHARIDIN 012 E06 168.15 anti-neoplastic, protein phosphatase 
inhibitor 
PRILOCAINE 
HYDROCHLORIDE 
012 E07 256.78 anesthetic (local) 
PENTOXIFYLLINE 012 E08 278.31 vasodilator 
BUPIVACAINE 
HYDROCHLORIDE 
012 E09 324.90 anesthetic (local) 
LEFUNOMIDE 012 E10 270.21 anti-neoplastic, PDGF receptor blocker 
ETHOSUXIMIDE 012 E11 141.17 anticonvulsant 
PYRITHYLDIONE 012 F02 167.21 hypnotic, sedative 
CINNARAZINE 012 F03 368.53 H1 antihistamine 
METARAMINOL BITARTRATE 012 F04 317.30 anti-hypotensive 
ROXITHROMYCIN 012 F05 837.07 anti-bacterial 
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PRONETALOL 
HYDROCHLORIDE 
012 F06 265.79 beta adrenergic agonist, anti-arrhythmic 
CYSTAMINE 
DIHYDROCHLORIDE 
012 F07 225.20 hepatoprotectant, radioprotectant 
MORANTEL CITRATE 012 F08 412.47 anthelmintic 
AVOBENZONE 012 F09 310.40 sunscreen 
CYCLOHEXIMIDE 012 F10 281.35 protein synthesis inhibitor 
METOLAZONE 012 F11 365.84 diuretic, anti-hypertensive 
CLOMIPRAMINE 
HYDROCHLORIDE 
012 G02 351.32 antidepressant 
DIPLOSALSALATE 012 G03 300.27 analgesic, antipyretic 
ACIVICIN 012 G04 178.58 anti-neoplastic 
ERYTHROMYCIN ESTOLATE 012 G05 1056.41 anti-bacterial 
1R,2S-PHENYLPROPYLAMINE 012 G06 151.21 decongestant 
CHLORMEZANONE 012 G07 273.74 anxiolytic, muscle relaxant 
FENBUTYRAMIDE 012 G08 163.22 antihyperlipidemic 
ANISOMYCIN 012 G09 265.31 anti-protozoal, antifungal, protein 
synthesis inhibitor 
SULFADIMETHOXINE 012 G10 310.33 anti-bacterial 
DILTIAZEM HYDROCHLORIDE 012 G11 450.99 Ca channel blocker, coronary 
vasodilator 
1,3-DIPROPYL-8-
CYCLOPENTYLXANTHINE 
[DPCPX] 
012 H02 304.40 A1 adenosine antagonist 
FLUOXETINE 012 H03 345.80 antidepressant 
2-
MERCAPTOBENZOTHIAZOLE 
012 H04 167.25 antifungal 
PYRILAMINE MALEATE 012 H05 401.47 anti-histaminic 
SULFAGUANIDINE 012 H06 214.25 anti-bacterial 
PARAXANTHINE 012 H07 180.17 adenosine receptor agonist 
ETHYL 1-BENZYL-3-HYDROXY- 
2-OXO[5H]PYRROLE-4-
CARBOXYLATE 
012 H08 261.28 aldose reductase inhibitor 
MERCAPTAMINE 012 H09 113.61 depigmentation, radiation protectant 
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HYDROCHLORIDE 
LOXAPINE SUCCINATE 012 H10 445.91 anti-psychotic 
CEPHALEXIN 012 H11 347.40 anti-bacterial 
DIAZOXIDE 013 A02 230.67 anti-hypertensive, diuretic, activates K 
channels and AMPA receptors 
METERGOLINE 013 A03 403.53 analgesic, antipyretic 
3-METHYLXANTHINE 013 A04 166.14 phosphodiesterase inhibitor 
beta-PELTATIN 013 A05 414.42 anti-neoplastic, cytotoxic 
LOPERAMIDE 
HYDROCHLORIDE 
013 A06 513.51 Ca channel blocker 
8-
CYCLOPENTYLTHEOPHYLLINE 
013 A07 248.29 A1 adenosine agonist 
AMOXAPINE 013 A08 313.79 antidepressant, inhibits norepinephrine 
uptake 
AMINOLEVULINIC ACID 
HYDROCHLORIDE 
013 A09 167.59 anti-neoplastic 
CHRYSANTHEMIC ACID 013 A10 168.24 esters as insecticide 
GEDUNIN 013 A11 482.58 anti-feedant 
MEFENAMIC ACID 013 B02 241.29 anti-inflammatory, analgesic 
VERAPAMIL HYDROCHLORIDE 013 B03 491.08 adrenegic blocker, Ca channel blocker, 
coronary vasodilator, anti-arrhythmic 
AMIODARONE 
HYDROCHLORIDE 
013 B04 681.78 adrenergic agonist, coronary 
vasodilator, Ca channel blocker 
DIETHYLTOLUAMIDE 013 B05 191.28 insect repellant 
TELENZEPINE 
HYDROCHLORIDE 
013 B06 406.94 anti-ulcer, M1 muscarinic antagonist 
PROPRANOLOL 
HYDROCHLORIDE (+/-) 
013 B07 295.81 anti-hypertensive, antianginal, anti-
arrhythmic 
TOLAZAMIDE 013 B08 311.41 anti-diabetic 
SULFACHLORPYRIDAZINE 013 B09 284.73 anti-bacterial 
PHENOXYBENZAMINE 
HYDROCHLORIDE 
013 B10 340.30 alpha adrenergic blocker 
COLFORSIN 013 B11 410.51 adenylate cyclase activator, 
antiglaucoma, hypotensive, vasodilator 
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METHACHOLINE CHLORIDE 013 C02 195.69 cholinergic, diagnostic aid 
PHENYLEPHRINE 
HYDROCHLORIDE 
013 C03 203.67 mydriatic, decongestant 
PRIMIDONE 013 C04 218.26 anticonvulsant 
ACETYLCHOLINE 013 C05 181.66 anti-arrhythmic, miotic, vasodilator 
(peripheral) 
EPHEDRINE (1R,2S) 
HYDROCHLORIDE 
013 C06 201.70 bronchodilator, cardiac stimulant 
METHICILLIN SODIUM 013 C07 402.40 anti-bacterial 
PINDOLOL 013 C08 248.33 anti-hypertensive, antianginal, anti-
arrhythmic, antiglaucoma agent 
PROBENECID 013 C09 285.36 uricosuric 
QUASSIN 013 C10 388.46 insecticide, antiamoebic 
PROADIFEN HYDROCHLORIDE 013 C11 389.97 cytochrome P450 inhibitor, Ca 
antagonist 
ERGOCALCIFEROL 013 D02 396.66 antirachitic vitamin; LD50 (rat) 56 mg/kg 
po  
METHOXAMINE 
HYDROCHLORIDE 
013 D03 247.72 alpha1 adrenoreceptor agonist, 
vasoconstrictor 
PIPERACILLIN SODIUM 013 D04 539.55 anti-bacterial 
PROCAINAMIDE 
HYDROCHLORIDE 
013 D05 271.79 anti-arrhythmic 
ASPIRIN 013 D06 180.16 analgesic, antipyretic, anti-inflammatory 
FLUMETHAZONE PIVALATE 013 D07 494.58 glucocorticoid, anti-inflammatory 
METHYLERGONOVINE 
MALEATE 
013 D08 455.52 oxytocic 
PIROXICAM 013 D09 331.35 anti-inflammatory 
PROCYCLIDINE 
HYDROCHLORIDE 
013 D10 323.91 anti-cholinergic 
CITRININ 013 D11 250.25 anti-bacterial 
alpha-TOCHOPHERYL 
ACETATE 
013 E02 472.76 vitamin E 
CEPHRADINE 013 E03 349.41 anti-bacterial 
FLUOROMETHOLONE 013 E04 376.47 glucocorticoid, anti-inflammatory 
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METHYLPREDNISOLONE 013 E05 374.48 glucocorticoid 
OXIDOPAMINE 
HYDROCHLORIDE 
013 E06 205.64 adrenergic agonist (opthalmic) 
PROGESTERONE 013 E07 314.47 progestogen 
DIETHYLSTILBESTROL 013 E08 268.36 estrogen 
HYDROCORTISONE 
HEMISUCCINATE 
013 E09 462.54 glucocorticoid 
PREDNISOLONE 013 E10 360.45 glucocorticoid 
APIGENIN 013 E11 270.24 antispasmodic, anti-neoplastic, 
topoisomerase I inhibitor 
FENSPIRIDE HYDROCHLORIDE 013 F02 296.80 anti-inflammatory, bronchodilator 
DIMETHADIONE 013 F03 129.12 anticonvulsant 
IPRATROPIUM BROMIDE 013 F04 412.37 bronchodilator, anti-arrhythmic 
PENICILLIN V POTASSIUM 013 F05 388.49 anti-bacterial 
PREDNISOLONE ACETATE 013 F06 402.49 glucocorticoid 
TAMOXIFEN CITRATE 013 F07 563.65 estrogen antagonist, anti-neoplastic 
VERATRINE SULFATE 013 F08 689.83 anti-hypertensive 
DOXEPIN HYDROCHLORIDE 013 F09 315.85 antidepressant 
LACTULOSE 013 F10 342.30 laxative 
GRISEOFULVIN 013 F11 352.77 antifungal, inhibits mitosis in metaphase 
PREDNISONE 013 G02 358.44 glucocorticoid 
TERBUTALINE HEMISULFATE 013 G03 323.37 betaadrenergic agonist, bronchodilator 
PHENIRAMINE MALEATE 013 G04 356.43 anti-histaminic 
RACEPHEDRINE 
HYDROCHLORIDE 
013 G05 201.70 bronchodilator, decongestant 
DESOXYCORTICOSTERONE 
ACETATE 
013 G06 372.51 mineralocorticoid 
ANTAZOLINE PHOSPHATE 013 G07 363.36 anti-histaminic 
DOXYLAMINE SUCCINATE 013 G08 388.47 anti-histaminic, hypnotic 
PERUVOSIDE 013 G09 548.68 cardiotonic 
PARAROSANILINE PAMOATE 013 G10 675.75 anthelmintic, antischistosomal 
MENADIONE 013 G11 172.19 prothrombogenic agent 
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AMINOTHIAZOLE 013 H02 100.14 antithyroid agent 
NALIDIXIC ACID 013 H03 232.24 anti-bacterial 
GABOXADOL 
HYDROCHLORIDE 
013 H04 176.60 GABAa agonist, GABAc antagonist 
DEXAMETHASONE 013 H05 392.47 glucocorticoid 
CLOTRIMAZOLE 013 H06 344.85 antifungal 
TOMATINE 013 H07 994.15 antifungal, anti-bacterial, anti-
inflammatory agent 
RETINYL ACETATE 013 H08 328.50 vitamin precursor 
EUCATROPINE 
HYDROCHLORIDE 
013 H09 327.85 anti-cholinergic (opthalmic) 
PINACIDIL 013 H10 245.33 K channel agonist, anti-hypertensive 
ALAPROCLATE 013 H11 255.75 antidepressant 
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Appendix 4 
 
 
Figure A3: Delayed calcium deregulation is characterised by an initial small Ca2+ rise in response to 
glutamate, followed up to two hours after initial glutamate exposure by a secondary, larger Ca2+ 
rise, simultaneous to a collapse of ΔΨm.   
To carry out DCD experiments, DIV14 neurons on 22mm glass coverslips were loaded for 30 minutes 
at 37C with either Fura-2 AM (2M), or Rhodamine-123 (10g/ml) in recording buffer (see page 
68), after which the buffer was removed, cells were gently rinsed, and recording bufferDCD (NaCl 
(150mM), KCl (4.25mM), NaH2PO4 (1.25mM), NaHCO3 (4mM), CaCl2 (1.2mM), HEPES (10mM), 
glucose (10mM), glycine (10M)) was replaced.  Cells were imaged using an Olympus TH4-200 
microscope, at 20X objective.  For Fura-2 AM, cells were excited at 340nm and 380nm (emission 
510nm), and for Rhodamine-123 at 488nm (emission 510nm).  A baseline was measured for 5 
minutes, prior to the addition of glutamate (G) (100M).  Cells were then imaged every 30 seconds 
for another 1 hour and 45 minutes, at which point either ionomycin (I) (2M, in the Fura-2 AM 
experiments),or FCCP (F) (2M, in the Rhodamine-123 experiments) was added.  Cells were imaged 
for a further 10 minutes.  Images were taken every 60 seconds, and were analysed using MetaFluor 
software: the background was subtracted, and ROIs were drawn.  The fluorescence intensity was 
then calculated, and for Fura -2 AM, a ratio was made of 340/380.  The blue line represents Fura-2 
ratio 340/380, the yellow line represents Rhodamine-123 Fluorescence.   
 
 
 
